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Abstract 
Background 
The physical health of people with serious mental illness [SMI] represents a significant 
public health challenge. It is estimated that they have a mortality rate two to three times 
greater than in the general population and the mortality gap is widening. Although suicide 
makes a significant contribution, cardiovascular disease [CVD] is the primary cause of 
death. A higher than expected prevalence of physical comorbidities in people with SMI 
has been identified in almost every system organ class [SOC] of the body with 
considerable overlap between them. This indicates multiple genetic, environmental, 
psychological, social, behavioural and system (of care) risk factors. A lower than expected 
incidence of comorbidities in the health records of people with SMI in primary and 
secondary care in the United Kingdom [UK] points to considerable under-diagnosis and 
treatment and presents an opportunity for intervention. There remains a paucity of 
evidence to support interventions that can be successfully implemented to make a 
difference to physical health outcomes in this vulnerable population.  
The SMI Health Improvement Profile [HIP] was developed by the author and two 
colleagues as a complex but pragmatic intervention to target physical wellbeing in SMI 
through the existing role of the mental health nurse in secondary care. The HIP 
Programme (the HIP and HIP training) is intended to support the mental health nurse 
working with people with SMI to undertake a structured health check and negotiate and 
implement an individualised physical health care plan as a result. 
Aim 
The aim of this research is to enable mental health nurses in secondary care to address 
the physical health needs of people with SMI by implementing a nurse-led structured 
physical health check and care planning process. 
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Methods  
This project used a programme of research to evaluate the impact of the HIP Programme 
on care processes and patient outcomes that included: 
1. A systematic review of the efficacy of educational interventions for healthcare 
professionals. 
2. Description of the development of the HIP Programme and a pilot study to test 
the clinical utility and effectiveness of the HIP Programme in 31 patients in a 
nurse-led outpatient clinic. 
3. A clinical audit of the use of the HIP in 108 patients. 
4. A cluster RCT of the HIP Programme across four National Health Service 
[NHS] sites. 
5. A process observation in a subsample of patient and nurse participants from 
the cluster randomised controlled trial. 
6. Evaluation of evidence of impact from national and international dissemination 
of the HIP and the HIP Programme. 
Results 
1. The systematic review identified that there was no evidence examining how to 
train healthcare professionals to deliver a structured health check for people with 
serious mental illness [SMI]. 
2. The pilot study identified that the HIP was acceptable to people with SMI and 
healthcare professionals and that two mental health nurses could successfully 
implement the HIP following brief training. 
3. The audit showed that it was possible to identify comorbidities in people with SMI 
using the structured health check in secondary care and that change in health 
behaviours and outcomes was possible. 
4. The cluster RCT in community mental health teams across four NHS sites 
demonstrated no difference in health outcomes between HIP Programme and 
Treatment As Usual [TAU] patients at 12 months. Despite acceptable levels of 
patient attrition in the trial, rates of implementation of the HIP by nurse participants 
was very low. 
5. The process evaluation highlighted the complexity of the processes we were trying 
to change. Barriers included service redesign and resource issues coupled with 
the time taken to complete the HIP and care plan. Nurse participants reported that 
they did not work with the same patients with SMI for long enough to follow 
through a (12 month) plan of physical health checks and intervention. There was a 
perception of structured physical health checks and care as a (new) extension to 
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an already pressured role where mental health risk assessment and management 
takes priority over physical health risk.  
6. The HIP is being used widely in practice but this is largely in inpatient services. 
Where it has been repeated at 12 months, improvements in some metabolic 
parameters have been seen. 
Discussion 
The need for better care for the physical health of people with SMIs is evident. This 
program of research developed a package of training and tool to support a structured 
health check and care planning process for people with SMI in secondary care. The 
cluster RCT did not demonstrate benefit on patient (quality of life) outcomes. Substantial 
structural barriers prevented the patients from receiving the intervention from the mental 
health nurses involved in the trial, despite the positive attitude of the nurse participants 
towards the importance of a physical health care role. Despite this disappointing finding 
the intervention is being used in practice across the United Kingdom [UK] and 
internationally with demonstrated benefits, including the achievement of commissioning 
targets for health screening and signs of improvement in some outcomes where it has 
been used in the same person over time. This programme of research demonstrates the 
challenge of conducting useful RCTs in rapidly changing service environments in the NHS. 
Future research should develop the intervention beyond the nurse and patient dyad to 
target the system barriers and levers to implementation.  
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THE AUTHOR 
I trained as a registered mental health nurse at St George’s Hospital School of Nursing 
and Springfield Hospital in South London, qualifying in 1986. I worked in a variety of 
community and hospital settings until 1993 when my daughter was born. After starting a 
part time degree I took up a post as Research Nurse in the Department of Psychiatry at 
the University of Hull Post Graduate Medical School in 1995, working with Professor Anne 
Mortimer. In this role I became interested in the contrast between the quality of medication 
management received by study participants compared to usual care. The focus of the 
research project for my degree dissertation was the role of the mental health nurse in 
medication management. Supported by a Florence Nightingale Research Scholarship, I 
conducted a survey of mental health nurses working in acute inpatient unites across Hull 
and East Yorkshire that demonstrated motivation for the role but a lack of education or 
support to achieve it. The local NHS Trust then funded me to implement a project to train 
nurses in medication management and set and audit standards for medication 
management. I contacted the three UK mental health nurse academics publishing in the 
area of medication management in mental health nursing at the end of the nineties, 
Richard Gray, Neil Harris and Joanna Bennett and I undertook Richard’s train the trainer 
Medication Management course in 1999. I obtained and adapted resources from two very 
generous people who were trying to make a difference; a neuropharmacologist who 
taught the first cohort of mental health nurse prescribers in Stafford and James Turner, a 
service manager in Sheffield who had implemented a medication management project in 
acute inpatient care known as ‘Medicines with Respect”. I worked with service users from 
Mind to evaluate the project. 
In 2000 I moved to work as a lecturer in clinical nursing at the University of Hull where I 
am now an Associate Dean in the Faculty of Health and Social Care. I set up a local 
medication management network to support the nurses I trained to implement their ideas 
for practice development and facilitated this for 8 years. In 2004, in recognition of a need 
for regional support I founded the M62 Network. As a result of collaboration through this 
network, a stepped approach to medication management nurse education is 
recommended and adopted by several HEEs and provider organisations across Yorkshire 
and Humber. 
I started my career in services that were transitioning from institutional to community care 
in the early 1980’s. Although there was much that was wrong in the old hospitals that I 
would never want to return to I witnessed the negative consequences of community care 
for many vulnerable people with psychotic diagnoses first hand. I thought I understood (or 
at least accepted) the focus of most mental health nurses work on the assessment and 
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management of the risk of violence and suicide. I suspected the so called “control-care 
paradox” within mental health care was working against the support of people with long-
term psychotic disorders to live long and fulfilling lives. Management of the risk of violence 
and suicide by its very nature focuses on immediate risk rather than in working over the 
longer term to support positive physical and mental health outcomes.  
I was personally motivated to do something to try and make a difference by the widening 
mortality gap between people with SMI and those in the general population. My students 
reported that early death from cardiovascular disease in their SMI patients was a far-too 
common experience that they felt uncomfortable about and wanted to change. I was not 
aware of any focus on the assessment of physical health risks in mental health nursing 
other than those tools designed to assess for the risk of falls in the elderly and the risk of 
loss of skin integrity (pressure sores). In adults, I was only aware of tools to assess 
medication side effects. There was a growing recognition of the need to address the 
unacceptable comorbidity and mortality in SMI in health policy and mental health nurse 
education standards. Students were required to demonstrate competency in areas of 
practice that qualified nurse mentors struggled with themselves.  
There were no physical health care texts in 2008 aimed at mental health nurses and 
information had to be drawn from a variety of sources. Survey research indicated that 
mental health nurses felt ill equipped in terms of knowledge but wanted to include physical 
health care in their work. I hoped that a knowledge and decision making tool in an 
accessible format would enable this to happen. 
.  
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Chapter One: Serious Mental Illness 
Mental health and illness 
Mental health is “a state of well-being in which the individual realises his or her own 
abilities, can cope with the normal stresses of life, can work productively and fruitfully, and 
is able to make a contribution to his or her community.” (World Health Organisation, 
2013a). Mental illness, also called mental or psychiatric disorder, is a diagnosable 
condition that significantly interferes with an individual's cognitive, emotional or social 
abilities. Mental and substance use disorders taken together account for about 7·4% of 
the global disease burden worldwide and were ranked 5th after the human 
immunodeficiency virus/acquired immunodeficiency syndrome [HIV/AIDS], tuberculosis, 
diabetes and transport injuries in the latest 2010 WHO survey (Whiteford et al.).  
Serious mental illness 
There are a number of different definitions of serious mental illness in the literature. The 
International Statistical Classification of Diseases and Related Health Problems 10th 
Revision [ICD-10] is the official classification system for diagnosis used by the majority of 
United Nations member states for epidemiological and quality assurance purposes and to 
compile national mortality and morbidity statistics (World Health Organisation, 2007). In 
this thesis the term serious mental illness [SMI] is used to denote adults over 18 years 
with an established diagnosis of either schizophrenia, schizoaffective or bipolar affective 
disorder according to ICD-10. 
Schizophrenia 
Schizophrenia is a persistent multidimensional disorder characterised by a range of 
symptoms that can be clustered into positive (psychotic), negative, cognitive and affective 
sets or dimensions (Van Os J et al., 2010). These symptoms are summarized in Figure 
1.1. These symptoms affect function in major areas of the person’s life such as occupation, 
relationships and self-care. They can be expressed differently in different individuals and 
in the same individuals over time.  
 
 
 
 
 
 
 22 
Figure 1:1 Symptom Domains of Schizophrenia 
 
Symptom Domain Examples 
 
Positive (psychotic) symptoms 
 
Delusions 
Hallucinations 
Thought disorder 
Distorted speech or behaviour 
Disorganised speech or behaviour 
Catatonic behaviour 
Agitation 
 
Negative symptoms Blunted affect 
Emotional withdrawal 
Poor rapport 
Passivity phenomena 
Apathetic social withdrawal 
Anhedonia 
Alogia 
Stereotypical thinking and behaviours 
 
Cognitive symptoms Problems with executive function e.g. 
problems directing and sustaining 
attention, difficulty prioritising and solving 
problems. 
Memory and learning problems 
 
Affective symptoms Depressed mood 
Anxious mood 
Guilt 
Tension 
Irritability 
 
 
 
 Adapted from (Stahl, 2000)  
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The heterogeneity of schizophrenia presents many challenges to clinicians and 
researchers leading to doubts about the existence of a unified underlying disease state, 
with some authors considering it a social construct ((Walker 2006, Szazs 1961)).  
Schizophrenia is classified as a mental or behavioral disorder in ICD-10 and allocated 
codes F20.0-F20.9 with nine potential subcategories depending on symptom clusters and 
course. These are paranoid, hebephrenic, catatonic, undifferentiated, post schizophrenic 
depression, residual, simple, other and unspecified. Similar disorders developing in the 
presence of organic brain disease or psychoactive substance intoxication are excluded. 
Please see Figure 2 for ICD-10 diagnostic criteria.  
The aetiology of schizophrenia is complex with a strong genetic influence hypothesised to 
interact with environmental risk factors. The hereditary component of schizophrenia is well 
established with a 48% risk of developing schizophrenia in monozygotic twins where one 
has the disorder. Risk in family members increases with the degree of biological 
relatedness (Gottesman, 1991). A shared familial environment cannot fully explain this as 
adoption studies indicate a similar prevalence to that in first degree relatives (Kety et al., 
1994). Environmental risk factors include developmental trauma and the exposure of the 
brain to chemicals and stress (particularly where there is neglect, abuse, victimisation 
and/or social exclusion) (van Os et al., 2010).  
A relatively low rate of new cases of schizophrenia over time (incidence) is reported. The 
most recent published systematic review and recalculation of 133,639 international cases 
by the Research Initiative into Schizophrenia Epidemiology [RISE] report a median value 
of 18.3 per 100,000 persons per year with a threefold higher rate in men, although when 
samples are stratified by age of onset the picture is complicated. An increased male 
incidence is detected in samples aged <40 years (Incidence rate ratio [IRR] 0.55, 
Interquartile range [IQR] 0.45-0.75), between 40 and 59 years no difference is detected 
and ≥ 60 years the trend becomes reversed with a greater incidence of new cases 
reported in women (IRR 1.55, IQR 0.92-2.19) (van der Werf et al., 2014). A rigorous 
systematic review of 188 studies covering 46 countries concluded that for every 1,000 
people in the international population a median of 4.6 will have the disorder at any specific 
time (point prevalence), 4 people will have received the diagnosis at some time and 7.2 
people risk developing it over their lifetime (lifetime morbid risk) (Saha  et al., 2005).  
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Figure 1:2 ICD-10 Diagnostic criteria for schizophrenia 
 
A minimum of one very clear symptom belonging to any one of groups 1-4 or 
symptoms from at least two of the groups 5-9 should have been clearly present 
for most of the time during a period  of one month or more 
Groups 
1 Thought echo, thought insertion or withdrawal and thought broadcasting 
2 Delusions of control, influence or passivity, clearly referred to body or limb 
movements or specific thoughts, actions or sensations: delusional 
perception. 
3 Hallucinatory voices giving a running commentary on the patient’s 
behaviour or discussing the patient among themselves, or other types of 
hallucinatory voices coming from some part of the body. 
4 Persistent delusions of other kinds that are culturally inappropriate and 
completely impossible, such as religious or political identity, or 
superhuman powers and abilities (e.g. being able to control the weather or 
being in communication with aliens from another world). 
5 Persistent hallucinations in any modality, when accompanied either by 
fleeting or half-formed delusions without clear affective content or by 
persistent over-valued ideas, or when occurring every day for weeks or 
months on end. 
6 Breaks or interpolations in the train of thought, resulting in incoherence or 
irrelevant speech, or neologisms. 
7 Catatonic behaviour, such as excitement, posturing or waxy flexibility, 
negativism, mutism and stupor. 
8 “Negative” symptoms such as marked apathy, paucity of speech and 
blunting or incongruity of emotional responses, usually resulting in social 
withdrawal and lowering of social performance; it must be clear that these 
are not due to depression or neuroleptic medication. 
9 A significant and consistent change in the overall quality of some aspects 
of personal behaviour, manifest as loss of interest, aimlessness, idleness, 
a self-absorbed attitude and social withdrawal. 
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Burden of disease is measured globally using Disability Life Adjusted Years [DALYs] that 
represents a sum of the years of life lost and the years living with a disability as a result of 
a condition or injury (Murray et al., 2012a). Despite schizophrenia being a relatively rare 
disorder, disease burden in DALYs is high. In 2010 schizophrenia accounted for 218 
DALYs per 100,000 population (95% CI 142-296) and the 43rd ranked leading cause of 
disability worldwide (Murray et al., 2012b). Of the other mental and behavioural disorders 
only major depression, anxiety disorders, drug use disorders and alcohol use disorders 
rank in the top 50 above schizophrenia (11th, 26th, 31st and 35th respectively).  
The annual economic burden of schizophrenia was estimated to be £6.7 billion in 2004/05 
in England (Mangalore and Knapp, 2007). Projection to 2011/12, costs increased this to 
£11.8 billion per year. Average societal costs of £60,000 were calculated (e.g. due to 
unemployment and early mortality) plus £36,000 to the public sector per person per year 
(Andrew et al., 2012). The largest proportion of the cost of treating schizophrenia relates 
to relapse and the cost of inpatient care (Hong et al., 2009).  
The high disease and economic burden of schizophrenia is probably linked to two 
important features: a) Onset and greatest deterioration usually occurs in early adulthood 
(Schultz et al., 1997) and therefore has a significant impact on occupational attainment, as 
well as the ability to form and maintain relationships; b) Despite treatment with medication 
with proven efficacy, approximately two-thirds of affected individuals continue to have 
symptoms (Kane, 1989). Positive and disorganised symptoms tend to improve over time 
but negative and cognitive symptoms may worsen, particularly in institutional 
environments and as a result of long-term treatment with most types of antipsychotic 
medication (Karim et al., 2005). A longer duration before treatment of the first episode and 
the number of relapses is correlated with worse outcomes (Lieberman et al., 1993). 
Negative and cognitive symptoms arguably have the greatest impact on function and 
disability. The pattern of worsening negative symptoms is more common in men across 
the life course, whereas in women this deterioration is observed to occur much later in life 
(Gur et al., 1996). 
Schizoaffective disorder 
Schizoaffective disorder is an episodic disorder in which both affective and schizophrenic 
symptoms are prominent but do not justify a diagnosis of either schizophrenia or 
depressive or manic episodes (World Health Organisation, 2007). It is allocated ICD-10 
codes F25.0-F25.2, F20.8 and F20.9 with five potential subcategories. These depend on 
the type of mood state that predominates and illness course (manic type, depressive type, 
mixed type, other and unspecified).  
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In what appears to be the only study to report the lifetime prevalence [LTP] of psychotic 
disorders separately using robust methods for diagnosis the Psychosis in Finland [PIF] 
Study identified participants from the Finnish Health 2000 (general population) survey. A 
representative sample of 8,028 persons ≥30 years of age were randomly selected using a 
2-stage stratified clustering method. Those screening positive for psychosis from this 
sample as a result of either self-report, semi-structured interviews, national hospital 
discharge and insurance registers, and/or case notes were reassessed using the research 
version of the Structured Clinical Interview for DSM-IV. A best estimate diagnosis was 
made by agreement of three psychiatrists and/or psychologists retrospectively using all 
available baseline data. This resulted in 692 people in the final best estimate diagnosis 
arm of the study. The results for schizophrenia (n=67) were similar to other prevalence 
estimates at 0.87 per 100,000 (95% CI 0.68-1.1) rising to 1% when non-responders were 
included. Lifetime prevalence for schizoaffective disorder (n=27) was 0.32 (0.21-0.46) and 
bipolar 1 disorder (n=20) 0.24 (0.16-0.37). Women were significantly more likely to have a 
diagnosis of schizoaffective disorder than men (p <0.05). When LTP was compared 
across age bands there were no men at all in the 30-39 year band for schizoaffective 
disorder.  
Bipolar affective disorder 
Bipolar affective disorder (also known as bipolar disorder or manic depressive disorder) is 
characterised by two or more episodes in which mood and activity levels are significantly 
disturbed causing significant personal distress or social dysfunction (World Health 
Organisation, 2007). There can be an elevation of mood, increased energy and activity 
(hypomania or mania) on some occasions and a lowering of mood, decreased energy and 
activity (depression) on others. Hypomania and mania are differentiated based on their 
effects on function with hypomanic symptoms often valued as positive by the person. 
Episodes can be predominantly in one direction or another (manic or depressed) or cycle 
between mood states. There are a number of types of bipolar affective disorders identified 
in ICD-10, see Figure 1.3 for a summary. In DSM-IV there is a differentiation of bipolar 
spectrum disorders into bipolar 1 disorder (where mania predominates or there is a history 
of at least one manic episode) and bipolar II disorder (where there is or has only been 
hypomania) (American Psychiatric Association, 1994). 
A recent systematic review of prevalence in adults identified 18 studies reporting lifetime 
prevalence ranging from 0.1 to 7.5% in bipolar disorder and 2.4 to 15.1% in the broader 
category of bipolar spectrum disorder (Dell'Aglio  et al.). The incidence of bipolar disorder 
is reported as 2.6 to 20.0 per 100,000 per year (Lloyd and Jones, 2002). In a further study 
where diagnostic criteria was applied prospectively to 75 patients from three UK NHS 
secondary care sites, the incidence was 4.0 per 100,000 population (95% CI 3.2-5.1) 
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(Lloyd et al., 2005). These differences may be related to the presence or absence of sub-
threshold criteria on diagnosis. Depressive symptoms are most likely to be presented to 
clinicians. Unless the presence/absence and frequency of hypomanic or manic symptoms 
are uncovered through specific enquiry, the risk of misdiagnosis is significant. 
Gender differences are largely found to be absent in prevalence studies of bipolar 
disorder with the exception of an increased lifetime prevalence in men, but only when 
manic presentation is differentiated from bipolar I disorder ((Szádóczky et al., 1998)). In 
bipolar II disorder the evidence is equivocal with some studies finding twice the lifetime 
prevalence of bipolar-II disorder and hypomania in women and others finding no 
difference at all between genders (Diflorio and Jones, 2010).  
Figure 1:3 ICD-10 Diagnostic criteria for bipolar affective disorders 
ICD-10    Diagnostic features 
Code 
F31.0 The current episode meets the criteria for 
hypomania. 
 
 
 
 
 
 
AND for each there has 
been at least one other 
affective episode in the past, 
meeting the criteria for 
hypomanic or manic 
episode, depressive episode 
or mixed episode. 
F31.1 The current episode meets the criteria for 
mania without psychotic symptoms. 
F31.2 The current episode meets the criteria for 
mania with psychotic symptoms. 
F31.3 The current episode meets the criteria for 
a depressive episode of either mild or 
moderate severity. 
F31.4 The current episode meets the criteria for 
a severe depressive episode without 
psychotic symptom. 
F31.5 The current episode meets the criteria for 
a severe depressive episode with 
psychotic symptom. 
F31.6 The current episode is characterised by 
either a mixture or a rapid alteration (i.e. 
within a few hours) of hypomanic, manic 
ands depressive symptoms. Both manic 
and depressive symptoms must be 
prominent most of the time over at least 
two weeks. 
 
Age of onset is thought to peak in late adolescence, a time when diagnosis is difficult and 
may be actively avoided. Early onset patients that present with depression face a 
considerable time-delay before first diagnosis. In one survey of 600 people with a 
diagnosis of BPD, one third reported they had sought professional help within a year of 
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the first onset of symptoms with 69% (414) receiving an incorrect diagnosis (most 
frequently unipolar depression). Just over a third reported waiting 10 years or more before 
receiving an accurate diagnosis (Hirschfeld et al., 2003). It has been suggested that 
between a half and two thirds of all unipolar depression diagnoses are bipolar II disorder 
(Akiskal et al., 2000). Substance and alcohol misuse is also highly prevalent and 
highlights another example where the presenting ‘problem’ becomes the primary 
diagnosis. There is also considerable crossover between bipolar disorder (particularly 
cyclothymia) and borderline personality disorder.  
A strong link between postpartum psychosis (that typically occurs in the first month after 
childbirth) and bipolar disorder is increasingly becoming evident, blurring diagnostic 
boundaries. The risk of developing postpartum psychosis is substantially increased in 
women with bipolar disorder, particularly where there is family history of postnatal bipolar 
episodes (Jones and Craddock, 2001).  
Like schizophrenia, the aetiology of bipolar disorder is thought to include a genetic 
predisposition that interacts with environmental and neurodevelopmental risk factors. The 
annual socioeconomic burden of bipolar disorder in the UK was estimated to be £2 billion 
in 1991-2000. Ten percent of this cost is attributable to NHS resource use, 4% to non-
health-care resource use and 86% to indirect costs (Das Gupta and Guest, 2002). The 
authors of this study used a prevalence estimate of 0.5% (297,000 people with the 
disorder), towards the lowest end of the range reported in the literature. Although it is not 
possible to compare this study directly with those in schizophrenia, the difference is 
striking. This could reflect a variety of factors and/or differences between the two 
disorders. It could be due to the low rates of diagnosis and treatment resulting in a much 
lower cost of medication and inpatient treatment in bipolar disorder. It could reflect a bias 
on the societal and health costs of mania, where the costs of bipolar depression are more 
hidden. The costs of comorbidity were not included although this is likely to be 
considerable, particularly that related to drug and alcohol use. It could reflect a lower cost 
due to the different treatment course that sometimes (but not always) leaves people 
cognitively intact and able to function, work and maintain relationships between episodes. 
Chapter Summary 
Schizophrenia and schizoaffective disorders are rare. The prevalence of bipolar affective 
disorder is less certain. All three disorders have a very high socioeconomic and disease 
burden due to their early age of onset, symptom course, management and associated 
comorbidities.  
 29 
Chapter Two: Physical comorbidity in serious mental illness 
There is a greater prevalence of a range of physical comorbidities in SMI with the highest 
prevalence reports in schizophrenia. This could be a feature of the studies focussing 
exclusively on this population and/or the smaller sub-group sample sizes nested within 
broader SMI datasets. There are no studies into comorbidity in schizoaffective disorder 
alone, but studies into bipolar spectrum disorders have increased in recent years. Two 
cross-sectional studies of primary care records for approximately a third of the population 
in Scotland demonstrated a significant association of having at least one comorbidity with 
schizophrenia (OR 1.21, 95% CI 1.16-1.27) and bipolar disorder (OR 1.27, 95% CI 1.16-
1.39) with greater odds for multiple comorbidities in both disorders (Smith et al., 2013a, 
Smith et al., 2013b). 
Comorbidities where there is evidence of increased prevalence or incidence in SMI are 
organised by their SOC and are summarised in Table 1. They are discussed in this 
chapter and where comorbidity can be classified in more than one SOC, this is indicated 
in the table. Risks are discussed in detail later but where the comorbidity is largely 
explained by the risk factors these are introduced here. 
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Table 2:1 Physical comorbidity by system organ class 
System organ class Schizophrenia Bipolar affective disorder 
Infections and 
infestations 
Tuberculosis 
Pneumonia  
Hepatitis B and C** 
HIV** 
Hepatitis C** 
HIV** 
Neoplasms Colon cancer (+/-) 
Breast cancer (+/-) 
 
Immune system 
disorders 
HIV** HIV** 
Psoriasis 
Rheumatoid arthritis (+/-) 
Inflammatory Bowel Disease 
(+/-) 
Endocrine disorders Hyperprolactinaemia* 
 
Thyroid disease 
Metabolism and 
nutrition disorders  
Metabolic syndrome 
Obesity, hyperlipidaemia, 
diabetes mellitus. 
Metabolic syndrome 
Obesity, hyperlipidaemia, 
diabetes mellitus. 
Nervous system 
disorders  
Cerebrovascular disease 
Epilepsies  
Parkinson’ s 
disease/parkinsonism 
Neuroleptic Malignancy 
Syndrome* 
Cerebrovascular disease 
Epilepsies  
Parkinson’ s 
disease/parkinsonism 
Eye disorders Blindness or low vision 
Ocular adverse effects* 
Blindness or low vision 
Ocular adverse effects* 
Ear and Labyrinth 
disorders 
Severe hearing loss  
Cardiac disorders Angina symptoms 
Sudden cardiac death 
 
Vascular disorders Peripheral vascular disease 
Cerebrovascular events 
Hypertension  
 
 
Cerebrovascular events 
Hypertension 
Respiratory disorders Impaired lung function 
Chronic obstructive pulmonary 
disease 
Asthma 
 
Chronic obstructive pulmonary 
disease 
 
Gastrointestinal 
disorders 
Poor oral and dental health 
Constipation 
Inflammatory Bowel Syndrome 
Poor oral and dental health 
Constipation 
Inflammatory Bowel Syndrome 
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System organ class Schizophrenia Bipolar affective disorder 
Hepatobilary 
disorders 
Hepatitis B/C** Hepatitis B/C** 
Skin and 
subcutaneous tissue  
 Psoriasis* 
Musculoskeletal and 
connective tissue 
disorders 
Osteoporosis/decreased 
mineral bone density 
 
Renal and urinary 
disorders 
Dehydration 
Polydipsia 
 
Dehydration 
Chronic kidney disease 
End stage renal disease* 
Pregnancy, 
peurperium and 
perinatal disorders 
Obstetric complications 
Gestational diabetes (+/-) 
Abnormal foetal growth 
Obstetric complications 
 
Low birth weight, 
Congenital birth defects* (+/-) 
Reproductive system 
and breast disorders 
Hyperprolactinaemia* 
Galactomastia, galactorrhea* 
Menstrual problems (women)* 
Arousal and orgasm problems 
(men)* 
Low libido (men and women) 
Low birth rate 
 
 
 
 
 
 
 
Low birth rate 
General disorders  Neuropathic or psychogenic 
pain 
Musculoskeletal, neuropathic 
or neurogenic pain 
Italics indicates comorbidities that are discussed in another system organ class 
* = evidence from medication studies alone 
** = only occurs where there is concurrent substance use  
+/- = discrepant results 
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Infections 
Bacterial infections 
Before the closure of large institutions, respiratory bacterial infections such as tuberculosis 
and pneumonia were the largest causes of mortality in SMI (Leucht et al., 2007). There 
are two reports of an increased prevalence of tuberculosis in schizophrenia from 
epidemiological studies of case registers in Nagasaki city and Oxford in the 1960’s and 
1970’s (Ohta et al., 1988, Baldwin, 1979). Baldwin et al. identified an increased 
prevalence in patients before their admission to hospital but reports of increased 
incidence in single studies since the 1970’s have all been associated with institutional or 
group-living environments ((Cavanaugh et al., 2012)).  
Viral infections 
There have been a number of reports of an increased prevalence of HIV in people with a 
very broad range reported in different epidemiological studies: 1.3- 2.9%, compared to 
0.6% in the global population (Leucht et al., 2007). Authors reporting the highest and 
lowest prevalence statistics may have accessed higher or lower risk samples by studying 
predominantly urban or rural populations. A failure to adjust estimates for confounding 
demographic, lifestyle and socioeconomic risks (e.g. ethnicity, substance use, unsafe 
sexual practices, poverty) and/or low levels of HIV testing in SMI are also likely to have 
contributed to this variability. Interestingly, in bipolar disorder where substance use, 
hypersexuality and increased risk taking are features of the illness, increased prevalence 
for HIV has not been separately identified, although a general increase in the prevalence 
of sexually transmitted diseases has (Jones et al., 2004). One well conducted case record 
linkage study that drew SMI samples equally from populations known to be at high and 
low risk found 8 times the US general population prevalence(Rosenberg et al., 2001).. 
Importantly they found 75% of HIV positive individuals had a co-current substance use 
disorder More recently increased prevalence of HIV in SMI has been identified in dual 
diagnosis of SMI and substance use/dependence at levels that explain the risk (2.1 and 
2.5 more likely respectively) and a much lower prevalence than the general population 
when substance use is absent (Prince et al., 2012). 
Viral hepatitis is one infectious disease where increased rates above those in the general 
population have consistently been reported in SMI. In cross sectional surveys of primary 
care case records representing one third of the Scottish population, viral hepatitis was the 
highest recorded comorbidity for both schizophrenia and bipolar disorder (Smith et al., 
2013a, Smith et al., 2013b). In the same case record linkage study in SMI discussed 
above rates of hepatitis B [HBV] were 5 times the US general population prevalence rate 
and hepatitis C [HBC] was 11 times more prevalent (Rosenberg et al., 2001). The much 
higher rate in HCV supports a strong link with substance use (particularly intravenous and 
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inhaled drug use) as HCV has the highest incidence of person-to-person transmission of 
any blood born virus (Garfein et al., 1996).  
Neoplasms 
There have been contradictory findings from studies into cancer in SMI, with some 
authors finding significantly increased prevalence rates, while others do not and some 
report less prevalence (De Hert et al., 2011b). Much of the evidence is weakened by small 
samples of convenience (e.g. hospital cohorts) and a failure to control for important 
potential confounding variables. There is some evidence for an increased prevalence of 
colorectal cancers (particularly colon cancer) in schizophrenia but evidence for breast 
cancer, cervical cancer and lung cancer is equivocal. Prostate cancer has consistently 
been found to have approximately 50% less incidence in schizophrenia than in the 
general population in hospital cohorts leading to speculation about inherent protective 
factors of the disorder or it’s treatment (Dalton et al., 2005, Grinshpoon et al., 2005, 
Mortensen, 1994). In bipolar disorder there is no evidence for increased prevalence of any 
single cancer. Three large cross sectional studies of primary care records in the UK found 
no increased incidence of recorded diagnosis of any cancer in schizophrenia or bipolar 
disorder (Osborn et al., 2013, Smith et al., 2013b, Smith and Roberts, 2006). Lifestyle risk 
factors (e.g. smoking, obesity, alcohol use, HCV infection) would theoretically increase the 
rates of cancers, as would some adverse effects of medication. However, low levels of 
diagnosis and mortality from diseases that develop earlier in the patient’s lifecycle (e.g. 
cardiovascular disease) may be important. One nested case-control study from a large 
primary care UK dataset that did find a significantly increased incidence of colon cancer in 
schizophrenia reported a high mean age of diagnosis in cases and controls (72 years) 
(Hippisley-Cox et al., 2007). 
Blood and lymphatic system disorders 
Blood dyscrasias can arise as result of adverse effects of many psychotropic medications 
but do not feature in the comorbidity literature. 
Immune system disorders 
There have been some reports of autoimmune inflammatory (rheumatoid) arthritis and 
inflammatory bowel diseases associated with bipolar disorder and, in contrast, a negative 
association with schizophrenia (Mors et al., 1999, Birgenheir et al., 2013). A number of 
studies have identified a lower prevalence of inflammatory arthritis and diverticular 
disease in people with schizophrenia than in general population controls. (Smith et al., 
2012a; Smith et al., 2013b; Mors et al., 1999). However, prevalence of both these 
comorbidities was roughly equal to the general population controls in bipolar disorder 
(Mors et al., 1999). It has been suggested that antipsychotic medication may have anti-
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inflammatory properties that explain the reduced risk in schizophrenia but these findings 
are still surprising when one considers the effects of obesity on development and 
prognosis of both conditions. In study of obese subjects with bipolar disorder from the 
National Epidemiologic Survey on Alcohol and Related Conditions [NESARC] in the US, 
obesity at baseline was positively associated with new diagnosis of arthritis (OR = 1.64, 
95% CI: 1.07–2.52), although osteoarthritis was not differentiated from rheumatoid arthritis 
(Goldstein et al., 2013). It seems more likely that the case register studies highlight low 
rates of diagnosis. 
Endocrine disorders 
Investigations of thyroid hormone levels for differential diagnosis are routinely made in 
SMI. There is a long association of bipolar disorders with thyroid disease among clinical 
and epidemiological populations (Chakrabarti, 2011). An overlap in symptom expression 
and contribution of thyroid hormone dysregulation to the aetiology, course and expression 
of symptoms, alongside the development of comorbidities such as obesity, metabolic 
syndrome and cardiovascular disease makes the hypothalamo-pituitary-thyroid (HPT) axis 
an important focus for investigation in all psychotic disorders.  
 Metabolism and nutrition disorders 
The metabolic syndrome is a cluster of cardiovascular risk factors including hypertension, 
central (abdominal) obesity, dyslipidaemia, insulin resistance and glucose intolerance 
(International Diabetes Federation, 2006). Prevalence of MetS varies globally with 
differences between ethnicities, genders and with increasing age, with prevalence rates 
ranging between 14.4%-31.8% (NCEP Expert Panel on Detection, 2002), (Ford et al., 
2002, Tillin et al., 2005) .With the rise of obesity and diabetes mellitus across the world, a 
corresponding increase in these rates seems inevitable. 
Metabolic syndrome has a complex aetiology but lifestyle factors such as smoking, diet, 
medication, hereditary factors and social deprivation are all recognised as important. 
Prevalence of MetS using ATP III definition is reported, from the most recent meta-
analyses, as 32.8% in schizophrenia (N = 80 studies, n = 17005 patients, 95% CI = 
30.0%–35.7%) and 29.9% in bipolar disorder (N=18, n=2,204; 95% CI=28.0–31.9) 
(Mitchell et al., 2011, Vancampfort et al., 2013b). When the results of studies that 
matched SMI patients to controls were analysed by the same authors, around two and a 
half times the general population prevalence in schizophrenia was identified and twice as 
many in bipolar disorder. It is not possible to directly compare prevalence between the two 
disorders as there was no adjustment for age or gender. However a lower prevalence of 
MetS at the beginning of the treatment course was identified that may be an important 
signal of the metabolic risks of treatment. This is supported by meta-analyses of untreated 
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and first episode patients with schizophrenia that showed rates of MetS of around 10%, 
similar to prevalence in the general population (Mitchell et al., 2012) 
In the recent MetS meta-analyses hypertension prevalence was reported at 38.7% in 
schizophrenia (N = 72; n = 18 657, 95% CI = 35.6%–41.9%) and 47.1% in bipolar disorder 
(N=72, n=2,615; 95% CI = 45.3–48.9). In Scottish primary care record studies, 
hypertension was the most commonly recorded diagnosed physical condition for 
schizophrenia (16%) and bipolar disorder (17.5%) although significantly less than in the 
control cases (Smith et al., 2013a, Smith et al., 2013b). The low prevalence identified 
appears to point to low rates of diagnosis.  
There is an increased risk of weight gain and central (abdominal) obesity in SMI and this 
has been observed in untreated populations and throughout the treatment course. Weight 
is expressed as body mass index [BMI] = weight/height2 that indicates normal, overweight 
and clinically obese individuals adjusted for age, gender and (ideally) ethnicity (World 
Health Organisation, 2013b). Meta-analyses of SMI patients from 8 studies that used the 
International Diabetes Federation [IDF] waist circumference criteria reported central 
obesity prevalence of 44.4% in schizophrenia (N= 263, 95% CI = 32.3%–56.8%) and 
61.0% in bipolar disorder (N=224; 95% CI = 51.9–63.4) (Mitchell et al., 2011, Vancampfort 
et al., 2013b). This represents 2-2.5 times the prevalence of 23.7% in men and 26.3% in 
women in the UK general population (World Health Organisation, 2010). 
Cholesterol is a waxy substance (fat) made by the liver and contained in some foods with 
a function in the manufacture of vitamin D, some hormones and bile, which is transported 
in the blood by specific proteins or lipids. Low-density lipoprotein [LDL] carries cholesterol 
from the lymph following digestion to the liver and fat cells. High-density lipoprotein [HDL] 
transports cholesterol from the liver for excretion in bile and faeces. Triglycerides are 
esters that perform the same function as LDL (transportation of dietary fat) but also 
transport glucose. If the ratio of LDL to HDL is too high, cholesterol is deposited in the 
walls of blood vessels, increasing the risk of atherosclerosis, heart disease and stroke. 
This same risk is associated with high triglycerides. Triglycerides are a major component 
of LDL although the exact relationship between them is not fully understood.. Rates for 
low HDL in schizophrenia have been reported as 42.6% (N = 76, n =19 280, 95% CI = 
39.3%–46.0%) and, in bipolar disorder as 42.1% (N=1,861 in 17 studies; 95% CI = 40.5–
43.7. The same prevalence rate was reported for hypertriglyceridemia in both disorders 
(39.3%) although the number of studies pooled for the schizophrenia meta-analysis was 
much greater (n=77:n=18) (Mitchell et al., 2011, Vancampfort et al., 2013b). In one UK 
cross sectional prospective screening study of 75 primary care patients with schizophrenia, 
significantly higher rates of dyslipidemia were identified independent of BMI and 
antipsychotic medication (Osborn et al., 2006). 
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Diabetes mellitus results from a failure of pancreatic beta-cells to compensate in insulin-
resistant individuals. Insulin resistance is a vital marker of the development of DM, 
particularly important as treatment can be effective in the pre-diabetes phase whereas 
once DM has developed the only strategy is management. Glucose intolerance indicates 
an elevated blood glucose level that is not as high as that required for a definitive 
diagnosis of diabetes. The function of insulin is to allow cells to use glucose, fats and 
amino acids for energy. When there is high blood glucose, the body compensates by 
producing insulin with the opposite mechanism, maintaining homeostasis. When blood 
glucose is elevated over time this mechanism can become disrupted. Cells develop 
resistance to insulin leading to raised blood glucose (hyperglycaemia), hyperlipidaemia, 
hypertriglyceridemia and the development of ketone bodies. Eventually (in DM) pancreatic 
beta cells stop producing insulin. Prevalence of hyperglycaemia (at the same level used 
by NICE to indicate the need for investigation) was 19.5% (N = 47, n = 13784, 95% CI = 
16.9%–22.2%) in schizophrenia and 11.4% in bipolar disorder (N=8, n=2,204; 95% CI = 
9.4–13). Rates of DM were 10.9% in schizophrenia (N = 14, n = 2186, 95% CI 7.0%–
15.5%) but prevalence was not reported in the bipolar disorder meta-analysis (Mitchell et 
al., 2011, Vancampfort et al., 2013b). Diabetes prevalence was significantly higher than in 
controls in recent Scottish primary care record studies for both schizophrenia (9% vs 5.2% 
p <0.001) and bipolar disorder (8.4% vs 5.3% p <0.001) (Smith et al., 2013a, Smith et al., 
2013b). Diabetic ketoacidosis [DKA], a potentially fatal consequence of untreated or 
poorly managed diabetes, may be the first indication of DM. Just over ten times the 
general population incidence of DKA was reported in patients with schizophrenia 
prescribed atypical antipsychotics (Henderson et al., 2007).  
Nervous system disorders 
Epilepsies are a group of conditions characterised by recurrent and usually unpredictable 
seizures caused by either genetic or environmental factors (e.g. brain trauma). Active 
epilepsy has a general population prevalence of between 4-10 per 1,000 people 
worldwide (World Health Organisation, 2012). A significantly higher prevalence of epilepsy 
than in general population controls has been reported in schizophrenia, bipolar 
depression and (to a lower extent) in mania but causation is unclear (Leucht et al., 2007, 
Mazza et al., 2007).  
Extrapyramidal side effects of antipsychotic medications (dystonia, dyskinesia and 
akathisia) are difficult to differentiate from Parkinson’s disease. Dyskinesias have been 
shown to be prevalent in untreated schizophrenia and treatment with dopamine 
antagonists (antipsychotics) can lead to tardive dyskinesias (Cunningham-Owens, 1999). 
In the most recent primary care records studies, extrapyramidal side effects were not 
extracted from diagnoses read code data and this may explain the high prevalence of 
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‘Parkinson’s Disease’ diagnoses in schizophrenia (OR 3.07, 95% CI 2.42-3.88) and 
bipolar disorder (OR 3.05, 95% CI 1.83-5.09), and the narrower confidence interval in 
schizophrenia (Smith et al, 2013a, Smith et al, 2013b). It was the third most common 
recorded comorbidity in both studies.  
Neuroleptic malignancy syndrome [NMS] and serotonin syndrome [SS] are rare but 
potentially fatal adverse effects of antipsychotic medicines, selective serotonin reuptake 
inhibitors and street drugs (e.g. 3,4-methylenedioxy-N-methylamfetamine [MDMA]). They 
increase in incidence with polypharmacy (including adjuvant lithium treatment) and dose 
escalation, and share similar neurological, autonomic and hyperpyrexia symptoms 
(Haddad and Dursun, 2008).There is also a rare and potentially fatal adverse effect of 
anticonvulsants with neurological symptoms (anticonvulsant sensitivity syndrome [ASS]) 
but this seems to have only been studied in populations with epilepsy (Knowles et al., 
1999). The majority of published literature into SS, NMS and ASS consists of case reports, 
case-control studies and retrospective reviews, so prevalence data is not available. NMS 
has the most extensive literature and a recent review reported incidence had dropped 
from a rate of 3% to between 0.01-0.03% in the literature since 2007 (Margetic and 
Margetic, 2010). It appears likely that earlier recognition and intervention and improved 
prescribing patterns have reduced the incidence.  
Eye disorders 
Leucht et al (2007) did not find any reference to an increased prevalence of the 
comorbidity of eye disorders in their comprehensive literature review but a significantly 
increased incidence of blindness or low vision was identified in Scottish primary care 
register studies (OR 1.44 in schizophrenia and 1.58 in bipolar disorder) (Smith et al., 
2013a, Smith et al., 2013b). A whole range of ocular adverse effects from dry eyes to 
retinopathy have been identified in a review of medications commonly used in SMI (Richa 
and Yazbek, 2010).  
Ear and Labyrinth disorders 
There is a long association between deafness and psychotic disorders and how functional 
disorder of the inner ear may be associated with hallucinatory and perceptual disturbance. 
There are no reports of increased prevalence of ear disorders from the meta-analyses in 
SMI, but one large epidemiological study that linked psychosis registers with army 
conscripts in Sweden reported a 1.8 greater prevalence of severe hearing loss in 
schizophrenia (David et al., 1995). A higher incidence (by a factor of 1.4 after adjustment 
for age) is reported in primary care schizophrenia cases in the UK (Smith et al., 2013a). 
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Cardiac disorders 
CHD (also called ischaemic heart disease or congestive heart disease) is associated with 
atherosclerosis in the arteries and veins of the heart. This may lead to heart failure and/or 
angina but can be asymptomatic. Myocardial infarction (where the blood supply to the 
heart is interrupted) is an acute and often fatal result. Coronary heart disease [CHD] and 
cerebrovascular disease together make the largest contribution to mortality worldwide 
from CVD representing 25% of all deaths reported in 2010 (Lozano et al., 2012). Rates 
have been rising in the developing world and where socioeconomic deprivation limits 
access to healthcare, while preventative health schemes in the developed world are 
lowering risk (e.g. smoking cessation programmes). However in SMI in the developed 
world a lower than expected incidence of CVD and its risk factors (other than smoking) 
points to unacceptably low levels of diagnosis and treatment.  
In the Smith et al (2013a, 2013b) case register studies, heart failure was no more 
prevalent for schizophrenia or bipolar disorder and CHD and atrial fibrillation was 
significantly lower than in the general population sample for schizophrenia. There was no 
significant difference in either for bipolar disorder. Symptoms of angina and possible 
myocardial infarction [MI] were investigated in a prospective, observational study of a 
community sample of 482 patients with schizophrenia across 6 UK sites and compared 
with UK health survey controls (Filik et al., 2006). There were significantly more reported 
angina symptoms over the last two years than in the general population sample, but no 
significant difference in symptoms predictive of an MI. The risk of angina remained after 
adjusting for age and lifestyle risk factors OR 2.17 (95% CI 1.35, 3.47). A relative risk of 
MI of between1.7 – 4.5 has been reported in major affective disorders but none of the 
studies reviewed by these authors investigated a bipolar disorder sub-group (De Hert  et 
al., 2011). 
Cardiac arrhythmia is any disorder of the heart rate or rhythm (Ames et al., 2002). It may 
be asymptomatic or present as dizziness, fainting and bradycardia. Although rare, it is 
potentially lethal as it can result in a form of ventricular tachycardia leading to sudden 
cardiac death [SCD] (Snowden, 2008). Potential causes include antipsychotic medication, 
tricyclic antidepressants, and medicine interactions (e.g. with antibiotics) (Correll et al., 
2009). Inpatients with schizophrenia are reported to be three times as likely to experience 
SCD as individuals from the general population (Appleby et al., 2000, Ruschena et al., 
1998). In a review of four studies, patients prescribed antipsychotics were reported to 
have higher rates of MI or ventricular arrhythmias than controls with ratios ranging from 
1.7 to 5.3 (Koponen et al., 2008). There is evidence from recent research that altered 
autonomic function of the heart is associated with both psychopathology and metabolic 
profiles in schizophrenia. A negative correlation between positive symptoms and cardiac 
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vagal control was identified in a case control study of un-medicated acute inpatients 
(N=314) and a correlation between negative symptoms, metabolic parameters and heart 
rate variability was identified in a study by the same research team (N=94) (Chang et al., 
2013, Chung et al., 2013). A known gene variant in schizophrenia has also been 
associated with records of 340 SCD cases in Oregon in the US (Huertas-Vazquez et al., 
2013). 
Vascular disorders 
Peripheral vascular disease [PVD] usually refers to occlusion of blood vessels in the limbs 
due to artherosclerosis and/or embolism. Symptoms include pain, ischaemia and 
ulceration and can result in considerable disability and sometimes amputation. 
Symptomatic and asymptomatic peripheral vascular disease is a powerful independent 
predictor of CHD and cerebrovascular events (Golomb et al., 2006). Cerebrovascular 
events (stroke) can be either ischaemic or haemorrhagic. Ischaemic stroke is due to 
occlusion of blood vessels in the brain by an embolism or atheroma and haemorrhagic 
stroke occurs when the walls of the blood vessels are weakened and leak or rupture 
under pressure.  
In the two recent case register studies in Scotland by Smith et al (2013a, 2013b) no 
significant difference was found between either disorder and general population controls 
for PVD or stroke. However, in the narrative review by De Hert et al (2011) a 1.5-2.9 fold 
increase of stroke in schizophrenia was reported (from 6 studies) and a 2.1-3.3 higher risk 
in bipolar disorder (2 studies).  
Respiratory disorders 
Respiratory symptoms were reported more often in the Filik et al (2006) prospective 
observational study with breathlessness, phlegm production and wheeze significantly 
higher in people with schizophrenia and schizoaffective disorder than in the national 
sample. Lung function was also significantly impaired, 41.9% had low lung function 
compared with only 9% in the general population sample. Chronic obstructive pulmonary 
disease (COPD) is progressive, strongly associated with smoking and results in 
considerable disability and heart failure as respiration and oxygenation becomes 
increasingly impaired. It effects 4.8% of the global population (Vos et al., 2012), but a 
significantly higher prevalence of 6% and 6.6% was identified in schizophrenia and bipolar 
disorder respectively, almost twice the rate in the control sample (Smith et al 2013a, 
2013b). Self-reported COPD rates in SMI patients in the US are much higher (22.6%) than 
in control samples (Himelhoch et al., 2004). 
Asthma is a common disorder of the airways, caused primarily by inflammatory processes 
and constriction of the smooth muscle in airway walls (bronchoconstriction). Symptoms 
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include wheezing, breathlessness, chest tightness and coughing. Symptoms can triggered 
by viral respiratory infections, exercise, smoke, cold, and allergens (e.g. pollen) and can 
be fatal. The lifetime prevalence of diagnosed asthma in England is estimated to be 16% 
in women and 13% in men (Department of Health, 2001). In studies where community 
patients were matched with general population samples, a significantly higher prevalence 
of asthma diagnosis in schizophrenia has been reported e.g. (Sokal et al., 2004, Smith et 
al., 2013a).  
Gastrointestinal disorders 
Dental caries and periodontal inflammation and disease is associated with diabetes 
mellitus, cardiovascular disease (e.g. endocarditis) and systemic infections (e.g. 
pneumonia) (Li et al., 2000). Poor oral and dental health is linked to many lifestyle risk 
factors prevalent in SMI and the planning and self-care required to optimise dental health 
may be impaired by cognitive and negative symptoms. Psychotropic medication may 
increase the risk of dental caries by increasing acidity and flow of saliva. A high incidence 
of poor oral health and dental status has been identified in SMI inpatients in a number of 
studies (Friedlander and Birch, 1990, Tang et al., 2004, Kilbourne et al., 2007, Bertaud-
Gounot et al., 2013). Pain, halitosis, tooth discoloration and loss may result and contribute 
to poor self-esteem, stigma, and social exclusion. 
Constipation can result from poor fluid intake, poor diet and low levels of physical activity. 
It is a common side effect of a variety of prescribed medications (such as antipsychotics 
and antidepressants). If left untreated, constipation can lead to bowel obstruction, 
intestinal ischemia, perforation and even death (De Hert et al., 2011c). Constipation is one 
of the symptoms of irritable bowel syndrome [IBS], a functional disorder of the gut that 
effects 14% of the general population (95% CI: 12-17%). IBS increases with age and 
lower socioeconomic status and is twice as common in women (Suares and Ford, 2011). 
IBS is more prevalent in major mood disorders and the most common gastrointestinal 
complaint in primary care (Weinryb et al., 2003). In Scottish primary care register studies, 
constipation was significantly more prevalent in schizophrenia (OR 3.24, 95% CI 3.00 – 
3.49) and bipolar disorder (OR 3.37, 95% CI 2.93-3.88) and was the second most 
prevalent comorbidity after viral hepatitis for both disorders (Smith et al, 2013a, Smith et al 
2013b). A diagnosis of IBS was less prevalent but still statistically significant in 
schizophrenia and bipolar disorder. It is worth noting that symptoms of IBS (constipation, 
diarrhoea and bloating) are also symptoms of withdrawal from a variety of substances 
(and alcohol) that may reflect comorbid substance and alcohol use or intermittent 
adherence to prescribed medicines. 
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Hepatobiliary disorders 
HBV and HCV can be classified as infection and hepatobiliary SOCs but were discussed 
under infections. 
Skin and subcutaneous tissue disorders  
Psoriasis is a common autoimmune inflammatory skin disorder that can be triggered in 
genetically predisposed individuals by stress, infection, skin injury and certain medicines 
(Lowes et al., 2007). Diabetes mellitus, hypertension, cardiovascular disease and lifestyle 
factors have all been associated with psoriasis, as has depression (Griffiths and Barker, 
2007). Exacerbation of psoriasis is one of many possible cutaneous adverse effects of 
lithium. An increased incidence of new presentations and exacerbation of existing 
psoriasis has been reported in bipolar disorder, all associated with lithium treatment 
(Jafferany, 2008).  
Musculoskeletal and connective tissue disorders 
Osteoporosis (OP) and osteoarthritis (OA) are two common age-related skeletal disorders. 
OP is characterised by low bone mineral density and fragility, leading to an increased 
susceptibility to fractures and OA results from cartilage loss and bone remodelling. An 
inverse relationship between OP and OA has been identified (Ichchou et al., 2010). Both 
OP and OA are thought to include genetic, environmental, metabolic and endocrine 
factors and are strongly associated with obesity and in women with hormone changes 
after the menopause (Garner et al., 2013). In the WHO Global Burden of Disease 2010 
epidemiological survey the prevalence of the most commonly diagnosed OA (of the knee) 
was reported as 3.6% in the general population (2.6% in males and 4.7% in females), the 
11th highest cause of disability worldwide (Vos et al., 2012). An increased prevalence was 
recently identified between metabolic syndrome risk factors and OA of the spine in a 
recent surgical sample of convenience OR 3.9 [1.4-11.6], P < 0.01, n=1502 (Gandhi et al., 
2014).   
Two reviews have identified a number of studies reporting OP or low bone mineral density 
in schizophrenia (Leucht et al., 2007) and in schizophrenia and major affective disorders 
but not bipolar disorder alone (De Hert  et al., 2011). Lifestyle risk factors are undoubtedly 
important but there are also studies into medication adverse events that report increased 
prevalence of OP and fractures with hyperprolactinaemia and medicines selective for 
serotonin. Selective serotonin re-uptake inhibitors [SSRI] antidepressants were reported 
to have a dose-responsive relationship and the greatest risk of OP fractures in a meta-
analysis of psychotropic medicine trials (Takkouche et al., 2007). However the small 
numbers of studies available for the sub-group analyses and publication bias of adverse 
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event data makes generalisation of these results problematic. In the Scottish primary care 
record studies neither OP nor OA were reported as raised in SMI populations. 
Renal and urinary disorders  
Dehydration has been reported in patients admitted to hospital with acute psychosis and 
there are numerous reports of polydipsia due to excessive water intoxication (rather than 
polyuria) in inpatient populations. One review estimated a prevalence of 5% (de Leon et 
al., 1994). Low fluid intake, excessive sweating or vomiting and diarrhoea and polyuria (a 
symptom of diabetes) may result in dehydration (Ruxton, 2012). Both dehydration and 
polydipsia may result in electrolyte imbalances and, if untreated, have serious 
cardiovascular and neurological consequences. Chronic dehydration increases the risk of 
urinary tract infections and kidney failure and chronic polydipsia may damage renal tube 
function. 
The prevalence of chronic kidney disease at 7.3% was significantly higher in bipolar 
disorder than 2.4% in controls (OR 2.42, 95% CI 2.04-2.86) in Scottish primary care 
register studies, but there was no significant difference in the prevalence for schizophrenia 
(Smith et al, 2013a, Smith et al, 2013b). None of the schizophrenia comorbidity reviews 
have identified chronic kidney disease but a decrease in renal function over time in bipolar 
disorder is associated with lithium medication treatment. In a well conducted study of 
patients receiving lithium treatment versus matched control subjects with affective 
disorders not taking lithium, lithium patients had significantly lower glomerular filtration 
rates and this difference increased with increasing age and was larger in women (Tredget 
et al., 2010). Renal diabetes insipidus is a known side-effect of lithium treatment and at 
high doses, renal toxicity can occur. The incidence rate of end stage renal disease in 
lithium-treated patients has been estimated at 0.5% - 1.2% in those who received lithium 
for over 15 years (Bendz et al., 2009). 
Pregnancy, puerperium and perinatal disorders 
Obstetric complications (i.e. preterm birth, gestational diabetes, abnormal foetal growth) 
have been associated with schizophrenia and bipolar disorder and antipsychotic 
medicines (Gentile, 2010). There are known teratogenic risks with anticonvulsant 
medicines (particularly neural tube defects) from studies in women with epilepsy where 
higher doses are more frequently used (Tomson and Battino, 2009). Meta-analyses and 
population based studies into women exposed to antidepressants have produced 
discrepant results, other than adjunctive benzodiazepine use where an increase in 
congenital heart defects has been highlighted (Knowles et al., 1999). An incidence of 
0.1% (20 times the general population rate) of the rare congenital heart valve defect 
Ebstein’s Anomaly has been estimated for lithium, highlighting first trimester exposure as 
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the greatest risk (Iqbal et al., 2001). Evidence is mainly from case report registers of 
incidence so the data from older medicines are more available, rather than providing a 
robust comparison of risk. One population based cohort study using data from national 
health registers in Sweden compared women with treated and untreated bipolar disorder 
who had given birth with general population controls (n= 320, 554, 331263) (Bodén et al., 
2012). If treated with antipsychotics, anticonvulsants or lithium or not, women with bipolar 
disorder in this study were found have an increased risk of preterm delivery, caesarean, 
instrumental delivery or an induction of labour (but not gestational diabetes) compared to 
controls. Neonates of the women with untreated bipolar disorder were at increased risk of 
microcephaly (small head circumference) and neonatal hypoglycaemia although both of 
these are features of low birth weight. Women in both bipolar groups were more likely to 
smoke cigarettes and use street drugs than the controls and this may have confounded 
the results. In addition women in the treated group may have reflected a population at the 
more severe end of the bipolar spectrum. As previously discussed, relapse in bipolar 
disorder is highly prevalent in the puerperium and increases in risk with each pregnancy. 
The risk of negative outcomes in women with SMI and their babies has to be carefully 
balanced against the risks of relapse if medications are reduced or stopped. 
Psychotropic medicines not only cross the placenta, but also enter breast milk and women 
are advised not to breastfeed who are treated with lithium, some antipsychotics (e.g. 
clozapine) and benzodiazepines (Scottish Intercollegiate Guidelines Network, 2012).  
Reproductive system and breast disorders 
Antipsychotic induced hyperprolactinaemia can cause menstrual disorders (e.g. 
amenorrhoea), female infertility and breast disorders (e.g. galactomastia, galactorrhea), 
osteoporosis and sexual dysfunction (in men and women) (O'Keane, 2008, Holt and 
Peveler, 2011). The reported incidence of hyperprolactinaemia in people prescribed 
antipsychotics varies between antipsychotics and studies and may be inaccurate in 
studies using case records due to underreporting of symptoms and investigation by 
clinicians. One UK study of a wellbeing intervention tested all patients receiving 
antipsychotics at baseline (n=178), of which 33.1% met the diagnostic blood level criteria 
for hyperprolactinaemia, with a higher incidence in females than males (47.3% and 
17.6%) (Bushe et al., 2008).  
Sexual dysfunction can occur as an adverse effect of medicines that effect adrenergic, 
serotonergic and/or dopaminergic neurotransmitter systems (Taylor et al., 2012). There is 
a long history of sexual dysfunction in the SMI literature although a paucity of high quality 
research. There have been attempts to identify correlations between sexual dysfunction 
symptoms with specific medications and the disorder in schizophrenia. In the European 
First Episode Schizophrenia Trial (N= 498) subjects were tested using a sexual 
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dysfunction scale at baseline and at five weekly intervals throughout the trial. General 
psychopathology symptoms, and higher plasma prolactin levels predicted higher rates of 
erectile and ejaculatory dysfunctions in men. In women, higher prolactin plasma levels 
were identified as a predictor of amenorrhea. Negative symptoms predicted decreased 
libido in both men and women (Malik et al., 2011). However, reduced libido in the absence 
of hyperprolactinaemia has also been identified (Marques et al., 2012). Those reporting 
sexual dysfunction had lower quality of life scores and were significantly less likely to 
report having a romantic partner. Those in relationships with sexual dysfunction were 
more likely to rate the quality of their relationships as poor. There was no significant 
difference between groups in reports of ability to make friends (Olfson et al., 2005). 
In epidemiological terms, ‘fertility’ refers to birth rate and not the ability to conceive. In an 
epidemiological study of the whole Danish population, the lowest first-child fertility (birth) 
rate was found among men (IRR=0.10) and women (IRR=0.18) with schizophrenia. In 
comparison, bipolar male patients had an IRR=0.32 and female patients an IRR=0.36. 
IRR in this study improved in both disorders and genders with increasing time from first 
diagnosis. Two large population based studies in Sweden and Taiwan reported the 
prevalence of any live birth of 0.26% and 0.06% in women with bipolar disorder compared 
to controls (Bodén et al., 2012, Lee and Lin, 2010).  
General disorders  
Reports of pain are common in the general population and even higher in clinical 
populations. Tension-type headache and migraine were the second and third highest 
sequelae of disease or injury in the last WHO Global Health Survey with a prevalence of 
20.8% and 14.7% respectively. The leading cause of disability worldwide was low back 
pain (Vos et al., 2012). Pain that is non-neoplasm in origin such as musculoskeletal, 
neuropathic or neurogenic pain and persists despite or without treatment is associated 
with anxiety, depression, poor quality of life and increased risk of suicide. Comorbid pain 
has most frequently been studied in relationship to clinical depression where it is highly 
prevalent. There is much less research available into the relationship between persistent 
pain conditions and SMI and probably reflecting the link with depression, and more 
studies in bipolar disorder than schizophrenia. One very large epidemiological study 
examined the association between schizophrenia, bipolar disorder or depression and 
chronic pain in a national sample of case records of just over five million patients seen in 
Veterans Health Affairs facilities in the US in 2008 (Birgenheir et al., 2013). After adjusting 
for medical comorbidity, gender and age covariates; patients with schizophrenia (n= 
93,874) compared to controls (without schizophrenia, bipolar disorder or depression) were 
significantly less likely to have any recorded pain condition (OR=0.91). When different 
types of pain were compared the schizophrenia subjects had significantly higher chronic 
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(OR=2.10), migraine (OR=1.13), other headache (OR=1.46) or psychogenic (OR=2.72) 
pain. In the bipolar disorder adjusted sample (n= 96,186) there were significantly higher 
recorded diagnoses of any pain condition (OR=1.83), as well as every specific pain 
condition (adjusted ORs ranged from 1.50 to 6.24). It was interesting that a significant 
odds ratio for arthritic and neuropathic pain was only present in the schizophrenia sample 
before adjustment for comorbidity and age covariates. This suggests an under reported 
and/or clinically identified level of chronic pain in this population.  
Chapter Summary 
In serious mental illness, a higher than expected prevalence of physical comorbidities has 
been identified in every system organ class except the blood and lymphatic system. There 
is considerable overlap between the physical comorbidities identified as important in SMI 
that points to genetic vulnerability, environmental risk factors and social/behavioural 
factors. A lower than expected incidence or absence of many conditions in primary care 
records highlights poor identification of physical comorbidity in this population. 
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Chapter Three: Mortality  
Early mortality in SMI 
In 2013 information linking data on adults who use secondary mental health services in 
England with mortality data from the Office of National Statistics was published for the first 
time (Health and Social Care Information Centre, 2013). In the year examined (2011-
2012), the mortality rate [MR] in people who had received at least one episode of mental 
health care was 3.6 times that expected in the general population. This represented 
83,393 deaths over the year (5.2% of patients). The cause of death that made the largest 
difference was dementia. However, the largest difference by age was in mental health 
service users in their 30’s where the rate was nearly five times above the general 
population. In service users under 74 years the main causes of death were ischaemic 
heart disease (9.9%) and liver disease (7.6%). Primary diagnosis was not captured in this 
analysis.  
In the WHO Global Burden of Disease study the contribution of Years of Life Lost [YLLs] 
to the calculation of Disability Adjusted Life Years [DALYs] in mental health and substance 
use disorders was small (Whiteford et al., 2013). Mortality data was largely taken from 
national death registers that rarely reflect mental health or substance use disorder as the 
primary cause of death. If a person dies as a result of an MI, for example, ischaemic heart 
disease will be recorded and not schizophrenia. Suicide is classified in ICD-10 in the 
‘injuries’ class. The mental health and substance use disorders group recalculated DALYs 
by adding estimates for suicide into their data model. This resulted in a substantial 
increase in the disease burden ranking for mental and substance use disorder, from 6th to 
the 3rd worldwide (Whiteford, 2013).  
Mortality can be calculated and presented in different ways and methods are not directly 
comparable. Standard mortality ratio [SMR], mortality rate [MR], Mortality Rate Ratio 
[MRR], risk ratio [RR], years of life lost [YLL] or life expectancy may be used. SMR reflects 
the number of observed deaths divided by the number of expected deaths in a population 
in the period studied. 
There have been three meta-analyses that have calculated SMR estimates in SMI. Harris 
and Barraclough (1998) calculated separate SMRs for schizophrenia and bipolar disorder 
from papers published between 1966 and 1995 (20 studies and 6 studies). Two meta-
analyses focused on schizophrenia alone (Brown, 1997, Saha  et al., 2007). The most 
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recent of these used robust reporting and analysis guidelines and international data from 
the largest number of studies (37, n=22 296 patient deaths) (Saha  et al., 2007). The 
earlier analyses reported all cause SMRs of between 1.48-1.6 in schizophrenia (Brown, 
1997, Harris and Barraclough, 1998). Saha et al (2007) reported a median all-cause 
mortality of 2.58, with 10% and 90% quantiles ranging from 1.18-5.76. There was no 
difference in SMR distributions by gender. In bipolar disorder, a slightly lower all-cause 
SMR of 2.02 (1.88-2.17) was estimated (6 studies, n= 4547 deaths) (Harris and 
Barraclough, 1998). A systematic review of 17 studies of 331,000 patients with bipolar 
spectrum disorders (that included schizoaffective disorder) reported a 2-3.5 higher 
mortality risk (Roshanaei-Moghaddam and Katon, 2009). 
Two case record linkage studies have examined cohorts of patients of UK secondary 
mental health services in Southampton (schizophrenia n=370) and London (schizophrenia 
n=7022, schizoaffective disorders n=1313 and bipolar disorder n=2700) (Brown et al., 
2010, Chang et al., 2010). In schizophrenia and bipolar disorder, SMR was broadly similar 
to that of Saha et al. The reported SMR for schizoaffective disorder was 2.52 (95% CI 
1.83-3.39). Although based on a relatively small number of deaths (n=44) this could 
represent a greater severity of illness and/or exposure to risk. In the 25-year follow-up 
study gender difference was non-significant despite an earlier mean age of death in men 
(Brown, 1997). In the 2 year follow-up study, a statistically significant association between 
higher all cause SMR and female gender for schizoaffective and bipolar disorder was 
identified (Chang et al., 2010).  
Both Brown (1997) and Saha et al (2007) identified a trend of increasing SMRs in 
schizophrenia compared to the general population since 1970. This is unlikely to mean 
that improvements in life expectancy in schizophrenia are failing to keep pace with those 
of the general population, but reflect a real and significant fall in life expectancy over time. 
There are many factors that may contribute to early mortality in SMI and could separately 
or cumulatively contribute to the growing SMR gap. These will first be considered under 
unnatural and natural causes of death before health behaviour risks and system factors 
are discussed in the next chapter. 
 
Unnatural causes of mortality 
In the UK doctors are required by law to report deaths to the coroner where they believe 
the cause is ‘unnatural’, where the death is sudden, the cause is unknown, there has 
been violence, the death occurred in custody or they suspect an industrial cause 1 . 
                                               
1 Section 8(1) Coroners Act 1988 
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Reporting of deaths in hospital or immediately post discharge is governed by local 
guidelines.  
With up to 80% of all deaths in mental health and substance use disorders attributable to 
suicide where suicide is studied as the primary outcome (Harris and Barraclough, 1997, 
Yoshimasu et al., 2008), it is not surprising that unnatural causes make up the largest 
proportion of mortality in SMI studies. In the Saha et al (2007) meta-analysis 7 studies 
contributed to the calculation of unnatural cause SMR in schizophrenia providing a 
median SMR of 7.40 (10% and 90% quantiles 5.56,12.73). People with schizophrenia 
were over 12 times more likely to die from suicide than those in the general population 
(median SMR 12.86). The SMR for accidents was less but still above the general 
population rate (Median SMR 1.73).  
In bipolar disorder Harris and Barraclough (1998) report an unnatural cause SMR of 9.18 
(95% CI 8.01-10.46) and a suicide SMR of 15.05 (95% CI 12.25-18.44). The highest 
suicide SMR was in the ‘affective disorders not otherwise specified’ diagnosis category 
(19.85 CI 17.14-22.86). The SMR for accidents was not reported but ‘other violent means’ 
were just over three times that of the general population (3.17 95% CI 1.17-6.91).  
Accidental death in SMI was investigated in a large cohort study of all adults in Sweden in 
2001 who were followed-up for 8 years (Crump et al., 2013). Accidental death was 2-4 
times above that of the general population and more prevalent in men. Women with 
bipolar disorder were most likely to die as a result of a fall and men with schizophrenia by 
accidental poisoning. After adjustment for comorbid alcohol and substance use disorders, 
accidental death risk remained over twice that of the general population, except in men 
with bipolar disorder (RR 1.63 95% CI 1.29–2.12).  
Reports of unnatural cause SMRs are all likely to be underestimates, particularly for 
women. An analysis of the proportion of reporting rates of unnatural deaths to coroners 
across all jurisdictions in England and Wales between 2001 and 2010 demonstrated a 
large variation, with women’s deaths much less likely to be reported or determined 
‘unnatural’ at an inquest (Mclean et al., 2013). Many deaths fall in the “grey” area between 
those that are clearly natural and those that are unnatural, and there are no guidelines to 
help doctors when certifying such cases (Roberts et al., 2000). Common examples 
include deaths after surgery or medical intervention, where there has been a disease 
process and trauma, or death as a result of infection. For example pneumonia from 
aspiration following intoxication or resulting from a fall and/or osteoporotic fracture may be 
recorded as a natural (respiratory system) death.  
Natural causes of mortality 
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As was discussed earlier, there is evidence for increased prevalence rates of physical 
comorbidities in all the system organ classes of the body in SMI apart from blood and 
lymphatic disorders.  
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Table 3:1 Natural mortality rates in SMI 
 Schizophrenia Affective 
disorder not 
otherwise 
specified 
Bipolar 
All natural causes SMR 2.31 (SD 
1.18) (Saha 2007) 
 MRR: males 5.61 
(95% CI 4.56, 
6.90): females 
3.73 (95% CI 3.03, 
4.56) (Laursen et 
al., 2011) 
Cardiovascular SMR 2.01 (SD 
0.83) (Saha et al, 
2007) 
SMR 2.25; 33% of 
deaths (Brown et 
al, 2010) 
SMR 1.60 (95%CI 
1.30-1.94) (Harris 
and Barraclough, 
1998) 
SMR 1.58 (95%CI 
1.39-2.34) (Harris 
and Barraclough, 
1998) 
SMR 2.00 
(Laursen et al., 
2013) 
Cancer SMR 1.44 (SD 
0.6) (Saha et al, 
2007) 
SMR 1.49 (Brown 
et al, 2010) 
  
Respiratory 19% of deaths 
(Brown et al, 
2010) 
 Unclear 
 
Table 3.3 summarises the data for the natural causes of death in these populations. 
Cardiovascular causes of death are the most common. Brown et al (2010) also 
demonstrated a trend in an increasing numbers of cardiovascular deaths over the 25 
years studied that approached significance (P = 0.053). A highly significant fall in suicide 
rates was identified over the same time period (P = 0.0002), suggesting it is 
cardiovascular disease that is making the greatest contribution to the widening SMR gap. 
The SMR data for respiratory disease as a cause of death in bipolar populations is less 
reliable in this analysis as it was estimated from only one study per subgroup with small 
numbers of deaths in each (n=3, n=12). Both studies were from inpatient populations 
where respiratory disease is more prevalent (Harris and Barraclough, 1998).  
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In the USA a range of 13.5-32.2 potential years of life lost [YLL] due to early mortality 
compared to the general population for patients of public mental health services has been 
reported (Colton and Manderscheid, 2006). A broad range of diagnoses including major 
depressive disorder were included and the data from the eight states involved was not 
combined because it covered different time frames and types of service. In Scandinavia 
YLL in schizophrenia and bipolar disorder is estimated to be 11 to 20 years for men and 
11 to 17 years for women, with a slightly better prognosis in bipolar disorder and a worse 
prognosis in men with schizophrenia (Laursen et al., 2013). In the UK there have been 
similar findings with the shortest life expectancy reported in women with schizoaffective 
disorder (17.5 YLL) and men with schizophrenia (14.6 YLL) (Chang et al., 2011).  
Chapter Summary 
A two-three times greater mortality in schizophrenia than in the general population and 
slightly lower (around twice the general population mortality) in bipolar disorder is 
estimated in the most recent cohort studies and meta-analyses (Saha et al., 2007, Brown, 
1997, Chang et al., 2010, Laursen et al., 2011). There is a paucity of mortality data 
specific to schizoaffective disorder. The highest rates of mortality are reported in younger 
men with schizophrenia and women with bipolar and schizoaffective disorder. This may be 
a feature of the course of illness and treatment, or represent a gender bias towards an 
affective diagnosis in women. Suicide makes a significant contribution to early mortality 
but rates have been generally falling since the 1980’s. In contrast a widening mortality gap 
in the same time frame for all-cause mortality points to an increase in natural causes, 
specifically cardiovascular disease. Unnatural causes of death are likely to be under 
reported and registered and this impacts considerably on the estimates made for the 
disease burden of all three disorders. 
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Chapter Four: Risk factors 
Why do people with SMI die early?  
There are multiple risk factors that contribute to early death in SMI and all are potentially 
modifiable and present targets for intervention. 
Symptoms and illness course  
A study that measured external locus of control found patients with SMI significantly more 
likely to believe their physical health is determined by powerful others and chance than 
those with non-psychotic disorders (Buhagiar et al., 2011). Hallucinations and delusions 
may theoretically increase risk by inferring protection, making people avoid or take certain 
actions or by distracting attention. Over-activity, hostility and impulsive behaviour may 
increase risk and all symptoms may result in a failure to attend to adequate self-care. 
Cognitive deficits and negative symptoms may reduce recognition of physical symptoms 
or help seeking behaviour (Jeste et al., 1996). A lower pain threshold is reported in 
schizophrenia, although it is not known if this is intrinsic to the disorder or related to 
analgesic effects of medication (Jarcho et al., 2012). Impaired dopaminergic reward 
pathways in the brain may result in compulsive behaviour and craving leading to 
increased risk taking and/or addiction (Comings and Blum, 2000). People with 
schizophrenia living in the community are less likely to perform self-care or health 
promotion activities than non-psychiatric samples (Lieberman and Test, 1987, Holmberg 
and Kane, 1999). Apathy that is distinct from depression can impact on engagement with 
health professionals, treatment or behaviour change (Yazbek et al., 2013). 
A study of 6,880 SMI patients linked mortality data with one retrospective clinical rating of 
symptom severity from case records per patient (Hayes et al., 2012). A second cohort 
study followed-up 300 patients with schizophrenia for 8.5 years using baseline symptom 
ratings (Loas et al., 2011). No significant association between positive symptoms or 
hostility and mortality was identified in either study. In the second study subjective ratings 
of symptom severity at baseline was significantly positively correlated with suicide 
mortality. There is evidence from a recent study that severity of positive symptoms in 
schizophrenia impacts negatively on cardiovascular recovery from exercise (Ostermann et 
al., 2013). This could be relevant to the aetiology of arrhythmias and sudden cardiac 
death [SCD]. A cross sectional study that used physical fitness as a proxy for CVD risk 
found a positive correlation between the severity of depressive, negative and cognitive 
symptoms in schizophrenia and low performance (Vancampfort et al., 2013a). Length of 
illness, smoking and self-rated inactivity at baseline were features of these patients 
compared to healthy controls.    
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Evidence on the impact of affective symptoms is mainly from unipolar depression where 
there is considerable evidence of increased all cause and CVD mortality risk (Cuijpers and 
Smit, 2002, Hare et al., 2013). One large US study investigated a general population 
cohort so is more likely to have been more representative of a bipolar population than 
studies utilising psychiatric registers (Ramsey et al., 2013). Participants were screened for 
mania at baseline and followed-up for 26 years. Subjects reporting at least one manic 
spectrum episode at baseline had significantly higher all cause mortality between 34-64 
years. Mortality risk was independent of depression and was not associated with 
hypomania alone. There was no investigation of the causes of death or adjustment for 
health behaviours.  
Sleep disruption and disorder 
Sleep of an adequate duration and quality is important for physical and mental health. 
Sleep is a complex process that enables the brain to recover, reorganise and regenerate 
(Mental Health Foundation, 2011). Shorter and longer sleep duration were associated with 
an increased risk of all cause mortality in the general population in a meta-analysis of 27 
studies (Cappuccio et al., 2010b). A recent meta-analysis found a significant association 
between sleep disturbance and an increased relative risk for suicidal ideation, attempt and 
completion (Pigeon et al., 2012). An important finding by these authors was that these 
risks were independent of depression. 
Insomnia is associated with fatigue, daytime sleepiness, poor concentration, irritability, 
memory loss, poor function, depression and a weakened immune system (Roth, 2007, 
Imeri and Opp, 2009). Insomnia and oversleeping are associated with the development of 
diabetes and CVD (Cappuccio et al., 2010a). A sleep-wake cycle that is synchronised with 
the environment (circadian rhythm) is important. Female night-shift workers have higher 
incident rates of breast cancer and a higher incidence of metabolic syndrome and CVD is 
observed in occupations that work at night (Megdal et al., 2005, Esquirol et al., 2011). 
Hypersomnia (a severe form of daytime sleepiness) may indicate the potentially serious 
respiratory condition, obstructive sleep apnea [OSA]. OSA is more common in obesity, 
post-menopausal women, smokers and users of alcohol and (untreated) is associated 
with hypertension, CVD, stroke, accidents and poor quality of life (Young et al., 2002).  
Originally thought to be a symptom of mental disorder, the causality of sleep dysfunction 
is now thought to be bidirectional (Krystal, 2012). Sleep problems commonly predate the 
diagnosis of schizophrenia and bipolar spectrum disorders (Spiegelhalder et al., 2013, 
Plante and Winkelman, 2008). A decreased need for sleep is part of the diagnostic criteria 
for mania and occurs just before a switch from depressed mood to hypomania and/or 
mania (Wehr et al., 1982). Circadian rhythm disorder is present in bipolar disorder and 
schizophrenia and disturbances of sleep architecture in schizophrenia (Gonzalez, 2014, 
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Wilson and Argyropoulos, 2012). Insomnia is associated with schizophrenia, unipolar and 
bipolar depression (Krystal, 2012). Some psychotropic medications improve sleep 
duration and quality but can lead to daytime sleepiness and others (and most substances 
of abuse) impair sleep. Objective or subjective improvements in sleep are early signs of 
recovery (Spiegelhalder et al., 2013). 
Physical and psychological stress  
Physical and psychological stress is a state where homeostasis is threatened or there is a 
perception of threat (Chrousos and Gold, 1992). Stress is mediated through the 
hypothalamic–pituitary–adrenal [HPA] axis and the sympathetic nervous system [SNS] to 
impact on the body, brain and behaviour (Bradley and Dinan, 2010). A dysfunctional 
response to acute or chronic stress may lead to the development of inflammatory, 
metabolic and cardiovascular disorders (McEwen, 2006). For example, a failure to 
deactivate the stress response can lead to over exposure to cortisol and result in 
metabolic syndrome [MeTS] (Rosmond, 2005). An extensive systematic review of all 
studies investigating HPA function in schizophrenia found evidence that over exposure to 
cortisol in schizophrenia predicted MeTS and cardiovascular disease mortality (Bradley 
and Dinan, 2010). High and low levels of cortisol were predictive of suicide. Studies in 
early intervention samples and of drug naive patients were equivocal but dysfunctions in 
the stress response were found across the illness course. 
Risk taking, suicide and accidental death 
Impulsivity and risk taking behaviour are increased in SMI, contribute to accidental death 
and suicide and are more prevalent when alcohol or substance use is present (Swann et 
al., 2005, Swann, 2009, Zhornitsky et al., 2012). Prescribed medications may contribute to 
risk through common side-effects (e.g. sedation), intentional or unintentional overdose 
(Reddy et al., 2014). Medication treatment is also important to the reduction of risk. 
Lithium treatment significantly reduces suicide rates and clozapine reduces suicidal intent 
(Cipriani et al., 2013, Meltzer et al., 2003). The highest suicide rates of all in SMI are 
reported in first episode schizophrenia patients who do not adhere to prescribed 
medication (Tiihonen et al., 2006).  
Health behaviour. 
Smoking 
Smoking behaviour is the largest modifiable risk factor for cardiovascular disease 
worldwide. The significant reduction in smoking seen in the general population in the 
developed world in recent years is not matched in SMI. Smoking rates of around 50% in 
SMI, twice that of the general population, are reported in the most recent meta-analyses 
(Vancampfort et al., 2013b, Mitchell et al., 2011). A study that investigated smoking 
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behaviour in patients enrolled in a variety of studies from 1999-2011 found higher rates of 
smoking in schizophrenia (64%) than bipolar disorder (44%) with heavier and longer 
smoking histories in the schizophrenia samples (Dickerson et al., 2013).  
Like all health behaviours, nicotine dependence and smoking behaviour cannot be 
divorced from psychopathology or other risk behaviours. In schizophrenia studies have 
shown an association between increased smoking behaviour, higher symptom scores and 
abuse of substances (Bobes et al., 2010). Activation of nicotinic acetylcholine receptors is 
demonstrated to enhance selective attention so may improve symptoms or functioning 
(Dervaux and Laqueille, 2008). Hydrocarbons in cigarette smoke have a direct 
pharmacokinetic effect on the liver metabolism of several psychotropic medicines, 
reducing effectiveness and side-effect burden (Kroon, 2007).  
Alcohol and substance use 
Alcohol and substance use disorders are highly prevalent in SMI, contribute to a worse 
prognosis and considerable mortality, including suicide (Swofford et al., 2000). A lifetime 
prevalence of around 50% has been estimated in systematic reviews of schizophrenia 
studies in North America (Selzer and Lieberman, 1993 ). A German study using a drug 
and alcohol questionnaire and biochemical screening estimated a lifetime prevalence of 
21.8-42.9% with the highest rates in male long stay patients (Soyka et al., 1993). Short-
term (2-3 month) estimated prevalence was also high (21.3-23.9%), with alcohol the most 
common substance of abuse. A cohort study that interviewed 1,208 patients from nine 
centres across Europe reported highest lifetime prevalence rates in the UK (35%) (Carrà 
et al., 2012). Choice of substance may be linked to availability, rather than preference 
(Verdoux et al., 1996). Cannabis is the street drug with the highest prevalence and has 
been associated with the development of schizophrenia, particularly use at an early age 
(Smith and Hucker, 1994, Zammit et al., 2002, Jablensky et al., 1992). Cannabis is 
reported to have negative and positive effects on psychotic symptoms and may ameliorate 
some side effects of psychotropic medication (Dixon et al., 1990). Cannabis is commonly 
smoked with tobacco making the exact mechanism of these effects difficult to determine. 
Caffeine 
Excessive caffeine consumption is reported in SMI and associated with insomnia and 
hostile/aggressive behaviour, particularly in acute settings (Simmons, 1996). 
Pharmacokinetic interactions between a range of psychotropic medicines and caffeine 
reduce their effects. Restriction of caffeine may have unintended consequences and 
withdrawal can increase agitated behaviour. High doses of caffeine are readily available 
from the diet but also from popular ‘high energy’ drinks, often consumed with alcohol. 
Caffeine can enable a greater consumption of alcohol over longer periods of time by 
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reducing the sedative effect (Arria et al., 2011). Risk-taking behaviour increases because 
the person overestimates their ability to function (Marczinski et al.). Additive effects in the 
dopamine reward system may increase the risk of addiction. A significant association 
between daily caffeine intake rate and cigarette smoking rate has been observed in 
schizophrenia compared to controls (Adolfo et al., 2009).  
Diet and fluid intake 
Problems accessing, affording, cooking or understanding a healthy diet are all cited as 
barriers to eating healthily in surveys of the general population in England (National 
Obesity Observatory, 2011). People reporting existing health problems were more likely 
report obesity and lower confidence in changing their current behaviour. Studies in 
schizophrenia report a much higher than recommended intake of sugar, salt, carbohydrate 
and fat and low intake of fruit, green vegetables and fibre (Scott and Happell, 2011, 
Dipasquale et al., 2013). Poor nutritional content, a lack of variety, overreliance on 
convenience foods and poor diet literacy is identified in studies using food diaries 
(Henderson et al., 2006, Hardy and Gray, 2012). Low fruit and vegetable intake, high 
consumption of carbohydrate and sugary ‘snacks’ or drinks and a higher incidence of 
binge eating is reported in bipolar disorder (Sylvia et al., 2013a, Elmslie et al., 2001, 
Kruger et al., 1996, Ramacciotti et al., 2005). There has been a recent focus on 
malnutrition in care environments associated with the elderly but the quality of nutrition in 
residential or supportive environments for adults with SMI has received little attention. 
Despite nurses reporting knowledge of an association between poor nutrition and 
psychotic disorders, 29% of patients who screened positive for malnutrition in one small 
study had not previously been identified (Abayomi and Hackett, 2004). Fluid intake may 
be impaired (or polydipsia may be present) in SMI leading to dehydration and electrolyte 
imbalance as discussed previously.  
Physical activity 
Physical activity and exercise has the potential to improve mood, symptoms, physical 
health and health related quality of life in SMI (Faulkner and Carless, 2006). Low levels of 
physical activity are reported in schizophrenia and are associated with negative symptoms 
and the sedative effects of medication (Brown and Birtwistle, 1999, Goff et al., 2005). 
There is limited evidence that exercise improves negative symptoms and physical fitness 
in this population (Gorczynski and Faulkner, 2010). Although there is robust evidence for 
the benefits of exercise in depressive disorders, there has been much less attention to 
physical activity in bipolar disorder. One European study surveyed 482 participants with 
bipolar disorder about their experience of exercise over the preceding year and reported 
an association between mood and reported activity levels (Sylvia et al., 2013b). No 
significant differences in physical health parameters at baseline, other than BMI (that was 
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higher in participants screening positively for depression) was found. The cross sectional 
design limits the interpretation of these results.  
Medication non-adherence 
Medication non-adherence is very common in all long-term conditions, including SMI. 
Non-adherence predicts suicide risk and would be expected to influence all the other risk 
factors in this chapter. Adherence in SMI has been defined as taking 80% or more of 
prescribed medication and partial non-adherence between 50 and 80% (Velligan et al., 
2009). Stopping and starting medication, particularly when unsupervised, risks withdrawal 
effects, relapse and adverse effects of titration. For example rebound insomnia may 
increase risk-taking behaviour, sedation and hypotensive effects may increase the risk of 
accidents. A meta-analysis in schizophrenia reported a relative risk of suicide of 4.2 (95% 
CI 1.7–10.1) in non-adherent compared to adherent patients (Leucht and Heres, 2006). 
Other than suicide, no independently sponsored reviews could be identified that 
specifically investigate the impact of non-adherence on mortality outcomes in SMI. Two 
out of three reviews into the consequences of partial non-adherence conclude with 
recommendations for the long acting injections promoted by the funder (Llorca, 2008, 
Higashi et al., 2013, Keith and Kane, 2003).   
Iatrogenic risks 
An iatrogenic risk is defined by the online Oxford English Dictionary as one ‘induced 
unintentionally by a physician through his diagnosis, manner, or treatment’ (Oxford 
English Dictionary, 2014). This definition has not changed since the first entry in the 
dictionary in 1924 although treatment and care is no longer totally led by the medical 
profession. Organisation and delivery of care by many professional groups and workers 
can significantly impact on patient safety and is included in this section.  
A meta-analysis of case record review studies of iatrogenic risk events in adult non-
psychiatric in-patients calculated a median incidence of 9.2% (IQR 4.6–12.4%) events 
across 74,485 patient records from 8 studies (de Vries et al., 2008). Many events (44%) 
were judged preventable and 7% resulted in death. The most common causes were 
related to surgery (40%) or medication (15%). System related factors accounted for 
around 8% of events in the 5 studies where this was investigated (n=2,324 records). 
There has been a surprising lack of good quality research into iatrogenic risk events in 
psychiatric populations. The majority of studies that do exist focus on the analysis of 
incident and accident reports from inpatient samples of convenience. In the UK these 
highlight the risk of falls and the consequences of the environment and management 
strategies for self-harm, aggression or suicide e.g. (Fairlie and Brown, 1994, Bowers et al., 
2007).  
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Medication risk 
Many medication-related comorbidity risks were discussed in the comorbidity chapter. For 
example, falls may be more common where there is sedation and more fatal where there 
is comorbid disease. Safe prescribing and medicines management practice could 
presumably moderate these risks.  
Medication errors include those associated with prescribing, transcription, dispensing, 
administration, monitoring and information exchange (National Reporting and Learning 
Centre, 2014). Incidence rates of medication errors in psychiatry vary considerably 
between studies, are largely of inpatient populations and are too heterogeneous to allow 
meta-analysis (Maidment et al., 2008, Procyshyn et al., 2010). In one survey of 22,036 
prescription items written in one week in mental health units across 9 NHS Trusts 
pharmacists identified 2.4% (n=523) prescribing errors (Stubbs et al., 2006). Of these, 22 
(4.3%) were judged likely to result in serious adverse effects or death. Non-psychotropic 
prescribing has been reported to generate more errors than psychotropic prescribing in 
these settings, indicating increased risk where there is physical comorbidity (Haw et al., 
2007b, Rothschild et al., 2007). There are, as yet, no studies into prescribing errors by 
non-medical prescribers in the UK.  
The administration of medication is by registered nurses in the UK, although this role can 
include the supervision of students and self-administration by patients in hospital and 
community settings (Nursing and Midwifery Council, 2007). Medication administration 
errors are a deviation from a valid prescription, standard or policy, including failing to 
correctly record the administration or reason for omitting medication. A retrospective 
analysis of incident reports over a period of 3.5 years in one UK psychiatric hospital 
identified 104 administration errors. Psychotropic, long-acting intramuscular antipsychotics 
and as-needed medicines were all significantly overrepresented. 14% of errors had the 
potential to cause moderate harm to patients and 1% could have led to severe harm (Haw 
et al., 2005). As this study was based on reports it is likely to have grossly underestimated 
the scale of the problem due to anxiety about disciplinary action. An observational study 
on two wards in the same hospital detected 369 errors in 1,423 administration items 
(25.9%). There were no incident reports in the same time period. The design meant there 
was an opportunity to intervene to prevent risk and only one error was rated as having the 
potential to cause serious effects (Haw et al., 2007a). Similar to prescribing errors, 
administration errors were significantly more likely to involve non-psychotropic than 
psychotropic medicines. 
The largest amount of information on iatrogenic risk of medication is from reviews of 
adverse event data from clinical trials funded by the pharmaceutical industry and this is 
subject to publication bias. A study of 162 randomized, double-blind, placebo-controlled 
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trials published in peer reviewed psychiatric journals between 2001 and 2003 found 
authors were 4.9 times more likely to report positive results if one of them declared a 
conflict of interest and the study was industry sponsored (Perlis et al., 2005). 
When considering mortality risks, the impact of medication on the risk factors with the 
greatest impact on mortality (suicidality and metabolic syndrome) are arguably the most 
important. With respect to suicide some psychotropic medication can be fatal in overdose, 
others have efficacy against suicidality and/or are proven to significantly reduce the 
suicide rate as previously discussed. The impact of antipsychotic medications on the risk 
of metabolic syndrome is highly controversial, with conflicting results from studies and 
reviews. There is evidence of elevated risk linked to weight gain (particularly for 
olanzapine and clozapine), largely from industry trial data (Newcomer, 2005, De Hert et al., 
2012). In clinical populations the association is less clear because the majority of patients 
have had long exposure to a variety of medications, do not always adhere to treatment 
and have multiple risk factors. In studies where subjects are antipsychotic naive at 
baseline, the greatest risk of weight gain and metabolic abnormalities is reported in the 
first few weeks of treatment (Tarricone et al., 2010). However, these results may be 
confounded by short duration of follow-up (≤3 months) and the use of lower risk 
antipsychotics where subjects have existing metabolic abnormalities or familial risk factors. 
Long-term exposure to any antipsychotic treatment was significantly associated with lower 
mortality than no drug use in an important independently funded cohort study in 
schizophrenia, with clozapine posing the lowest risk (Tiihonen et al., 2009). This study 
followed up 66,881 patients for 11 years so represented survivors at each census point. 
Causality for death was not investigated but it is possible that patients who survived the 
longest were more adherent and/or that medication had more successfully targeted risk 
factors such as psychopathology, sleep dysfunction, substance use or suicidality. 
Supporting this argument is the relative success of clozapine in this study and it’s known 
action and/or proven efficacy against each of these important factors (Essali et al., 2009, 
Asenjo Lobos et al., 2010, Armitage et al., 2004, Brunette et al., 2006, Meltzer et al., 
2003). Alternatively long-term antipsychotic exposure could be an indication (a proxy 
measure for) of engagement with health care.  
Systems risk 
The risk to individual patients extends beyond actions or omissions by individuals or 
specific professional groups to how care is organised and risk factors within or as a result 
of this system. There is a culture of risk assessment in SMI in mental health services in 
the UK that focuses on the risk of suicide or potential harm due to violence or vulnerability 
to exploitation. Risk assessment tools currently used in UK mental health services only 
include items on the potential risk (of self-harm) or any difficulty accepting or managing a 
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known physical health problem, for example, the widely used Sainsbury’s Risk 
Assessment Tool (Morgan, 2000). A new guide to risk assessment and management 
designed for mental health professionals does not include any assessment of previously 
unknown physical health risk (Hart, 2014).  
The requirement for mental health nursing students to achieve competence in physical 
health skills at the point of registration in the UK was implemented into undergraduate 
curricula from 2011 (Nursing and Midwifery Council, 2010a, Nursing and Midwifery 
Council, 2010b). Surveys of mental health nurses [MHNs] and Care-Coordinators in the 
existing workforce report a positive attitude towards a physical health care role but 
highlight a number of barriers to carrying this out in practice (Hyland et al., 2003, Nash, 
2005, Howard and Gamble, 2011, Nash, 2010, Robson and Haddad, 2012). Barriers 
include workload, time, other priorities, a lack of resources, education and equipment and 
problems sharing information between providers across service interfaces. One small 
study (of 37 MHNs in acute inpatient units in one NHS Trust) included an audit of the 
patient record and found low levels of documented physical health assessment or 
interventions (Howard and Gamble, 2011). Confusion is often expressed about whose role 
it is to provide physical care. Some mental health nurses in these studies expressed the 
view that ‘we don’t do physical health’ and ‘it is the role of the GP’. In the study by Hyland 
et al (2003), case managers were largely pessimistic about their ability to change the 
health behaviours of patients with SMI. All studies so far have been into convenience 
samples and subject to response bias so how widely these views are shared is not known. 
Cross sectional surveys have demonstrated that people with SMI attend primary care 
more frequently than the general population, have longer consultation times and contact 
with primary care represents about two thirds of all health contacts (Nazareth and King, 
1992, Burns and Cohen, 1998, Kendrick et al., 1994, Kai et al., 2000, Reilly et al., 2012). 
Until 2014, GPs in England were paid to provide annual CVD screening to people with 
SMI registered with their practices through the Quality and Outcomes Framework (British 
Medical Association and NHS Employers, 2012 ). Studies have demonstrated that this 
screening does not routinely take place and, where it does, is less frequent and less 
comprehensive than the CVD screening provided to people with other long term 
conditions (Mitchell and Hardy, 2013, Hardy et al., 2013, Roberts et al., 2007). Surveys of 
GPs and practice nurses report that many feel ill equipped to provide care for people with 
SMI and some believe it is beyond their remit (Bindman et al., 1997, Lester et al., 2005). 
The incentive for cardio-metabolic testing in SMI in primary care (other than for blood 
pressure) was removed from the GP contract in 2014 (British Medical Association and 
NHS_Employers., 2014). Physical health monitoring and intervention must now be 
provided or coordinated from secondary (mental health) services for the first year 
following admission (National Collaborating Centre for Mental Health, 2014) 
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Multi-disciplinary Community Mental Health Teams [CMHTs] have provided mental health 
care in the UK since the 1980’s. There are specialist CMHTs (e.g. assertive outreach 
teams) and generic CMHTs. CMHTs usually include psychiatrists, mental health nurses, 
social workers, occupational therapists and support workers. Core functions of CMHTs 
are defined locally and include case management and coordination of care for people with 
SMI between primary care, secondary mental health services and social care. Guidance 
issued from the Department of Health [DOH] emphasizes the importance of joint working 
with primary care to achieve optimal physical health care for people with SMI (Department 
of Health, 2002). Joint working is also known as ‘collaborative care’ and is recognised as 
a complex intervention (Butler et al., 2008). Problems have been identified in the ability of 
CMHTs to effectively perform this function for people with SMI due to high caseloads, low 
contact time and problems with interface communication (Sainsbury Centre for Mental 
Health, 1998, Crawford et al., 2004, Freeman, 2002). A recent systematic review of 
collaborative care approaches for people with SMI failed to find any evidence of 
effectiveness for collaborative care over standard care for physical health related quality 
of life (Reilly et al., 2013). Research into specialist CMHTs is limited. Assertive outreach 
teams are more effective at engaging patients than generic CMHTs, but no more effective 
in preventing rehospitalisation (Killaspy et al., 2006). An upward trend in suicide rates has 
been observed in UK NHS Trusts where specialist community teams have merged into 
generic teams, prompting guidance to preserve assertive outreach and early intervention 
services (National Confidential Inquiry into Suicide and Homicide by People with Mental 
Illness). In times of austerity, commissioners may focus on short-term expensive 
outcomes such as preventing hospitalisation rather than health promotion and harm 
minimisation that can take a considerable time to result in measurable change.   
In England, integrated CMHTs that include health and social care staff in one team are 
now being formed based on clustering of patients by need to enable a ‘payment by results’ 
currency system to operate between commissioners and providers of services 
(Department of Health, 2013). The effectiveness of this approach for people with SMI has 
not been tested, although a mismatch between ICD-10 diagnosis and allocation to the 
correct cluster has been identified, particularly for psychotic disorders (Bekas and Michev, 
2013). An increase in the suicide rates of patients of organisations where integrated 
teams have replaced specialist community teams has been highlighted (While et al., 
2012).   
Stigma and social exclusion 
People with SMI are identified as being amongst the most excluded groups in society 
(Social Exclusion Unit, 2004). Stigma is a social construction that devalues or 
dehumanises people as a result of a distinguishing characteristic or label (Lauber). 
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Discrimination and stigma increase the likelihood of unemployment, poverty, social 
isolation and poor housing. These factors not only contribute to disease and mortality risk 
but interact with each other. For example, poverty may lead to inadequate nutrition and, 
along with poor transport links, reduce access to health care to treat the results. Even 
where there is contact with services and health professionals, being identified as ‘mentally 
ill’ may mean a failure to treat the whole person (Schulze, 2007). Symptoms and risk 
factors may be overlooked in a process known as ‘diagnostic overshadowing’ (Jones et al., 
2008). Self-stigma may reduce help seeking behaviour and/or the confidence to make 
positive changes to health behaviours (Watson et al., 2007). Low expectations from staff 
or ‘therapeutic pessimism’ may result in a culture of less engagement, investment of 
resources and intervention (Thornicroft et al., 2007, Horsfall et al., 2010). People with SMI 
may find it difficult to navigate the fragmentation of health services, i.e. separation of 
psychiatric and medical services. Carers of people with SMI and the staff who work with 
them may themselves face negative attitudes that impact on collaborative care. 
The consequences of multiple risk factors 
The distribution of risk in individuals differs from what would be predicted from individual 
risk factor prevalence alone. Major risk factors tend to cluster together in individuals, as in 
metabolic syndrome. Risk factors interact with each other to multiply an individual’s risk of 
developing comorbid disease over time. This is recognised in the prediction of the risk of 
cerebral and cardiovascular disease (Anderson et al., 1991, Chang et al., 2001, Jackson 
et al., 2005). As a consequence, a number of multivariate risk prediction models have 
been developed to allow calculation of the future likelihood of cardiovascular disease in 
the general population, for example, the Framingham risk score (D'Agostino et al., 2008) 
and the QRISK (Hippisley-Cox et al., 2008). In SMI the main focus of risk prediction 
research has been violence and suicide, highlighting the central importance of concurrent 
substance use (Elbogen and Johnson, 2009, Morgan, 2000). The importance of multiple 
risk factors is identified in the SMI physical comorbidity literature (e.g. substance use and 
HIV). Algorithms to predict the broad range of physical comorbidity in this population, 
including cardiovascular disease, have not been published.  
Risk assessment and intervention  
There have been 17 selective and systematic reviews of physical health interventions in 
SMI (Faulkner et al., 2003, Werneke et al., 2003, Bradshaw et al., 2005, Faulkner and 
Cohn, 2006, Loh et al., 2006, Faulkner et al., 2007, Ganguli, 2007, Strassnig and Ganguli, 
2007, Alvarez-Jimenez et al., 2006, Beebe, 2008, Kemp et al., 2009, Banham and 
Gilbody, 2010, Maayan et al., 2010, Tsoi et al., 2010, Roberts and Bailey, 2011, 
Papanastasiou, 2012, Tosh et al., 2014). The most recent included 95 and 7 studies 
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respectively; no specific trials of risk assessment (e.g. health checks) were reported 
(Papanastasiou, 2012, Tosh et al., 2014). 
There is low uptake of public health screening programs in SMI. A review of 12 studies in 
the US, Canada, Australia and Europe concluded people with SMI were less likely to 
access cervical, breast, colorectal or prostate screening than other groups (Howard et al., 
2010). A systematic review of HIV testing in SMI reported a very broad range of lifetime 
testing rates (11-89%, n=13 studies) (Senn and Carey, 2009). Lifetime testing for HCV or 
HCB was 41% in 200 community SMI patients in the US, with no evidence of increased 
screening or immunization where high risk sexual or substance use behaviour was 
documented (Goldberg et al., 2005). Patients with comorbid psychiatric and substance 
use disorders have been found to have lower rates of immunization, smoking cessation 
interventions and cancer screening compared to those with a single SMI diagnosis (Druss 
et al., 2002). A comparison of screening for metabolic risk parameters in patients with SMI 
compared to patients with diabetes from 8,123 GP practices in England reported 
significantly lower rates in SMI (74.7%, versus 97.3% p<.001) (Mitchell and Hardy, 2013).  
A systematic review of 31 studies concluded people with mental disorder and/or 
substance use are less likely to receive recommended treatments (including surgery) for 
comorbid diagnoses than controls (i.e. in general medicine, cardiovascular disease, breast 
cancer and diabetes) (Mitchell et al., 2009). In the small number of studies that reported 
bipolar disorder separately, this disparity was not seen (3 studies). The most recent case 
linkage study of patients with bipolar disorder registered in primary care in Scotland also 
identified lower than expected rates of treatment (Smith et al., 2013b). Patients with 
bipolar disorder and CVD and/or hypertension were significantly less likely to be 
prescribed statins or one or more antihypertensive medicines than controls. These rates 
do not seem to be associated with problems of access to an appointment and people with 
SMI are known to make more frequent and longer visits to their GP than general 
population controls (Daumit et al., 2002).  
Disparities in physical health care also exist in hospital and community mental health 
services. A baseline audit of records on four randomly selected inpatient wards and one 
CMHT in the largest UK Mental Health NHS Trust identified 100% adult inpatients but only 
22% community patients with records of smoking status (Parker et al., 2012). Of the 62 
inpatients who said they smoked, only 25% had a record of a conversation about risk and 
only one had been referred to smoking cessation services. For the five cardio-metabolic 
risk factors considered most important in SMI (BMI, blood glucose, lipids, blood pressure 
and smoking status) the rate for a record of assessment of all five was a disappointing 
33% (range 1%-77%) in the second National Audit of Schizophrenia [NAS] (Royal College 
of Psychiatrists, 2014). Wide disparity between NHS Trusts and inadequate rates of 
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intervention, even where there is a diagnosis of comorbid physical disease remain. 
Selection of community patients with schizophrenia for the NAS is made by the 
organisation so may overestimate adherence to the standards as a result of selection bias. 
Chapter Summary 
There are multiple risk factors that contribute to early death in SMI. These include those 
related to psychopathology and illness course, sleep disorders, stress, risk taking, health 
behaviour, iatrogenic causes and the consequences of stigma and social exclusion. All 
these risks are potentially modifiable and present targets for intervention. A simple sum of 
individual risk factors cannot determine the total risk faced by an individual as each risk 
interacts on a personal and system level to multiply risk. There is as yet no specific 
algorithm to predict the risk of early mortality in SMI. Despite nearly a decade of practice 
guidance in the UK highlighting the need for physical health care in SMI, there is very little 
evidence that physical health risk assessment or intervention is consistently taking place 
in either primary or secondary care. 
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Chapter Five: Identifying the best available evidence on how to 
educate nurses to undertake a physical health care role in 
serious mental illness 
Introduction 
Researchers are recommended to pay attention to three key phases when developing 
complex interventions; identifying existing evidence, identifying and developing theory and 
then modeling processes and outcomes (Medical Research Council, 2008). This chapter 
examines existing evidence for the education of nurses to support nurse-led interventions 
in physical wellbeing.  
Background 
As discussed earlier, there is as yet no published evidence for the efficacy of screening 
interventions in SMI although healthcare workers in primary or secondary care are 
expected to monitor the physical health of all people with SMI at least annually. This role 
is in step with health policy in England that expects all staff and every healthcare 
professional working for the NHS to “make every contact count” (Department of Health, 
2012, Department of Health, 2014). Staff should “use every contact with an individual to 
maintain or improve their mental and physical health and wellbeing, whatever their 
specialty or the purpose of the contact” (Department of Health, 2012 p6).   
All nurses in the UK, at the point of registration, are expected to be competent in making a 
holistic and systematic assessment of physical, emotional, psychological, cultural, spiritual 
and social needs, including assessing risk and creating a comprehensive plan of care in 
partnership with the patient and others (Nursing and Midwifery Council, 2010a, Nursing 
and Midwifery Council, 2010b). The first registrants from nursing courses subject to this 
new standard graduated in 2014. Therefore the potential impact of curriculum change on 
the knowledge, attitudes and skills of newly qualified nurses, existing registrants and the 
physical care of people with SMI is not yet known.  
The 2010 standards for nurse education post-date two reviews by the Department of 
Health that highlighted poor preparation for a physical health care role provided by mental 
health nurses in secondary care (Department of Health 2006) and for adult nurses to work 
effectively with patients with SMI in primary care (Department of Health, 2003). The 
reviews support the UK governments mental health strategy that expects “parity of esteem 
between services for people with mental and physical health problems” to tackle inequality 
so that fewer people with mental health problems have physical comorbidity and early 
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mortality. This strategy has now been enshrined in law (The Health and Social Care Act 
2012).  
Nurses qualified in the mental health field of practice are recorded under the first level sub 
part of the UK Nursing and Midwifery Council register. First level nurses are most likely to 
work directly with patients and their numbers are reported separately from nurse 
consultants, matrons and managers in NHS workforce statistics. The NHS reported 
36,220 first level nurses working in secondary mental health services in England in 2013, 
with (24%) 14,733 working in community roles (Health and Social Care Information Centre, 
2014). Just over 1.5 million people were in contact with secondary mental health services 
in England between 2011 and 2012. Although the use of the Mental Health Minimum 
dataset was experimental in this round of data collection and analysis, the largest 
proportion of patients were reported to be assigned to a ‘on-going recurrent psychosis, 
low symptoms’ care cluster (57,706, 13.8% patients) (Health and Social Care Information 
Centre, 2013). With the majority of clinical contacts reported to take place via Community 
Mental Health Teams [CMHTs] it is Community Mental Health Nurses [CMHNs] who are 
the largest number of health care professionals in secondary care in routine clinical 
contact with SMI patients.  
One potential way to achieve a positive impact on the physical health of people with SMI 
patients is to exploit the opportunity to monitor physical health and offer appropriate 
intervention through the usual contact and role of mental health nurses [MHNs] (Robson 
and Gray, 2007, Happell et al., 2011). Surveys indicate that MHNs regard physical health 
as an important part of their role, but deficits in clinical practice persist hampered by a lack 
of knowledge, skills and resources and problems facilitating access to care across the 
primary-secondary care interface (Nash, 2005, Nash, 2010, Howard and Gamble, 2011, 
Robson and Haddad, 2012). This research largely represents MHNs working in inpatient 
settings although the largest survey to date (n=585) did not report any significant 
differences in the 30% of their sample who worked in community teams (Robson and 
Haddad, 2012). 
Although assessment is considered a core feature of mental health nursing practice, 
reviewers have highlighted a lack of underpinning evidence that is both detrimental to the 
profession and care of patients (Coombs et al., 2011, Harris and Happell, 1999). Although 
regulatory agencies define practice standards the structure of a comprehensive mental 
health nursing assessment and therefore the underpinning knowledge, attitudes and skills 
required to deliver it has not been standardised. Academics have either focused on one 
aspect (usually the assessment of risk of suicide or violence) or the philosophy of the 
approach. MHN assessment has been described as an informal process driven by the 
need to develop a therapeutic nurse-patient relationship (Muller and Poggenpoel, 1996, 
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O'Brien, 1999). Research highlights an inconsistent approach to assessment, poor 
documentation and a lack of focus on physical health care within a whole system 
approach (Harris and Happell, 1999, Coombs et al., 2011). 
I intended to educate mental health nurses to equip them with skills to carry out physical 
health checks and decide how best to intervene to reduce physical health risk in patients 
with SMI. I wanted this education to be evidence based so I conducted a systematic 
review with my fellow student Sheila Hardy (Sheila Hardy was studying for a PhD at the 
University of East Anglia with a focus on health checks in SMI by health professionals in 
primary care). The aim of the systematic review was to identify the efficacy of education of 
qualified healthcare professionals to deliver interventions aimed at improving the physical 
health of adults with SMI. 
Method 
We undertook a systematic search of the literature in June 2010 using the terms Severe 
Mental Illness, Physical Health and Education (please see Fig. 5.1 for MEDLINE search 
terms) utilising the component databases: MEDLINE (Ovid;1950–June 2010; 55 results), 
CINAHL (EBSCO; 1981–June 2010; 24), AMED (Ovid; 1985–June 2010; 0), Psychinfo 
(EBSCO; 1806–June 2010; 21), Cochrane (June 2010; 0), WHO (June 2010; 4), 
OpenSIGLE (June 2010; 216), EMBASE (Ovid; 1980–week 23 2010; 94) and Health 
Technology Assessments (June 2010; 0). No limitations on year of publication or 
language were applied and we translated the MEDLINE terms for the other databases. 
We additionally inspected the references of all identified studies and relevant reviews for 
other appropriate studies to determine if any material may have been overlooked. 
 
Inclusion criteria and justification 
 
 Education to deliver interventions to improve the physical health of people with 
severe mental illness 
 Assessment of the impact of the education package on the healthcare 
professionals 
 Patient specific outcomes 
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Figure 5:1 MEDLINE search  
 
At first, we planned to only include randomised control trials as they are considered to be 
the highest standard of research evidence to determine the efficacy or effectiveness of a 
healthcare intervention or service (Health Development Agency, 2009). We searched for 
RCTs that evaluated the efficacy of the education of qualified health care professionals to 
deliver interventions aimed at improving the physical health of adults with Serious Mental 
Illness. As this criteria did not uncover any relevant papers, and the ‘most appropriate’ (or 
highest level of) evidence is not necessarily the RCT (Sanson-Fisher et al., 2007), we 
expanded our criteria to include service evaluations. However, searching for service 
evaluations did not prove fruitful either, so we removed all study design descriptors from 
the search criteria while making sure any reported outcomes included some assessment 
of the impact of the education package on the healthcare professionals as well as patient 
specific outcomes. 
We anticipated that the education packages would involve some face-to-face training (of 
any duration) backed up by the provision of written materials and potentially prompting 
processes when the trainees returned to practice. We intended to note the character of 
training delivery (group, on-to-one, experiential, didactic, duration, location, etc.), the 
character of the trainer (profession, level of training, etc.), the character of the group (multi 
or uniprofessional, level of qualifications and area of expertise, etc.) and the provision of 
support subsequent to the training event (written resources, access to trainers, web 
groups, etc.). 
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Results of systematic search 
We identified 414 publications from the databases: MEDLINE (55), CINHAL (24), AMED 
(0), Psychinfo (21), Cochrane (0), WHO (4), OpenSIGLE (216), EMBASE (94), HTA (0) 
and none from other sources. After removing duplicates (267), we independently 
screened the results and discussed our findings. One hundred and forty-seven papers 
were excluded because they did not meet our inclusion criteria. There were no difficulties 
or disputes during this process.  
A number of studies were excluded from this review as although there was an implicit 
education package provided to healthcare professionals, no information was reported on 
the outcomes of this education with regard to healthcare professionals’ knowledge, 
attitudes and behaviours. The only information that these studies provided was patient-
specific outcomes. Therefore no studies were identified as suitable for a systematic 
review. See flow diagram (Figure 5.2). 
 
Figure 5:2 Results of systematic review 
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Discussion 
It is significant that we were unable to identify any studies. There was an apparent lack of 
understanding of the importance of disseminating the education component of evidence-
based interventions by publication. The impact of any education package aimed at 
healthcare professionals on their competence (knowledge, attitudes and behaviours) was 
absent from study reports. Paucity of this information in the public domain may account for 
the insufficiency of long-term impact for programmes such as the Wellbeing Support 
Programme [WSP], as the information needed to apply the intervention in practice with 
fidelity is missing (Smith et al., 2007a, Ohlsen et al., 2005, Smith et al., 2007b). 
Providing health checks for people with severe mental illness in the UK has become a 
requirement of the Quality and Outcomes framework; along with providing health checks 
for people with other conditions such as diabetes that carry a high risk of developing 
cardiovascular disease. The difference is however, as well as an abundance of accredited 
courses available for nurses to monitor people with diabetes, there is an acceptance by 
nurses that this should be part of their role. The lack of evidence-based training available 
for qualified nurses to monitor the physical health of people with SMI adds to the view that 
this is not their responsibility. The lack of evidence to demonstrate that training the nurses 
will improve patients’ health makes advocating any training (should it be available) a 
difficult task.   
Practitioners worry, quite rightly, about patients with SMI committing suicide (Gray et al., 
2009). There is an abundance of research regarding interventions to prevent suicide in 
patients with severe mental illness. A systematic review uncovered no less than 24 
studies in this area (Leitner et al., 2008). Given the plethora of papers advocating the 
importance of monitoring the physical health of people with SMI, we were astonished that 
both our own attempt and that of Tosh et al. (2010) to evaluate the evidence in this area 
unearthed no studies. As more patients with SMI die from cardiovascular disease than 
suicide, it is vital that researchers start to publish details of healthcare professional 
education in physical health and SMI research. 
Limitations 
Our search criteria should have been robust enough to detect relevant studies or service 
evaluations. It is possible, however, that we have failed to identify small studies and 
evaluations or studies and evaluations in progress. 
Chapter summary 
There is a need not only to develop education for qualified nurses and other relevant 
healthcare professionals to provide physical health checks and appropriate interventions 
 71 
for people with SMI, it is also necessary to demonstrate that offering this education will 
change healthcare professional’s behaviour in such a manner that it can be demonstrated 
to improve patient outcomes. 
This study was published as: 
Hardy, S. White, J. Deane, K. Gray, R. (2011) Educating healthcare professionals to act 
on the physical health needs of people with serious mental illness: a systematic search for 
evidence. Journal of Psychiatric and Mental Health Nursing. 18 (8) 721-727. 
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Chapter Six: Development of the HIP Programme  
Introduction 
An education and clinical decision support intervention was designed to exploit the 
therapeutic nurse-patient relationship. The aim was to raise the profile of physical health 
need, support physical health care risk assessment and prompt evidence based 
intervention within existing MHN practice and roles. It was hoped by helping MHNs profile 
the physical health risks of the SMI patients they work with and directing them towards 
evidence based interventions to address identified need, an informed physical health 
conversation could take place to support the patient to choose what to do next. This 
approach assumes physical health is not being fully attended to and needs to be bought 
into consciousness to be recognised and acted on. The profile was specifically designed 
to require minimal education and support and be more sustainable than a program of 
extensive retraining of the primary care workforce, or the funding of adjunct physical 
health services across secondary care.  
Although pragmatic, this solution was still complex in terms of its development, evaluation 
and dissemination. It required several interacting components to enable it to target the 
mental health nurse, the patient and the organisation (e.g. the primary-secondary care 
interface). It also required a number of behaviours by the nurses tasked with implementing 
the HIP process and the patients receiving it, including working together and with others to 
identify appropriate treatment or initiate health behaviour change. 
Development of the HIP and HIP Manual 
Building on existing experiential and research knowledge from delivering medication 
management education and practice change to healthcare professionals over many years, 
a need to develop a pragmatic intervention to support practice change in physical health 
in SMI was identified in 2007. A literature review had already been undertaken that 
highlighted specific areas of comorbidity risk in SMI and the potential of the MHN 
workforce to address these (Robson and Gray, 2007). From this paper and discussion 
between Professor Richard Gray, Dr Martin Jones and myself, 28 risk parameters were 
identified as a priority for assessment in SMI (Figure 6.1). A series of literature searches 
then established the normal and abnormal ranges for each of these parameters, and the 
recommended action/guidance for parameters found to be abnormal. A 27-item gender 
specific profiling tool was designed that would enable mental health nurses to use ‘red flag’ 
aspects of physical health when undertaking a physical health risk assessment with SMI 
patients. We believed it was important that the HIP was not just a checklist for 
assessment but prompted evidence based action for abnormal findings. The HIP was 
therefore designed to direct the nurse and patient to select the action or actions to take 
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next that best suited the individual by providing a menu of possible interventions to select 
from. Citations were provided for all parameter ranges and recommended actions and 
where there was the potential of different tests being used in practice (e.g. for blood 
glucose) a range of alternatives were provided (Please see Appendices 1 and 2 for a copy 
of the HIP and the HIP Manual).  
 
 
Figure 6:1 Physical health risk parameters included in the HIP 
 
1. Body Mass Index 
2. Waist Circumference 
3. Pulse 
4. Blood Pressure 
5. Temperature 
6. Liver Function Tests 
7. Lipid levels 
8. Glucose 
9. Cervical smear (female) 
10. Prostate and testicles check (male) 
11. Sleep 
12. Teeth 
13. Eyes 
14. Feet 
 
 
15. Breast check (female and male) 
16. Menstrual cycle (female) 
17. Smoking status 
18. Exercise 
19. Alcohol intake 
20. Diet: 5-a-day 
21. Diet: fat intake 
22. Fluid intake 
23. Caffeine intake 
24. Cannabis use 
25. Safe sex 
26. Urine 
27. Bowels 
28. Sexual satisfaction 
 
 
 
The considerable practice and education experience of all three authors was used when 
determining how to present the HIP to mental health nurses. The only other physical 
health tool available, known as the Rethink tool (Phelan et al., 2004), extends over 9 
pages and its size had been reported to us as a barrier to its use from those we knew who 
had tried to implement it. Practitioners regularly complain about the amount of 
administrative paperwork they are required to complete in their role. I had witnessed the 
benefits of presenting assessment information in a systematic format from my experience 
of the use of side-effect scales in nurse-led SMI medication management clinics. This 
approach had been welcomed as a way to improve interface communication by both 
psychiatrists and GPs. We wanted the HIP to be used as a support to practice and not 
seen as yet another administrative task or form to fill in. We therefore decided to keep the 
HIP to one side of a sheet of paper. We also decided to produce the HIP as a paper 
version, rather than a software or online version. This was to avoid problems in 
dissemination and use due to NHS governance and the low levels of use of information 
technology in clinical MHN practice. Use of electronic record systems was at a very early 
stage in secondary mental health services in 2007. A variety of different software was in 
use with its purpose largely to collect data for quality assurance purposes, rather than to 
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support clinical decision-making. This is very much in contrast to primary care where it 
would have been impossible to introduce a paper-based tool. It was believed that a paper-
based tool, completed on one side of A4 paper could easily be photocopied and sent to 
the patient’s GP or other agency with a cover letter to provide supporting evidence for any 
recommended referral. 
 
The HIP has columns indicating the variable at risk for assessment (e.g. smoking status), 
level (result), Green (e.g. ‘non smoker’), Red (e.g. ‘passive smoker/smoker’) and the 
recommended action for red group (e.g. advice that all smoking is associated with health 
risks, refer to NHS smoking cessation service). The HIP is intended to be completed at 
least annually, the recommended frequency of screening for patients with SMI in England. 
There was a need to consider issues of intellectual property against motivation to 
disseminate the HIP as widely as possible and encourage healthcare professionals to use 
it. The Journal of Psychiatric and Mental Health Nursing is the leading journal for mental 
health nurses in the UK. A paper describing the development of the HIP and its initial 
dissemination was published (White et al., 2009). A copy of the HIP was not included in 
the publication but released to anyone in contact with me and agreed to provide feedback 
in future via email. This continues today and the on-going dialogue with the large network 
of users is helpful in regularly updating the HIP. For example in 2012 changes were made 
to the blood pressure parameter and in 2014 to the diet parameters, due to new published 
guidance and feedback from users. 
 
A comprehensive HIP Manual was written expanding in detail the evidence for each of the 
HIP Parameters and the recommended action (Appendix 2). Specific information about 
how to complete and use the HIP in practice is included. The manual has been adapted 
for different purposes, for example there is a version for primary care (to support the HIP-
PC) and versions to support the Commissioning for Quality and Innovation [CQUIN] 
payment targets in specific NHS Trusts where the HIP is now implemented. 
 
Development of the education part of the HIP Programme  
The aim was to develop an education package for mental health nurses caring for people 
with SMI to enable them to offer better physical care through use of the HIP in their 
practice. As discussed earlier there was no published evidence to draw on to inform this 
process. In a systematic review of the outcomes of educational meetings, the use of 
mixed didactic and interactive methods was found to be more effective in changing 
professional behavior than didactic methods alone (Forsetlund et al., 2009). Harnessing 
the motivation and enthusiasm of participants for a topic through discussion has been 
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identified as important in supporting implementation of learning into practice after 
continuing professional development (Lee, 2011).  
Educational materials were designed (together with Professor Richard Gray and Dr Martin 
Jones) that integrated didactic teaching with experiential activities and discussion. These 
materials were initially used in a series of two national ‘train the trainer’ events in October 
2007 and February 2008 at the University of Aston Business School, Birmingham. 
Training in presentation skills was included and the workshops were funded by Bristol 
Myers Squib and Otzuka Pharmaceuticals UK. The learning activities were delivered by all 
three of us was attended by 24-experienced MHN from different mental health provider 
organisations around the UK (59% from community teams). The aim was to enable 
delegates to deliver at least three workshops for MHNs on return to their organisations. In 
2009 Bristol Myers Squib disbanded its nurse education department following a Europe 
wide marketing strategy review and ceased their support of dissemination of the 
programme. 
Building on previous extensive education experience and experience from the ‘train the 
trainer’ stage, the final HIP Programme training package was re-written by me as a series 
of four PowerPoint presentations with a view to flexible delivery i.e. selecting from the 
slides to meet the needs of mental health nurses and the time available to teach them (i.e. 
a 1-4 hour workshop).  
 
The intended learning outcomes were: 
 
At the completion of the training workshop participants will be able to: 
 
1. Explain why physical health is important in serious mental illness and nurses need 
to act. 
2. Use the HIP and HIP Manual to systematically examine the physical health of 
individual patients and identify the best next steps to take for items that flag red. 
3. Describe how to engage patients in health behaviour change and work with them 
to develop a patient specific health action plan  
4. Construct at least three action points to support the implementation of the HIP into 
their practice.  
5. Know what to do every time a HIP is completed with a patient 
6. Know how to access further information and resources to support their physical 
health care practice. 
 
The following four presentations were created and adapted by me from the materials used 
in the initial “train the trainers” dissemination of the HIP: 
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1. Background: Physical health is important in serious mental illness and nurses 
need to act. 
2. Review of the Physical Health Improvement Profile (HIP) Parameters 
3. Using the HIP to engage patients with serious mental illness in health behaviour 
change. 
4. Developing an action plan to take away. 
 
The first presentation supports a didactic presentation of the evidence relating to physical 
comorbidity, mortality and risk in SMI (although discussion of practice experience and 
views of participants is actively facilitated). The final few slides in this first slide set were 
developed in cooperation with Dr Sheila Hardy (who adapted the HIP for primary care) 
and include a brief overview of type II diabetes, heart disease, stroke and chronic 
obstructive pulmonary disease. The other three presentations support experiential 
learning through use of the HIP and HIP Manual to investigate how to manage a variety of 
practice scenarios related to “flagged red” items on the HIP (2), how to introduce the HIP 
and how to use the results to agree an individual health action plan (3) and support to 
identify and share potential ways to reduce anticipated barriers and increase levers to 
implementation (4).  
 
Evaluation of the HIP education package 
I initially piloted and refined the HIP Programme presentations in sessions in the 
undergraduate post and pre-registration modules that I deliver at the University of Hull. 
These materials have now been used for a variety of MHN audiences locally, regionally, 
nationally and (translated versions) internationally. In 2012, I delivered the HIP in a 
regional masterclass as part of a series of workshops that aimed to provide knowledge 
and skills matched to the NMC essential skills cluster competencies to mental health 
nurses from the Yorkshire and Humber NHS region.  
 
Method 
A pre- and post-test design was used. All 53 nurses who attended were asked to 
complete a questionnaire regarding their current knowledge of physical health in SMI just 
before the workshop started. This was repeated on immediate completion of the workshop, 
together with a post-evaluation of the workshop content, materials, and delivery. A 
multiple-choice format was used for knowledge questions and a Likert scale for the 
attitudinal items with spaces for answers to open-ended questions. Paired questionnaires 
(from the same participant) were identified using numbered forms. No personal data was 
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collected although some brief details of the participants gender, age, length of MHN 
experience and service context were requested 
 
Permission to undertake the study was granted by the School of Health and Human 
Sciences Research Ethics Panel at the University of Huddersfield. Information about the 
study was verbally exchanged with the participants at the beginning of the workshop, with 
consent presumed if questionnaires were completed and returned.  
 
Each participant was assessed on their response to 10 equally weighted multiple-choice 
questions relating to physical health assessment in SMI and the recommended action to 
take if a physical health parameter was at risk (Knowledge MCQ). A maximum of 10 
marks could be obtained from the summation of answer scores. 
 
Results 
The questionnaires were subject to statistical analysis using SPSS (version 18.0). Thirty-
nine questionnaires were submitted at the beginning of the workshop (74%), and 44 at the 
end (83%), the higher number reflects participants who arrived late. Responses submitted 
before and after the intervention were paired and 38 (72%) participants were included in 
the analysis as they provided valid responses. Thirty-six participants were female (78.3%) 
and 10 participants (21.7%) male. The majority of participants (23; 47.9%) had been 
working in health care for less than 5 years. Service contexts were approximately equally 
represented, with 18 inpatient nurses (38.3%), 14 community nurses (29.8%), and 15 
(31.9%) who recorded their context as “Other.” 
 
Figure 6:2 Pre and post test scores of knowledge MCQs 
 
The mean score recorded pretest was 4.47(SD 1.59) and post-test was 8.11(SD 
1.67) .The spread of pre- and post-scores is shown in Figure 6.2. A paired samples t test 
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found a statistically significant difference between pre- and post-scores (p < .001, 95% 
confidence interval 3.00, 4.58). Although all groups of participants recorded higher post-
test scores indicating knowledge transfer participants indicating they were from the 
inpatient context demonstrated less improvement (2.84 points: SD 2.31) than those from 
the community (4.27 points :SD 1.19) and who had indicated “other” (4.36 points :SD 
3.04). 
All participants except one reported themselves to be either “satisfied” or “very satisfied” 
with both the topic delivery and with the content of the workshop and its relevance to 
practice, with 38 respondents (77.6%) reporting themselves to be “very satisfied”. 
 
Discussion 
This small study demonstrated knowledge gain post workshop and also provided useful 
evidence of the range of scores for the knowledge MCQs that could potentially aid the 
analysis of knowledge gain in future. It is interesting that inpatient MHNs had less 
knowledge to gain, but maybe not surprising as inpatient MHNs tend to be more recently 
qualified and more likely to have up to date clinical physical health assessment skills (e.g. 
due to regular monitoring of vital signs in their practice). It is not clear why some workshop 
attendees indicated their work context as ‘other’, this could potentially be tertiary (e,g. 
forensic) services. There were limitations regarding the MCQ that was not 
psychometrically developed. Post session learning has a recency effect (Deese and 
Kaufman, 1957). The findings are encouraging but do not indicate if knowledge gained 
was retained or had any impact on future practice. 
 
 First pilot of the HIP in a nurse-led clinic in secondary care 
A senior mental health nurse trained in the first “train the trainer” event in 2007 piloted the 
HIP in a nurse-led ‘medication management’ clinic for community patients with SMI in 
Scotland, alongside one other mental health nurse she had trained.  
Method 
Frances Shuel [FS], and I obtained governance approval for a service evaluation that 
included a retrospective documentation audit of case notes for all patients where the HIP 
had been implemented in the clinic, semi-structured interviews with these patients and 
their secondary care clinicians and a postal survey of their GPs. Patients were assessed 
between 13/11/2007 and 17/09/2008 and consented to their anonymous data being used 
following information exchange from FS.  
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Patients who had used the HIP, their psychiatrists and MHNs who worked in the clinic 
and/or two acute inpatient wards at the hospital were invited to participate in short semi-
structured interviews. GPs were invited to complete a short postal questionnaire. After 
being reminded that anonymous data was being collected and asked to consent 
separately to this part of the study, participants were asked for feedback about their 
experience of the HIP. Open-ended questions included what they thought about the tool, 
what happened next, if they thought it had had any effect on communication with others 
and if they thought the tool could be improved. 
Each interview was conducted by FS on a one-to-one basis in a private room over 
approximately 10-20 minutes. Answers were recorded verbatim on to an anonymous data 
collection form for later collation and analysis. Analysis was undertaken of anonymised 
data using SPSS v15 and content analysis of the interview records by all three authors of 
the HIP. Where a patient identified that action had been taken about an out of range 
parameter following use of the HIP, FS was asked to provide further information from the 
case notes if available. 
The study did not meet the criteria of a research study as defined by the National Patient 
Safety Agency [NPSA] National Research Ethics Service (NPSA, 2008) and was, 
therefore, approved as a clinical audit and service evaluation by the Hospital’s Medical 
Director, including permission to publish data and results. 
Results 
All 31 patients agreed to participate in the semi-structured interviews that took place with 
FS at their next visit to the clinic. All MHNs (with the exception of FS who conducted the 
interviews) and psychiatrists working in the clinic and/or wards at the hospital agreed to 
take part in the interviews (n=8; n=4). 57% GPs returned the short postal questionnaires 
(n = 12). 
 
One hundred and eighty nine physical health issues were identified in this first case series 
(mean 6.1 per patient). Please see Table 6.1 for details of the frequency of issues 
reported. The items most frequently flagged ‘red’ on the HIP, suggesting that intervention 
was required, were body mass index [BMI] (n = 24), breast self-examination (n = 23), 
waist circumference (n = 21), pulse (n = 14) and diet (n = 13). At least one physical health 
issue was identified in every patient. There was a high prevalence of obesity, poor diet 
(particularly eating five portions of fresh fruit and vegetables a day) and lack of exercise. 
Breast self-monitoring was inadequate and cardiac problems (tachycardia) were common.  
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Table 6:1 Frequency of HIP parameters (N=31) 
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Mean BMI and waist circumference were indicative of obesity, although average lipid and 
glucose levels were normal (Figure 6.3). Smoking, alcohol and cannabis use were 
recorded in a smaller number of patients than might be expected. The two items most 
often omitted from completion by the HIP by the nurse were safe sex and sexual 
satisfaction. These were not determined in at least half of all patients but where 
satisfaction was assessed, over a third reported experiencing problems. 
Figure 6:3 Mean scores for HIP parameters (N=31) 
 
There were 14 referrals for potentially serious conditions including raised glucose and 
lipids, hypertension and cardiac problems. Individualised care was planned and delivered 
with each patient based on the profile. Twenty-eight discreet interventions were used that 
included providing advice, promoting health behavioural change, performing an 
electrocardiogram and making a referral to professional colleagues. The range and 
frequency with which each intervention was used is shown in Table 6.2. 
Participants in the semi-structured interviews and GP survey were largely positive about 
the HIP process. Patients expressed surprise that the MHN was paying attention to their 
physical health but liked the opportunity to have a physical health conversation. There 
was evidence from the patient responses and the case notes that the nurse went on to 
plan care to address physical health need. Several patients reported positive outcomes as 
result of changes to their health behaviour or medication following use of the HIP (e.g. 
weight loss, lower blood pressure). Negative comments included one from a patient about 
the (financial) cost of having to buy new clothes after losing weight and four (50%) mental 
health nurses who were concerned about the potential additional workload of 
implementation. All four psychiatrists commented positively about the HIPs 
comprehensiveness and evidence base. The GPs also liked the comprehensiveness and 
welcomed the HIP as a way of sharing of data to benefit them. Two GP’s thought the 
amount of information on the form meant they could miss red-flagged parameters and one 
suggested the HIP or accompanying letter should highlight which interventions they were 
required to do. 
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Table 6:2 Interventions delivered to patients following the HIP  
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Discussion 
This pragmatic service evaluation provided evidence that the HIP is a useful clinical tool 
that enables MHNs to profile and plan physical health care and treatment for patients with 
SMI.  
Patients welcomed and actively participated in the process. Rates of physical health 
problems observed using the HIP were broadly similar to a study of patients in the North 
East of England receiving antipsychotics in primary care (Macklin et al, 2007). Some of 
the findings concerning lower than expected rates of smoking and high levels of 
tachycardia may be related to the sample, who were all drawn from those attended an 
outpatient clinic for medicines management (i.e. that they had already been engaged in 
smoking cessation interventions and that they were likely to be prescribed an 
anticholinergic antipsychotic (e.g. clozapine). The comments from the patients and 
secondary care record evidence suggested that many of the problems identified in the HIP 
process was new information to the patient and secondary care team and (possibly) 
primary care, e.g. where a decision was taken to initiate statins. We received very positive 
qualitative feedback from patients, mental health nurses, psychiatrists and GPs about the 
utility of the tool.  
 
Limitations included possible bias in the data collection method. All data was collected by 
FS who was very supportive of the HIP Programme and had introduced the HIP to her 
own her own and others’ practice. Patient participants may have been keen to provide 
positive comments about their care to the person who was providing it. Clinicians 
interviewed were those who had an existing professional relationship with FS, in some 
cases she was their line manager. It was not possible to compare identified physical 
problems with previously diagnosed comorbidities as access to all records was not 
possible within the confines of the permission granted for the audit (i.e. both primary and 
secondary care). Nevertheless this study provided enough evidence of acceptability and 
utility for a clinical trial of the HIP Programme. It also suggested the need for a greater 
focus on having conversations about sex and the need to make sure barriers to 
implementation are afforded enough time for discussion and problem solving in the HIP 
workshops (highlighting how to communicate with GPs and MHN workload issues) if this 
is not raised by participants. At an organisational level shared care pathways between 
primary and secondary care that clearly identify roles and responsibilities for physical 
health care in SMI may help to address some of the role confusion that was highlighted by 
a few of the GPs.  
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Chapter summary 
This chapter has described the development of the HIP Programme intervention designed 
to target physical wellbeing in SMI through the existing role of the mental health nurse 
from the initial idea in 2007. Pragmatic evaluations of the impact of the ‘train the trainer’ 
method and evaluation of implementation of the HIP with 31 patients in one secondary 
care nurse-led community clinic provided evidence of acceptability and utility. Since this 
PhD study commenced in early 2009, the data from the service evaluation has been 
analysed and published in a peer-reviewed journal and used to inform a grant application 
to the National Institute for Health Research [NIHR] for a clinical trial. A small opportunistic 
study demonstrated that the final education package significantly improved MHNs 
physical health knowledge at the end of a 3-hour version of the HIP workshop. 
The development and piloting work described in this chapter was published as: 
 
White, J., Gray, R. & Jones, M. 2009. The development of the serious mental illness 
physical Health Improvement Profile [HIP]. Journal of Psychiatric and Mental Health 
Nursing, 16, 493-498. 
 
 
Shuel, F., White, J., Jones, M. & Gray, R. 2010. Using the serious mental illness 
health improvement profile [HIP] to identify physical problems in a cohort of 
community patients: A pragmatic case series evaluation. International Journal of 
Nursing Studies, 47, 136-145. 
 
White, J., Hemingway, S. & Stephenson, J. 2013. Training Mental Health Nurses to 
Assess the Physical Health Needs of Mental Health Service Users: A Pre- and Post 
test Analysis. Perspectives in Psychiatric Care, Early View 25 NOV 2013 DOI: 
10.1111/ppc.12048, E1-8. 
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Chapter Seven: Further evaluations of the HIP in practice 
 
Introduction 
Frances Shuel [FS] delivered HIP training to all eight mental health nurses working across 
the two acute inpatient wards of the hospital in Scotland that she managed within her role. 
With the agreement of the multidisciplinary teams and under her direction, a practice 
standard was agreed to complete a HIP for every patient on admission to either ward, or 
as soon afterwards as was practically possible. As with the nurse-led (community) clinic 
data described in the previous chapter, FS transcribed data from each completed paper 
HIP into an excel database with a view to future evaluation. Patients were assigned a 
unique number in the database that could be linked to their case records by FS if required. 
Details of the patient’s gender, date of birth, diagnosis, medication and date of completion 
of the HIP were included, alongside the results of each parameter assessed using the HIP. 
A free text “comments” field was used to record information about interventions.  
Method 
FS obtained governance permission for a retrospective clinical audit of the HIP inpatient 
database in July 2010. I analysed the (anonymised) data after cleaning it and then 
importing it to SPSS 17 from Excel. Duplicates were removed (if there had been more 
than one HIP completed for the same patient). Several data entry errors were observed at 
this stage and resolved by communicating with FS (e.g. measurement queries, missing 
data). Unfortunately, it was not possible to revisit all the original forms to check and/or 
repeat the original data entry so interventions were only captured if FS had considered 
them important. 
Results  
108 ‘first contact’ HIPs were completed between November 2007 and June 2010 for 
patients admitted to the two inpatient wards. Characteristics of the sample are 
summarised in Table 7.1.  
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Table 7:1 Characteristics of the acute inpatient sample who received a HIP (N=108). 
 N (%) 
Age (mean, SD) 43 (11) 
Male gender 71 (66) 
Ethnicity (white) 106 (98) 
Diagnosis 
Schizophrenia (or schizoaffective 
disorder) 
72 (67) 
Bipolar disorder 14 (13%) 
Other (e.g. borderline personality 
disorder,  
substance and/or alcohol use 
disorder, depression) 
22 (20%) 
Psychiatric Medication 
Prescribed medication 
 
98 (96) 
Prescribed antipsychotic medication 91 (84) 
Prescribed no medication 4 (3.7) 
 
Please see Table 7.2 for a summary of the HIP parameters that flagged red in this cohort. 
934 physical health issues were identified per patient (mean 11.43 sd = 5.08, 95% 
confidence interval ±0.76).  
Every patient had at least 2 parameters that flagged red, indicating the need for 
intervention. Although there was a slightly different distribution of parameters compared to 
the HIP, 31 CVD risk parameters continued to predominate. Four of these (BMI, lipids, 
waist circumference, smoking) flagged red in over half of the sample, along with the diet 
and self-examination parameters. However, in common with the community (HIP 31) 
sample, mean blood pressure, glucose and cholesterol values were within their normal 
range (Table 7.3).  
There was evidence of intervention to improve health status from information entered in 
the comment fields. For example, of 41 patients with an abnormal pulse, 29% (12) had a 
comment to indicate they were then found to have an abnormal electrocardiogram [ECG] 
that led to a change in medication. Of 21 patients who reported sexual dissatisfaction 
through use of the HIP, 71% (15) had raised prolactin and 6 went on to try a change of 
antipsychotic. Of patients who were asked, 20% (17) reported not practicing safe sex so 
the opportunity to have a conversation with them about this and exchange information 
was exploited. 
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Table:7:2 HIP parameters that flagged red in the inpatient HIP cohort (n=108) 
a = men only, b = women only , c = All patients have liver function tests on admission as standard. 
 
 
 
 
 
 
 
 
 
 
Rank	 Item	 Not	assessed	 Men	(%)	
n=71	
Women	(%)	
n=37	
Total	(%)	
n=108	
		1	 Diet	(fat	intake)	 -	 68	(96%)	 29	(78%)	 97	(90%)	
		2	 Breast	check	 -	 69	(97%)	 20	(54%)	 89	(82%)	
=3	 Body	Mass	Index	 -	 53	(75%)	 23	(62%)	 76	(70%)	
=3	 Prostate/testicles	check	
a
	 -	 50	(70%)	 -	 -	
	4	 Diet	(5	a	day)	 -	 47	(66%)	 24	(65%)	 71	(66%)	
=5	 Lipids	 13	(12%)	 43(66%)	 19	(63%)	 62(57%)	
=5	 Waist	circumference	 -	 41	(58%)	 21(58%)	 62	(57%)	
		6	 Smoking	status	 -	 39	(55%)	 19	(52%)	 58	(54%)	
		7	 Alcohol	 -	 41(58%)	 8	(22%)	 49	(45%)	
		8	 Feet	 -	 35(49%)	 13	(35%)	 48	(44%)	
		9	 Teeth	 -	 33	(46%)	 11	(30%)	 44	(41%)	
10	 Urine	 1	(1%)	 33	(46%)	 10	(28%)	 43	(40%)	
11=	 Exercise	 -	 26	(37%)	 15	(41%)	 41	(38%)	
11=	 Pulse	 -	 31	(44%)	 10	(27%)	 41	(38%)	
12	 Caffeine	intake	 -	 23	(32%)	 13	(35%)	 36	(33%)	
13	 Eyes	 -	 24	(34%)	 8	(22%)	 32	(30%)	
14	 Menstrual	Cycle	 1	(1%)	 -	 10	(28%)	 -	
15	 Bowels	 -	 19	(27%)	 9	(24%)	 28	(26%)	
15=	 Safe	sex	 22	(20%)	 11	(20%)	 6	(19%)	 17	(25%)	
16=	 Cannabis	use	 -	 20(28%)	 7	(19%)	 27	(25%)	
16=	 Cervical	smear	
b
	 1	(1%)	 -	 9	(25%)	 -	
17	 Fluid	intake	 -	 19	(27%)	 6	(16%)	 25	(23%)	
18	 Glucose	 5	(5%)	 14	(61%)	 9	(39%)	 23	(21%)	
19=	 Sex	satisfaction	 30	(28%)	 14	(20%)	 7	(24%)	 21	(19%)	
19=	 Sleep	 6	(6%)	 8	(12%)	 8	(23%)	 16	(19%)	
20	 Blood	pressure	 -	 13	(18%)	 6	(16%)	 19	(18%)	
21	 Temperature	 -	 5	(7%)	 5	(13%)	 10	(9%)	
22	 Liver	Function	
c
	 	 	 	 0	(0%)	
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Table 7:3 Cardiovascular risk in the inpatient HIP cohort (N=108) 
 N Minimum Maximum Mean (SD) 
Body Mass Index 108 18.0 48.5 29.7 (6.6) 
Waist circumference 
(cm) 
108 70.0 155.0 98.5 (16.3) 
Pulse  108 66 151 100.5 (14.9) 
Systolic Blood Pressure 108 85 174 124.1 (15.4) 
Diastolic Blood Pressure 108 50 99 75.8 (9.9) 
Random Plasma Glucose 103 3.0 12.5 5.9 (1.4) 
HBA1C 75 3.9 6.8 5.2 (0.5) 
Total cholesterol 97 2.3 8.9 4.9 (1.3) 
HDL cholesterol 96 0.6 7.8 1.6 (1.1) 
LDL cholesterol 96 0.9 5.6 2.9 (1.0) 
Triglycerides 97 0.5 10.4 2.2 (1.5) 
Smoking 108 58 (54%) smokers 
 
Discussion 
Compared to the 16,240 patients admitted to 136 acute wards across England reported in 
the City 128 ‘Safewards’ Cohort (Bowers et al., 2006), our sample had a higher proportion 
of males (0.66 versus 0.49), patients with a diagnosis of schizophrenia (0.67 versus 0.32) 
and white ethnicity (0.98 versus 0.67). Duration of illness was not reported in the City 128 
study but in 73% of our sample it was more than 10 years. This may explain the relatively 
older age of our sample and high number of comorbidities detected.  
Mean body mass index, waist circumference, pulse and raised triglycerides were similar to 
that seen in the (community) HIP 31 sample, as were smoking rates. Smoking at 55% was 
comparable to that reported in the sample recruited from primary care SMI registers from 
eight sites across England and Wales for the Wellbeing Support Programme (51%, n = 
479) (Smith et al., 2007a).  
Reported levels of alcohol use indicating a need for intervention occurred in just under half 
this acute inpatient sample (45%). This may have reflected acuity and drinking as a 
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coping strategy just prior to admission or been skewed as a result of those admitted for 
detoxification. It is also possible that the number of alcohol units were inaccurately 
recorded on the HIP form by the nurse (units per day are required, not per week requiring 
an estimation based on information disclosed). Similar to the results of the HIP 31 study, 
the parameters that were most often omitted were those related to safe sex and sexual 
satisfaction. This adds weight to the earlier observation that there are barriers to nurses 
and patients having conversations about sex. 
Limitations are similar to those described for the HIP 31 cohort and included possible bias 
in the data collection and recording methods. FS is an advocate of the HIP Programme 
and had introduced it and decided what data to collect for evaluation purposes at the 
hospital. Data was not available on patients’ previous comorbid physical diagnoses, the 
outcome of interventions or about patients where a HIP had not been completed 
(presumably some patients had refused or nurses were unable to engage some in the 
whole process). The sample was not restricted to patients with SMI because it was a ‘real 
practice’ cohort of those admitted for acute inpatient care. Although there were some 
repeat HIP records in the database, numbers of these were far too small to enable any 
meaningful comparison so the evaluation was restricted to ‘first contact’ HIPs. 
This further opportunistic evaluation of a convenience sample added to the evidence of 
utility and acceptability of the HIP, supporting its ongoing use in clinical settings. 
Community patients already engaged in attending a medication management clinic in 
secondary care had similar comorbidity incidence to previous evaluations of primary care 
cohorts receiving antipsychotic medication, but less than that reported in epidemiological 
studies. Patients in acute inpatient settings with a broader range of diagnoses than SMI 
alone had a worse physical health profile than community patients but were still willing to 
engage in the HIP process. For some patients intervention following implementation of the 
HIP for potentially serious problems may have prevented premature mortality. It appeared 
that the HIP could be successfully implemented through a brief cascade of training without 
reconfiguring services and roles. However, this work indicated that the HIP Programme 
training would benefit from more of a focus on the importance of initiating conversations 
with patients about their sexual health (with discussion of potential barriers and how to 
overcome them) and clarification about how to record items that rely on estimation (e.g. 
alcohol units, fluid intake, urine output).  
The HIP Programme in Switzerland: The Gesundheitsfoerderungsprofil  
[GEPPsy]. 
Following publication of the development paper and at the invitation of Dr Chris 
Abderhalden, Director of the University Psychiatric Hospital, Bern, Switzerland the HIP 
Manual, HIP and the HIP Programme slides were translated into Swiss-German. I 
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delivered a series of workshops to Swiss mental health nurses through translators in 
August 2011. This was followed by a project to evaluate implementation of the Swiss-
German version of the HIP, the Gesundheitsfoerderungsprofil [GEPPsy]. Sulin Bänziger 
analysed GEPPsy data for a cohort of 151 adult patients with SMI (96 from three 
community teams and 55 from the two inpatient wards serving the same catchment area) 
for her Master’s thesis. The cohort was predominantly male (80%) and either had a 
diagnosis of schizophrenia 68% (n=103) or bipolar affective disorder 48% (n=32). Rates of 
comorbidity were similar to those seen in the Scottish HIP cohorts, with body mass index 
(68%), waist circumference (66%) and smoking (61%) the highest ranked risk items. 
Interestingly it appeared to be the items that required a blood test that were least likely to 
be completed on the GEPPsy, with 30 patients having no record for lipids and 17 none for 
glucose. Swiss mental health nurses and patients appeared to have less difficulty talking 
about sex; 5 patients had no record for the safe sex item and 1 for sexual satisfaction. A 
positive evaluation from surveys of patients (n=21), nurses (n=21), and home doctors 
(n=8) provided further evidence of acceptability, flexibility and (international) utility of the 
programme (Bänziger 2013). 
 
Chapter Summary 
In this chapter opportunistic and pragmatic evaluations of data from implementation of the 
HIP (including a translated version) provided evidence of acceptability and utility in acute 
inpatient care in one hospital in Scotland and in secondary (inpatient and community) care 
in Switzerland. The inpatient cohort in Scotland had a worse physical comorbidity profile 
than community patients from the same area who were engaged in and attending a nurse-
led clinic. Patterns of completion of the HIPs suggested barriers to having conversations 
about sex. 
The evaluation work of the HIP inpatient cohort described in this chapter was 
disseminated by conference presentation in 2010: 
White, J. 2010. Evaluation of the serious mental illness Health Improvement Profile [HIP]: 
The HIP 100. . 16th International Network for Psychiatric Nursing Research (NPNR) 
Conference: Collaborative research and partnership working 23rd September 2010.  . 
Wadham College, Oxford , Royal College of Nursing. 
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Chapter Eight: Cluster Randomised Controlled Trial and Process 
Observation Methodology 
The earlier chapters have established that physical comorbidity is a major cause of early 
mortality in serious mental illness and that the recommended annual health checks to 
address physical comorbidity in this population are not being routinely undertaken in any 
care setting. Although mental health nurses [MHNs] have a positive attitude towards a 
physical health role, deficits in knowledge and poor preparation are reported to impair 
their ability to deliver physical health care in practice. Training MHNs in physical health 
risk assessment could potentially address the physical health care deficit for SMI patients 
in contact with secondary (mental health) services.  
A pre and post training evaluation established that MHNs gain knowledge from HIP 
training and are positive about their ability to use the HIP to support their future practice 
(White et al., 2013). The largest numbers of people with SMI in the UK are in community 
settings. A pilot and service evaluation of the HIP Programme demonstrated utility in 31 
community patients (Shuel et al., 2010).  Considerable physical comorbidity in this small 
sample of convenience was confirmed. Patients, nurses, psychiatrists and GPs reported 
they liked the HIP process and there was some evidence of appropriate intervention and 
health behaviour change following its use. 
We do not know if receipt of an annual health check using the HIP in routine community 
mental health practice improves patient outcomes. It seems reasonable to progress from 
the pilot work to address the central research question: 
Does the HIP and the brief HIP training package for nurses [HIP Programme] 
result in improved health outcomes for patien 
Funding and approvals for a clinical trial  
To achieve adequate grant funding for the clinical trial stage an application was made for 
a grant from the 9th competition for the National Institute for Health Research [NIHR] 
Research for Patient Benefit [RfPB] programme in the East of England. The application 
was developed with a group of collaborators led by Professor Richard Gray (as Chief 
Investigator), and included a medical statistician, health economist and public and patient 
involvement representatives. My role was to write and submit the grant application and 
respond to feedback from the research team and the NIHR peer reviewers (under 
supervision). I began the grant writing process in April 2009. The first attempt was 
shortlisted but unsuccessful, the second attempt was successful and the sponsor NHS 
Trust was awarded the grant of £249,159 in April 2011 to coincide with NHS approvals. 
My role as Project Lead was funded at 20% between April 2011 and April 2014. The trial 
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was prospectively registered with ISRCTN on 04/03/2011 
(http://www.isrctn.com/ISRCTN41137900) and is included in the NIHR Portfolio database 
at http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=8505.  
Securing NHS ethics and governance approvals had to start before the outcome of the 
grant competition was known. Utilising knowledge and skills gained from an Integrated 
Research Approvals System (IRAS) course, under supervision and with collaboration from 
the research team, I constructed the 80 separate documents required for the approvals 
process and the Case Record Form [CRF]. This included a detailed research protocol and 
all participant information, consent forms, outcome measures and adaptation of existing 
validated measures. In collaboration with the Mental Health Research Network [MHRN], 
public and patient involvement representatives with SMI provided feedback on the 
structure of patient information and the feasibility of the design of the process observation 
phase when investigating the perceptions of patients. A second NHS site in Lincolnshire 
was engaged, as through my existing networks, as it was clear that we would be unlikely 
to achieve the required sample size from recruitment within the sponsor NHS Trust. The 
trial was granted ethical approval in December 2010 by the Cambridge East (previously 
Cambridge 4) Research Ethics Committee. NHS governance approvals for both Trusts 
were achieved in April 2011. 
Once all approvals were achieved and the trial registration number (ISRCTN41137900) 
issued, the trial protocol was finalised by the Trial Steering Committee and I prepared it for 
submission to Trials. 
Design 
The most robust method for answering the research question is a randomised controlled 
trial comparing health outcomes of patients treated by Community Mental Health Nurses 
[CMHNs] trained to use the HIP with those delivering routine treatment as usual. Patients 
of CMHNs are not independent of each other (one of the assumptions of standard 
statistical procedures) rather they are under the care of a nurse who is likely to provide 
similar care to all patients on their caseload. A design with the patient as the unit of 
randomisation would therefore risk contamination between groups. The community mental 
health team was rejected as a unit of randomisation for pragmatic reasons due to the 
small number of CMHNs in some teams and uncertainty about the ability to recruit from all 
available teams across all sites in such a large geographical region. In a cluster RCT that 
trained CMHNs in an adherence intervention with the CMHN as the unit of randomisation, 
there was no evidence of contamination between nurses in the same team (e.g. by 
sharing the intervention manual) (Gray et al., 2004). The CMHN was therefore selected as 
the unit of randomisation for this trial.  
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There were two parts to the study. In Part 1 a single-blind, parallel group randomised 
controlled trial design, clustered at the level of the CMHN was used. The study was 
planned in accordance with the Consolidated Standards of Reporting Trials [CONSORT] 
cluster trial extension reporting standards (Campbell et al., 2004). Knowledge of and 
attitude of the CMHNs towards a physical health role was to be investigated and 
compared between groups using a pre and post-test survey. It was planned to investigate 
any impact on cardiovascular risk modification using demographic data and data from the 
HIP in a pre and post ‘within-treatment’ group design. Part 2 of the study investigated the 
process and experience of the use of the HIP by patients and staff using semi-structured 
interviews and a case note audit. The retrospective nature of Part 2 meant that it had to 
take place after Part 1 had been completed. 
Main hypothesis 
The aim was to test the hypothesis that patients with SMI on the caseload of Community 
Mental Health Nurses [CMHNs] trained to use the HIP would have improved physical 
health related quality of life after a year compared to patients on the caseloads of nurses 
delivering usual care.  
Primary objective 
There have been no clinical trials to educate health professionals in physical health 
screening or intervention (including health advice) that have demonstrated a significant 
effect on physical health related quality of life in SMI patients (Hardy et al., 2011, Tosh et 
al., 2010, Tosh et al., 2014). Health related quality of life includes the physical, functional, 
social and emotional wellbeing domains unique to each individual that are effected by 
health and illness (Guyatt et al., 1993, Testa and Simonson, 1996). Physical health 
related quality of life attempts to quantify a person’s subjective perceptions of their ability 
to cope in their physical health domain (Testa and Simonson, 1996).  
The primary objective of the study was to determine the effects of the HIP Programme on 
patients’ physical health-related quality of life over 12 months compared to treatment as 
usual (Objective 1). Objective measures of health gain were considered for this study (e.g. 
improvement in body mass index, blood cholesterol). However because the HIP 
addresses multiple health risks, multiple measures would have been required in both 
groups contaminating the TAU group with screening interventions so this approach was 
rejected.  
Secondary objectives 
The burden of CMHN training and additional screening and treatment of unmasked 
physical comorbidity in patients would incur additional service costs so an economic 
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evaluation assessed if the HIP Programme represented a cost-effective use of NHS 
resources (Objective 2). Little is known about the impact of physical health screening and 
care on the mental health of patients or training on nurse attitudes and knowledge. The 
impact of the HIP Programme on patients’ mental health related quality of life (Objective 
3) and CMHNs attitude towards and knowledge of physical health care (Objective 4) was 
evaluated. It was also planned to test the impact of the HIP Programme on modification of 
patients’ cardiovascular risk (Objective 5), as cardiovascular risk represents the greatest 
physical health risk to mortality in this population. In addition the process of using the HIP, 
including patient and staff experience and impact on communication and care planning 
was explored (Objective 6).  
Outcome measures 
The outcome measures used in the study are summarised in Tables 8.1and 8.3  
Table 0:1 Part 1 cluster RCT outcome measures  
 HIP  
(baseline and 52 weeks*) 
TAU  
(baseline and 52 weeks*) 
  
Patient subjects 
 
Nurse subjects 
 
Patient subjects 
 
Nurse subjects 
SF36v2  
 
X  X  
EQ-5D X  
 
X  
 
HRU-patient X  
 
X  
 
HIP 
 
X    
QRISK
®
2 
 
X    
HRU-Nurse  X 
 
 X 
Adapted 
PHASe  
 
  
X 
 
  
X 
 
* = ± 14 days 
 
Table 0:2 Part 2 process observation outcome measures  
 HIP TAU 
  
Patient subjects 
 
Nurse subjects 
 
Patient subjects 
 
Nurse subjects 
Semi 
structured 
interview 
 
X 
 
X 
  
 
HIP Audit 
Form 
 
HIP 
returned 
HIP not 
returned 
   
 
X 
 
X 
  
X  
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CMHNs were randomised to either the HIP Programme or TAU Group to compare impact 
and cost effectiveness of the HIP Programme (Objectives 1-3).   
The Medical Outcome Study (MOS) 36 Item Short Form Health Survey version 2 [SF-
36v2] is a self-report multidimensional measure of health-related quality of life and 
wellbeing with well-established psychometric properties (Ware, 2007). The revised version 
of the SF36 has improvements in item wording and format and a 6-fold increase in the 
range of scores produced without increase in participant burden (Ware, 2004). It has been 
shown to have good sensitivity to change in outpatients with schizophrenia, uncommon 
among QoL measures (Russo et al., 1998). The scales of the SF-36v2 address eight 
health domains: physical functioning, role limitations due to physical health problems, 
bodily pain, general health perceptions, vitality, social functioning, role limitations due to 
emotional problems, and mental health. It allows the calculation of two summary scores: a 
physical component summary score [PCS] and a mental component summary score 
[MCS] both ranging from zero (poor health) to 100 (perfect health) (high = good). The 
PCS was selected as the main health quality of life outcome measure for the primary 
objective (Objective 1). As it was hypothesised that mental health-related quality of life 
may change as a result of the HIP Programme, this was evaluated using the MCS 
(Objective 3).  
In line with a previous economic evaluations for patients with schizophrenia (Barton et al., 
2009), levels of health care resource use [HRU] were captured via amended versions of 
the Client Service Receipt Inventory [CRSI] (Chisholm et al., 2000). Two HRU forms were 
designed for nurse and patient participants. The HRU-Patient monitored health 
professional visits, hospital admissions, medication etc. and was administered by a 
researcher blind to group allocation at baseline and at a 52 week follow-up visit. Nurses 
were asked to report the time taken to complete each HIP and any action taken as a result. 
using the HRU-Nurse.  
The EuroQol 5 Dimensions Questionnaire [EQ-5D] is an established, standardised health-
related quality of life instrument used extensively in clinical studies (The EuroQol Group, 
1990). It provides a simple descriptive profile of each respondent and a single index value 
for their perceived current health status allowing a calculation of Quality Life Adjusted 
Years [QALYs]. It comprises five items covering the domains of mobility, self-care, usual 
activity, pain/discomfort, anxiety/depression and a visual analogue scale. The EQ-5D was 
selected for the effectiveness component of the economic analysis because it is 
cognitively simple and takes only a few minutes to complete, thus reducing participant 
burden. It was administered to all patient participants at baseline and at the 52 weeks post 
randomisation visit by a researcher. 
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The Mental Health Nurse Physical Health Attitude Scale [PHASe] is a 29-item 
questionnaire with established validity, designed to capture MHNs attitude towards their 
physical health care role (Robson and Haddad, 2010). The PHASe does not evaluate 
knowledge so it was adapted to include 20 physical health care multiple-choice questions 
[MCQs]. These questions were piloted and used to evaluate knowledge with forty-six 
nurses attending a physical health master class (White et al., 2013). All MHNs in the study 
were invited to complete the adapted PHASe online at baseline post randomisation and 
then again at the end of one year (Objective 4). Where the nurse failed to respond to two 
email reminders to complete the adapted PHASe online or they specifically requested it, 
they were sent a paper version in the post with a request to complete and return it in a 
stamped addressed envelope. 
It was intended to measure cardiovascular risk using a ‘within treatment’ group design in 
the HIP Programme group patients at baseline and at 12 months to allow before-after 
change to be estimated (Objective 5). There are no cardiovascular risk prediction tools yet 
available specifically designed for an SMI population. QRISK®2 is a cardiovascular 
disease prediction algorithm providing an individualised estimate of risk using cholesterol, 
blood pressure and body mass index values, medical history and taking account of the 
independent contributions of ethnicity and social deprivation in the UK (by post code). 
Face validity, good discrimination and calibration of items has been established for 
QRISK®2 in the general population (Hippisley-Cox et al., 2008, Hippisley-Cox, 2009). It 
was intended to extract data from the HIP form and patient demographics for all subjects 
in the HIP Programme Group to enable a calculation of individual QRISK®2. Unfortunately 
the amount and poor quality of data entered into the HIP forms prevented this.  
A process observation was conducted to assess the acceptability of the HIP Programme 
in the NHS (Objective 6). A retrospective documentation audit of the secondary care 
patient record compared details of documented physical health care and communication 
in a sub-sample of patient participants. Perceptions of the HIP were explored in a sample 
of patients and health professionals using a cross sectional semi-structured interview 
design. Outcome measures specifically designed for this process observation part of the 
study were used.  
The HIP Audit form was designed by the Project Lead (the author) and piloted with four 
patients that also enabled researchers to become familiar with its use. No modifications 
were required after piloting.  The HIP Audit form captured details of recorded physical 
health needs, care plan interventions, goals, review dates and interface communication 
(e.g. letters) from the secondary (mental health) care patient record. A researcher (MHN) 
administered the audit at the site with the largest number of participants. 
 97 
Topic guides that included a series of open-ended questions and prompts guided the 
semi-structured face-to-face interviews with patients and nurses, and telephone interviews 
with psychiatrists. It was intended to interview GPs of the patient participants but none 
responded to the invitations. The Project Lead (me) and Process Observation Lead 
conducted face-to-face interviews and the Project Lead conducted the telephone 
interviews. Questions aimed to: 
 Obtain insights into the patients’ and health professionals’ experiences of using the 
HIP 
 Consider which elements of the HIP were perceived as being most and least 
helpful 
 Explore participants’ perceptions of the effect that they think the HIP (as opposed 
to TAU) has on them 
 Uncover any potential barriers and blocks to using the HIP 
 Explore how the HIP could be refined and enhanced.  
 
Sample size 
Part 1: Power Calculation 
A sample size of 50 MHNs were sought (25 in the HIP and 25 in the TAU group), with 5 
patients each resulting in an overall sample size of 250 patients (125 in the HIP and 125 
in the TAU group). This was based on the following assumptions: 
1. The data (scores on the outcome measures) are independent of each other. That is, 
scores of one participant are not systematically related to scores of the other 
participants. 
2. The primary outcome of interest is improvement in community SMI patient’s physical 
health related quality of life measured using the total Physical Component Score 
[PCS] of the SF36v2. 
3. A two-tailed assumption is made for the (normal) distribution of PCS scores across the 
samples from participants in the two unrelated groups (HIP Programme and TAU). 
4. A mean standard deviation of the PCS of 12 points was selected. This was identified 
from a reference group of 407 community patients with SMI in a trial of nurse led 
community care management in the US (Druss et al., 2010).  
5. The level of significance for detecting an effect of the HIP Programme intervention 
was set at 5%.  
6. A difference in means between intervention and TAU of 6 points in the PCS subscale 
is equivalent to an effect size of 5% (0.05). 
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7. As the intervention [HIP Programme] is directed at the CMHN (the cluster) with 
outcomes measured at the patient (individual) level, some within-cluster dependence 
was anticipated that required inflation in the sample size. An intraclass correlation 
coefficient [ICC] was calculated to determine the degree of within-cluster dependence 
(Donner, 1992). The degree of certainty that a true difference between groups (of at 
least 6 points) would be detected was 86% if an ICC of 0.1 is assumed, and nearly 
80% if an ICC of 0.2 is assumed.  
8. Applying an ICC of 0.2, using a 2-sided significance level of 0.05 requires 
randomisation of 200 patients.  
9. The patient attrition rate in a previous cluster randomised controlled trial of a training 
intervention directed at CMHNs in the UK was 20% (Gray et al., 2004). Assuming a 
similar rate (50 patients) the randomisation of 5 patients per nurse at baseline was 
required.  
 
All MHNs in the HIP and TAU groups were invited to participate in the online adapted 
PHASe at baseline and one year. All patients remaining the HIP Group at one year were 
intended to provide data for evaluation of any change in their QRISK®2 Scores.  
Part 2: Audit and semi-structured interview sample 
Thirty patients were purposefully selected from the HIP Programme Group (10 who 
received the HIP at baseline, 10 who did not receive the HIP at baseline) and 10 patients 
from the TAU Group to participate in the HIP Audit. All 30 patients were selected from the 
largest recruiting NHS site to make the best use of research staff time as this was the first 
site to complete Part 1 follow-up and data collection and un-blinding of research staff was 
required to facilitate data collection. This was therefore a sample of convenience. 
It was intended to purposefully recruit from the HIP Group (on completion of Part 1) 10 
patients to participate in the Patient Semi-structured Interviews, 10 nurses to participate in 
one-to-one interviews, 5 psychiatrists and 5 GPs to participate in the telephone interviews 
(30 in total). Small numbers of well-selected homogeneous interviewees (with adequate 
exposure to the phenomenon under study) can produce highly relevant information for 
analysis (Cleary et al., 2014). This qualitative part of the study was planned in accordance 
with the consolidated criteria for reporting qualitative research [COREQ] standards (Tong 
et al., 2007) 
 
Recruitment to Part 1 
CMHNs were recruited from working age adult community, assertive outreach, 
rehabilitation, forensic and recovery teams serving the urban, coastal and rural 
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communities of the East of England that together serve a population of 4.3 million people. 
The sponsor NHS Trust expanded to include a neighbouring geographical area and this 
was approved as a third study site. A fourth NHS site was included after approaching the 
study team via the CLRN. Recruitment was undertaken by research assistants based in 
each of the four NHS sites, supported by the Project Lead and a Trial Coordinator. As 
Project Lead I managed all aspects of the study, supervised by the Chief Investigator.  
It was intended to ask Team Leaders to nominate MHNs who met the inclusion criteria to 
the researcher who would then invite the MHN to participate in the trial by letter. Team 
Leaders reported they were too busy to perform this role so the Chief Investigator and/or 
Project Lead and researchers visited teams to present the study and distribute invitation 
packs. Recruitment events were also held at each of the sites with presentations from the 
Chief Investigator and/or Project Lead. 
Inclusion and exclusion criteria (CMHNs) 
CMHNs were included if they had been registered with the Nursing and Midwifery Council 
[NMC] for at least 6 months, were employed at Agenda for Change band 5-7 and had at 
least 5 patients on their caseload with a primary diagnosis of SMI. MHNs who responded 
positively to the invitation were briefly screened and excluded if they were still in 
preceptorship, about to go on maternity leave or pregnant. This was to try to make sure 
our nurse sample were likely to work with study patients across the 52 weeks of the trial.  
Patient recruitment took place once a nurse was consented. It was intended to minimize 
self-selection bias by asking Team Leaders to list eligible patients on consented nurses’ 
caseloads but this role was declined due to workload pressures. The researchers at site 
worked with each consented nurse to generate a list of eligible patients. Where the nurse 
thought that one of their patients who met the inclusion criteria diagnosis should be 
excluded, they were encouraged to discuss the reason for this with the Project Lead. Each 
patient was given a personal identification number [PID] to maintain anonymity. 
Inclusion and exclusion criteria (patients) 
Patients were included in the selection list if they were over 18 years of age, on the 
caseload of the consented CMHN and had a primary diagnosis of schizophrenia, 
schizoaffective disorder or bipolar disorder. Patients were excluded if they lacked the 
capacity to consent as documented by a heath professional in their case notes, had a 
serious or unstable medical condition (e.g. advanced cancer), were pregnant or 6 months 
post-partum or if participation in the trial may put the patient, nurse, team or researcher at 
increased risk or increased cost to the service to manage risk.  
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From the list of potentially eligible patients PIDs, 5 were selected at random using an 
algorithm designed by the Clinical Trials Research Unit [CTRU] at the University of East 
Anglia [UEA]. Selected patients were then approached and invited to participate by their 
nurse. If they expressed an interest they were seen by a researcher who provided detailed 
information about the study, checked their understanding and obtained their written 
informed consent to participate if they wished to proceed. If after completing a recruitment 
cycle five patients had not been recruited the process was repeated. The cycle was 
repeated until five patients had been recruited or all eligible patients on the nurse’s 
caseload had been approached or six weeks had elapsed from the time the nurse’s first 
patient consented. At this point, the nurse was randomized to receive either the HIP 
Programme or provide treatment as usual (TAU). 
Randomisation Method 
Once the Trial Coordinator or Project Lead received notification of consent they allocated 
the CMHN a unique participant identification number [Nurse-PID]. All eligible patients on 
the CMHNs caseload were also allocated unique participant identification numbers by 
their nurse based on the Site ID, Nurse PID plus 001,002,003 etc. Patients from this list of 
PID numbers were randomly selected for invitation to the trial as described above. All 
Nurse and Patient PIDs were stored on the Trial Database at the CTRU. Only the Project 
Lead, Trial coordinator and database manager had access to the database to maintain 
blinding of researchers at site. Information about patients who declined, became no longer 
eligible (for example, due to a change in their capacity) or consented was entered in the 
database. Once either 5 patients had been consented per nurse or all eligible patients on 
the caseload had been exhausted or 6 weeks had elapsed from the first patient consent, 
the Project Lead or Trial Coordinator requested randomisation from CTRU.  
The randomisation schedule, designed and held by the CTRU, used permuted blocks of 
random size to ensure equal allocation between clusters. With randomly permuted blocks, 
subjects are assigned to treatment in blocks to insure that equal numbers of subjects are 
assigned to each group. The Project Lead and Trial Coordinator or were informed of the 
result of randomisation by email and the Project Lead informed the CMHN of their group 
allocation by telephone. If the nurse was allocated to the HIP Programme Group 
information was exchanged about training. The opportunity was taken during this phone 
call to remind the nurse of the importance of maintaining the blinding of the researchers at 
site  
Recruitment to Part 2  
This commenced once participants in the two NHS sites with the most participants had 
completed Part 1 and the researcher undertaking the audit at the largest site had 
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completed blinding tests. Sampling was undertaken by the Project Lead in a change to 
the published protocol, due to illness of the Process Observation Lead.   
It was intended to purposefully sample patients for the retrospective case note audit from 
the pool of patients who remained in the study at Part 1 follow-up in the sponsor NHS site. 
However the relatively small numbers with completed HIPs and problems accessing 
teams and case notes due to service reconfiguration meant a pragmatic approach was 
taken. The researcher at site audited all available patients on a list generated by the 
Project Lead until the required sample size was achieved. 
The Project Lead selected potential subjects for the semi-structured interviews from the 
two largest recruiting NHS sites using information from screening and the trial database. 
All patients in the HIP Group who remained in the study at Part 1 follow-up plus their study 
nurses, psychiatrists and GPs were invited to participate. The Project Lead sent an 
invitation pack directly to nurses, psychiatrists and GPs and to all eligible patients via their 
(study) nurse. Arrangements were made to interview every patient and health professional 
who responded positively to the invitation.  
Obtaining informed consent 
A mental health service user group affiliated with the East of England Mental Health 
Research Network worked with the Project Lead to design the participant invitation letters, 
information sheets and consent forms used for patients in both parts of the study. All 
versions were approved by Cambridge East Research Ethics Committee and via NHS 
research governance at each site before use (please see Appendix 4 for the latest 
versions of the information sheets used the study). The study team were all experienced 
in exchanging information with patients with SMI and their carers and trained in taking 
consent in clinical trials. The same written information and contact with the research team 
was available for carers if required. 
Informed consent of CMHNs, Psychiatrists and GPs 
 
Potential nurse participants who responded positively to the invitation to Part 1 received a 
Nurse Information Sheet Part 1 from a researcher who met with them and provide detailed 
explanation about the exact nature of the study. The researcher checked their 
understanding of the information and witnessed their written informed consent if they 
chose to proceed. Written information about the purpose of the PHASe (adapted) was 
available to read in a separate window before the CMHN decided if they wished to 
participate in the online survey or not, and in a cover letter if a postal questionnaire was 
sent. CMHNs were not required to sign a specific consent form for the survey as 
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completion and submission (or return) was considered implicit consent and this was 
included in the accompanying information. 
In Part 2 potential nurse participants were sent an information pack with their invitation. If 
the response slip was returned indicating they were interested or they telephoned the 
Project lead or Process Observation Lead, detailed verbal information was exchanged 
and questions answered. Written individual informed consent was obtained just before the 
start of the interview for all participants who choose to attend in person and written 
informed consent was requested by fax from those who booked a telephone interview. At 
the start of each interview, ongoing process consent was verbally checked and recorded. 
Informed consent of patients 
A researcher contacted patients who responded positively to the initial invitation letter 
gven to them by their nurse. The researcher exchanged detailed written and verbal 
versions of the Patient Information Sheet Part 1 with them. Information about the 
evaluation of risk of physical health problems (including cardiovascular risk) is included in 
this information. The researcher checked their understanding of the information and 
witnessed their written informed consent if they chose to proceed. 
Potential patient participants in the semi-structured interviews recieved detailed written 
versions of Patient Information Sheet Part 2 from the Project Lead or Process Observation 
Lead when invited to participate in this part of the study. Written individual informed 
consent was obtained just before the start of the one-to-one interview for all participants 
who agreed to an interview visit.  
A copy of the signed Informed Consent form was given every participant. The original 
signed form was retained at the study site (for Part 1) or the central Trial Office at UEA 
(for Part 2). Where the participant was a patient of NHS Trust sites, an additional copy 
was filed in their Trust case record and their GP, Psychiatrist and Care-coordinator were 
informed in writing of their participation in the trial. At each data collection point involving 
an interview, ongoing verbal consent was sought and subjects reminded of their right to 
withdraw at any stage. Participants were also reminded that although data is anonymised, 
any disclosure that potentially puts them or others at risk would be communicated back to 
their CMHN and Care Co-ordinator (if this is a different person to the nurse). 
Description and core principles of Treatment as Usual   
Community mental health teams are specialist, multi-disciplinary, multi agency teams that 
provide mental health assessments and interventions to individuals accessing mental 
health services. They prioritise interventions based on an assessment of need, risk and 
vulnerability, where complexity of care cannot be met within primary care. Services are 
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planned, delivered and reviewed in an integrated and co-ordinated way through the 
framework of the Care Programme Approach [CPA]. Working age adults with SMI under 
the care of these teams have a Care-Coordinator (usually a nurse, social worker or 
occupational therapist) who helps the individual identify their goals and package of care 
to achieve these. Core interventions will usually include assessment of risk of harm to self 
and others, assessment of substance misuse (including the delivery of basic harm 
minimisation and motivational interviewing interventions), medication management, risk 
and relapse prevention and planning, access to psychosocial support (e.g housing, 
employment, benefits), support to access primary care and other agencies (e.g. 
substance misuse services) and support for closely involved family and/or carer(s). All 
patient participants in the trial received treatment as usual. 
Description and core principles of the HIP Programme intervention 
The core principles and elements of the education part of the intervention were described 
in detail in Chapter 6. 
Baseline and follow-up assessments   
Assessments were completed by a site researcher blind to group allocation and took 
place at baseline and 52 weeks post-randomisation. Planning of 52-week appointments 
allowed for a two week window either side of the exact date appointments were due.  
Exact appointment dates may have fallen at a weekend, were not always convenient for 
patients or researchers and the window allowed at least one attempt at rearranging any 
missed or forgotten appointments.  
Demographic information included gender, age, grade, caseload size, year of qualification, 
previous physical health care education (CMHNs), age, gender, ethnicity, post-code, 
primary diagnosis, recorded physical comorbidity diagnoses and medication (patients).  
Procedures to administer outcome measures and protect against sources of bias 
Researchers were introduced to the protocol and trained to use the outcome measures by 
the Project Lead (me) and Chief Investigator using the Protocol, Case Record Form [CRF] 
and user manuals of the Sf36v2 and EQ-5D. Both measures are self-report, so training 
focussed on how to introduce them to participants and tests of inter-rater reliability were 
not required. The Project Lead was available to answer questions about the 
implementation of the protocol and support researchers throughout the trial via email and 
mobile and through the fortnightly Trial Management Group [TMG] meeting. Protocol 
violations and adverse events were recorded and reported to the sponsor and to the Trial 
Steering Committee [TSC]. 
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The refusal of Team Leaders to be involved in patient selection from nurse’s caseloads 
(as per protocol) meant the list of eligible patients identified had to be taken on trust and it 
is possible this introduced some selection bias. Where patients were identified and then 
reported as no longer eligible (e.g. due to a change in capacity or perception of increased 
risk) a conversation took place with the Project Lead and, sometimes if willing, the Team 
Leader was included. It was not possible to influence selection-bias regarding the 
intervention. Nurses were expected to complete HIPs with their study patients but did not 
always do so. When HIPs were not returned as expected, the Project Lead followed up 
with reminders by telephone and email. It was agreed that two attempts to contact the 
nurse by telephone and one email was an appropriate level of prompt.  
The researchers at site who undertook patient baseline and follow-up outcome 
assessments did not have access to the database, randomisation process or email files 
and were blind to group allocation. All communication with participant nurses regarding 
the results of randomisation, their group allocation and training was from the Project Lead 
and Trial Coordinator who were not blinded. At every communication (telephone or email) 
participants were reminded about the importance of retaining blinding of the researchers. 
Nurses were asked to remind patient participants as the Project Lead and Trial Co-
ordinator did not have or hold any personal patient data (e.g. names). There was one 
incident where a researcher at site was told the group allocation of a nurse. This was 
immediately reported and as patient follow-up had not yet taken place a different 
researcher was allocated to this task and blinding was maintained. Blinding tests were 
carried out once follow-up data collection was completed at each site. Researchers were 
asked to predict the group allocation of the patient participants at their sites and the 
results were compared with allocation and analysed. 
Part 2 recruitment and data collection required staff who were aware of group allocation 
and took place (in the two largest sites) once Part 1 had ended. The Project Lead and 
Process Observation Lead undertook recruitment activity and the interviews. A researcher 
in the sponsor NHS site undertook the audits once all data collection and blinding tests 
had been completed for that site. 
Statistical analysis 
Efficacy of the intervention was estimated by comparing the patient outcomes at 52 weeks 
between the two groups using mixed effects models including a random effect for the 
nurse to allow for the clustering. Our primary aim was to achieve an unbiased treatment 
comparison that took account of baseline factors, especially those factors that had some 
imbalance between treatment groups and could therefore potentially predict the outcome 
(Pocock et al., 2002). Models were fitted using Stata v12.1 and restricted log likelihood. 
Fifteen variables were identified a priori by the TSC as potential covariates i.e. that they 
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could possibly predict the outcome (Figure 8.1). We assessed the prognostic value of 
each of these in predicting the primary outcome SF36-PCS by fitting a mixed model for 
each with the potential covariate, baseline PCS as independent variables and follow up 
PCS as the dependent variable. It was agreed that any potential covariate with P < 0.10 
would be included in models to obtain adjusted estimates.  
 
Figure 0:1 Potential covariates identified a priori 
Potential covariates (baseline scores) 
 
NHS site 
Type of Community Mental Health Team (e.g. assertive outreach) 
Months on nurse’s caseload 
Nurse’s knowledge score (adapted PHASe) 
Nurse’s attitude score (adapted PHASe) 
 
 
Age (in years at consent) 
Gender 
Primary diagnosis 
Living status 
Smokes cigarettes 
Diagnosed medical comorbidity  
Total number of prescribed medications 
Total number of prescribed antipsychotics 
Prescribed a typical antipsychotic 
Prescribed an atypical antipsychotic 
 
 
An intention to treat (ITT) analysis was performed. The ITT analysis set comprised all 
patients who were randomised, irrespective of their receipt of the intervention or not after 
randomisation. This is the main analysis and was used for the evaluation of all endpoints. 
Adjusted estimates in the ITT analysis were obtained by including all of the covariates with 
a prognostic value of P = >0.1 in a mixed model to estimate effect size.  
Two per protocol analyses were planned. In per protocol analysis 1 [PP1] only patients 
who had a completed baseline HIP were included. In per protocol analysis 2 [PP2] only 
patients who had a HIP completed at baseline and at 52-week follow-up were included. A 
further per protocol analysis was necessary [PP Swap] due to a protocol violation. One 
nurse was randomised to the TAU group but assigned to the HIP training in error and 
therefore received the intervention. In the ITT analysis this nurse and 4 study patients was 
analysed in the TAU group, in the PP-Swap analysis they were analysed in the HIP 
Programme Group. 
Descriptive statistics were used for the nurse and patient sample characteristics, counts 
and percentages for dichotomous variables (e.g. gender) and means and standard 
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deviations for continuous variables (e.g. age). Data from the adapted Mental Health Nurse 
Physical Health Attitude Scale [PHASe] and the supplementary twenty knowledge 
multiple-choice questions was compared between groups using student’s t-tests to 
compare the mean scores and calculate 95% confidence intervals. All data were analysed 
using the Statistical Package for the Social Sciences [SPSS] (version 19; SPSS, Chicago, 
IL, USA). The planned analysis of QRISK®2 was not undertaken due to poor quality of HIP 
data. 
In line with guidance by the National Institute of Health and Care Excellence [NICE], costs 
for the economic analysis were calculated from the perspective of the NHS and personal 
social services and encompassed those costs that were potentially related to the 
intervention (National Institute of Health and Care Excellence, 2008). We monitored the 
levels of resource use associated with completing the HIP (including those associated 
with recommended tests/investigations, changes in medication use and referrals to other 
services). For patients in both arms, we monitored visits to other health care professionals, 
admissions to hospital and medication usage. Appropriate unit costs were assigned to 
each of these items by the research team health economist. The EQ-5D -3L is a generic 
measure of health status designed to compare the benefits of different interventions 
(Brooks, 1996). The respondent is asked to indicate their health state by ticking a box 
against the most appropriate of three statements of level (representing no problems, some 
problems, severe problems) for five dimensions of health state (mobility, self-care, usual 
activities, pain, anxiety and depression). Respondents are then asked to place a cross on 
a vertical, visual analogue scale [EQ-5D VAS] with endpoints for the day of rating labelled 
‘Best imaginable health state’ and ‘Worst imaginable health state’. The dimensions of the 
EQ-5D were used to calculate quality-adjusted-life-years (QALYs) associated with both 
the intervention and TAU. 
An economic model was constructed to estimate both the mean overall cost and mean 
overall effect associated with both the intervention and treatment as usual. If one of these 
options was shown to be less costly and more effective than the other then this would 
suggest that it ‘dominates’ the other, and represents a cost-effective use of scarce 
resources. Alternatively, the incremental cost-effectiveness ratio associated with the HIP 
will be estimated and assessed in relation to a range of cost-effectiveness thresholds e.g. 
a threshold of £20,000-£30,000 per QALY is recommended by NICE (NICE, 2008). The 
associated level of uncertainty was also characterised e.g. by estimating the cost-
effectiveness acceptability curve [CEAC] for each intervention. Additionally, sensitivity 
analysis was undertaken to assess the robustness of conclusions to key assumptions. 
Descriptive statistics were used to describe the nurse and patient sample characteristics 
for the nurses and patients participating in the interviews and the audit in the process 
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observation phase. All data collected in the HIP Audit Form represented dichotomous 
variables (i.e. the presence or absence of evidence in the patient record). These were 
compared between the three groups using a chi-square test. Data was analysed using 
SPSS (version 19; SPSS, Chicago, IL, USA). 
Thematic analysis of interview data 
Interview data was analysed using thematic analysis and a constant comparative method. 
Thematic analysis involves searching across data sets for patterns of meaning (Braun and 
Clarke, 2006). The analysis method used to do this in this study was theoretical, rather 
than inductive because we were interested in the perceived drivers and barriers to the use 
of the HIP from the perspective of those patients and staff who had used it. The method 
described by Braun and Clark (2006) was used to analyse the data. All interview 
transcripts were read and re-read by a core group (the Project Lead (me), Chief 
Investigator and Process Observation Lead). The Process Observation Lead identified 
initial codes in the data and agreed these with the other two members of the group. NVivo 
Version 10 qualitative data analysis software (QSR International Pty Ltd, 2012) was then 
used to code all the transcript data and identify other possible theme groupings. Themes 
were agreed through a three-way process of discussion and by referring back to the 
transcripts until final themes were agreed, named and defined. 
Project schedule 
A Gantt chart in Figure 8.2  summarises the project schedule for both parts of the study. 
Ethical and governance issues 
Preparation and submission of all necessary documents through the integrated Research 
Approval Service [IRAS] was undertaken by the Project Lead (the author). The NHS 
Cambridge East Research Ethics Committee granted approval for the study in December 
2010. NHS research governance approval was gained from the sponsor Trust in March 
2011. Governance approval for the other NHS sites was granted in April 2011, December 
2011 and February 2012 and for the former associated Primary Care Trusts in April 2013 
Active recruitment to Part 1 of the study commenced on 04 April 2011. There were 8 
minor amendments and 2 major (protocol) amendments during the study. The minor 
amendments to study documentation related to additional study sites, staff changes and 
an extension to the recruitment phase. The two major amendments were;  
1) Due to a lower than expected recruitment of patients per nurse the number of nurses in 
each arm of the study was increased to 32 per arm. Assuming 4 patients per nurse (3 
after drop out) this retains the power calculated previously, under the original assumptions 
and  
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2) a change to individual (rather than focus group) nurse interviews to facilitate 
recruitment in Part 2 and the introduction of three per protocol analyses. All amendments 
were approved by the Cambridge East Research Ethics Committee and managed by the 
Project Lead with the support of the Trial Coordinator. 
Every effort was made to ensure that risks were minimised. Participants were provided 
with contact details of the research team and the local NHS Patient Advisory and Liaison 
Service [PALS]. The Project Lead, Trial Coordinator and all data collectors were 
experienced mental health researchers with training in Good Clinical Practice [GCP],  
NHS Research Governance and if appropriate, a current NHS Research Passport, Letter 
of Access or Honorary Research Contract. Researchers followed local Trust policies and 
procedures, including lone worker policies. Although data collected for the trial was 
anonymous, patients were reminded that any disclosure that potentially put them or others 
at risk (e.g. suicidal ideation, harm to self or others, or any identified medication risk) 
would be communicated back to their CMHN and/or care team. Similarly nurse 
participants were reminded that any disclosure or evidence of poor practice would be 
communicated back to their Team Leader. No complaints were received during the study. 
One patient withdrew consent because they found the data collection questions ‘too 
intrusive’ and another withdrew because they were unhappy with a medication review that 
was prompted when potential medication interactions were identified at baseline and 
reported to their care coordinator and psychiatrist. 
CMHNs were asked to communicate details of any adverse events to participants and 
action taken to site researchers or the Trial Coordinator/Project Lead. All members of the 
research team followed the NHS research governance regulations and the National 
Research Ethics Service and standard operating procedures for safety reporting at all the 
NHS study sites. (Department of Health, 2005, Norfolk and Suffolk Foundation NHS Trust).  
Role of funder and sponsor 
This study was supported by a National Institute of Health Research [NIHR], Research for 
Patient Benefit grant. The sponsor Trust was Norfolk and Waveney Mental Health NHS 
Trust at the time of the award, but later merged with Suffolk Mental Health Partnerships 
NHS Trust on 1st April 2012 to form Norfolk and Suffolk NHS Foundation Trust. 
Annual and final reports were written and submitted to the NIHR, the sponsor, 
participating NHS sites and the Cambridge East Research Ethics Committee.  
Trial management and quality assurance  
The study was conducted in accordance with the NHS research governance framework 
and requirements of the National Research Ethics Service and standard operating 
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procedures of the sponsor NHS Trust. As Project Lead, I managed the study and was 
accountable to the Chief Investigator. I chaired a Trial Management Group [TMG] that 
included the Trial Coordinator and site researchers that met fortnightly by telephone 
conference. An independently chaired Trial Steering Committee [TSC] had the role of 
overseeing the conduct and progress of the trial. It met quarterly and included the Chief 
Investigator, all members of the research team, the sponsor representative, 
representatives from participating NHS sites and two public and patient involvement [PPI] 
representatives from the South Norfolk Care Commissioning Group. I met with PPI 
members before every TSC meeting to brief them on progress and make sure issues they 
wanted to raise were included in the main meeting.
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Figure 0:2 Project schedule 
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The sponsor was responsible for evaluating compliance with regulations and standard 
operating procedures. Data was evaluated for compliance with the protocol and accuracy 
in relation to source documents by a team of auditors at the end of May 2012 and 2013. 
This included scrutiny of the Trial Master File, the Trial Site File and participant Case 
Records Forms at the University of East Anglia and the sponsor NHS site. The auditors 
reported that ‘the standard of trial management and site files was excellent and a 
testament to the work of the trial coordinators and research assistants’.   
Chapter summary 
To evaluate the success of the intervention, the HIP and the training package together 
[the HIP Programme], a clinical trial and additional process observation were planned. A 
single-blind, parallel group cluster randomised controlled trial design was adopted to test 
the effectiveness of the implementation of the HIP by CMHNs (the cluster) with SMI 
patients on their caseload. The primary end point of the study, a change in patients’ 
physical related quality of life, was selected because it has meaning to patients, carers, 
practitioners and policy makers. The aim was to test the hypothesis that patients with SMI 
on the caseload of CMHNs trained to use the HIP would have improved physical health 
related quality of life after a year compared to patients on the caseloads of nurses 
delivering usual care. A health economic analysis was designed to provide information 
about the costs of disseminating this approach across the NHS. In addition to the primary 
evaluation of effectiveness and cost effectiveness, a pre and post survey design would 
test education (knowledge and attitude) outcomes in CMHNs in the HIP Programme group 
and a process observation phase would explore patient and practitioner experience of 
implementation using qualitative and audit data. The protocol was finalised by the TSC in 
March 2011 and the study took place between April 2011 and April 2013. The NHS 
research governance framework and requirements of the National Research Ethics 
Service and the sponsor NHS Trust were closely adhered to at all times. Pragmatic 
changes to the original finalised (and published) protocol to facilitate recruitment and to 
allow per protocol analyses were approved through these processes. These included 
recruitment from two additional NHS sites, an increase in the cluster size in the main trial 
and the replacement of nurse focus groups with individual semi structured interviews in 
the process observation phase. 
 
The methodology described in this chapter was published in July 2011 as 
 
White, J., Gray, R. J., Swift, L., Barton, G. R. & Jones, M. 2011. The serious mental illness 
health improvement profile [HIP]: study protocol for a cluster randomised controlled trial. 
Trials, 12, 167. 
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Chapter Nine: Results of the HIP Cluster RCT (Part 1) 
 
Part 1 Participant Flow 
Figure 9.1 shows the flow of nurses and patients through the trial. Out of 198 community 
mental health nurses [CMHNs] reported by the NHS sites to be working in their eligible 
community mental health teams [CMHTs], 131 did not respond to the invitation to 
participate (66%). Reasons are unknown due to the voluntary nature of recruitment 
following presentation to groups of staff. Sixty-seven CMHNs consented to take part but 
seven withdrew after consent but prior to randomisation due to a change in their 
circumstances. One nurse moved to work in a different service, one withdrew due to ill 
health, one stated the short-term nature of their role meant they could not complete 
annual health checks, two cited increased workload and two withdrew after all their 
eligible patients declined, citing workload reasons. Sixty (90%) of the original eligible 
CMHNs continued to work with researchers to recruit patients from their caseload and 
were randomised. 
Six hundred and twelve patients were reported by their CMHN as eligible for inclusion in 
the study and entered the recruitment cycle process as described earlier. A third of eligible 
patients were not invited due to closure of the 6-week recruitment window before they 
could be approached. Of the remaining 402 patients, 52 (13%) were reported as no longer 
eligible by their nurse when selected for invitation so were not approached. Reasons cited 
were a change in capacity due to relapse (n=21), risk to mental health (n=20), risk to 
others (n=3), risk to self (n=2), and a new serious medical condition (n=2). One patient 
was discharged from the service, one moved out of area and another had disengaged 
from the team and did not respond to contact attempts. Despite research governance 
agreements, one eligible patient could not be invited because interpretation services were 
not available. 
Of the 350 eligible patients who were invited to participate by their nurse, 173 (49%) 
provided written informed consent to enter the trial representing a mean of 2.6 patients 
per nurse (sd 1.93, 95% CI 1.73-2.10). We failed to recruit any patients at all from the 
caseloads of 16 consented nurses although 9 of these proceeded to randomisation.  
The consented nurses were randomised between May 2011 and February 2012 to the 
HIP Programme intervention group (29 nurses, 90 patients) and the Treatment as Usual 
[TAU] group (31 nurses, 83 patients). In the intervention group 26 nurses received HIP 
training (corresponding to 84 patients). A protocol violation occurred due to an error in 
communicating the correct randomisation result. One nurse (and 4 study patients) who 
should have been in the TAU group received HIP Programme training.   
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CMHN withdrawals and lost to follow up 
Of the 60 CMHNs who were randomised and entered the trial, 3 then withdrew their 
consent (5%). All three of these nurses were in the intervention group and withdrew after 
randomisation but before completing HIP Programme training (one nurse took up a 
position in a different service, the other two cited workload and personal reasons). Two of 
these nurses had patient participants who remained in the trial and were successfully 
followed-up. A CMHN in the TAU group completed baseline assessments but was lost to 
follow-up due to leaving to work for a different organisation. Their three consented 
patients remained in the trial and were successfully followed up. 
Patient withdrawals and lost to follow up 
Of the 173 patients who entered the trial, 18 withdrew from the study, 10 from the 
intervention group and 8 from the TAU group. One patient withdrew after consent but 
before baseline data collection. Their primary diagnosis was confirmed as psychotic 
depression and not bipolar disorder as initially reported by their CMHN. The patient was 
given the option of continuing but chose to withdraw at that stage. Of the remaining 172 
patients, 17 withdrew before follow up (10%). Five withdrawals occurred in the 12 months 
before follow-up, three patients gave no reason, one was annoyed that their medication 
had been reviewed as a result of being in the study and one had received a change in 
diagnosis so chose not to remain in the study at this point. Twelve withdrawals occurred 
when field researchers were attempting to arrange or begin the follow-up visit. Two thirds 
gave no reason (n=8). The remaining four provided different reasons; stress from life 
events, too unwell, that they did not like being interviewed as “the patient” and due to their 
discharge from the service.  
Follow-up visits were arranged through the participating nurse (or current Care-
Coordinator if the patient had moved to a different caseload during the intervening 12 
months). An individual follow up window of 53 weeks ± 2 weeks from baseline data 
collection was imposed to maintain equity between participants across all sites. 23 (13%) 
patient participants either could not be contacted or were unable to arrange a data 
collection visit within their individual follow-up window: 10 from the intervention group and 
13 from TAU.  
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Figure 9:1 Participant flow through the trial 
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Completed outcome measures 
This section reports numbers with complete data available in the Case Record Form 
[CRF] for each of the measures used to analyse trial outcomes. Data collection visits took 
place with 168 patients at baseline and 132 patients at 53 week follow up. All nurse 
participants remaining in the trial were asked to complete the online adapted PHASe 
questionnaire at baseline and 53 week follow-up. Although the CONSORT diagram 
(Figure X) indicates the numbers of nurses who completed the adapted PHASe and 
completed HIPs with their study patients, it only indicates numbers completing the SF36v2 
PCS for the primary outcome intention to treat analysis condition. The numbers of patients 
who had complete data for every measure at each time point are summarised in Table 9.1 
 
Table 9:1 Completed outcome measures (ITT condition): 
 Patients with complete data at baseline 
Patients with complete data at follow-
up 
Group 
Number of Patients 
HIP   
n=90 
TAU  
n=83 
HIP  
n=70 
TAU 
n=62 
SF36v2 PCS and MCS 86 82 70 61 
SF-6D
a
 82 77 64 57 
EQ-5D-3L
b
 88 82 67 58 
HRU-Patient 51 50  63 57 
     
HIP 38 4
c
 22 2
c
 
HRU-Nurse 26 - 10 - 
     
 
 
Nurses with complete data at baseline Nurses with complete data at follow-up 
Group 
HIP  
n = 29 
TAU 
n=31 
HIP 
n=26 
TAU 
n=30 
Adapted PHASe 
 
27 24 8 13 
a
 The SF-6D requires complete data for 11 questions on the SF36v2  
b 
The
 
EQ-5D-3L requires complete data from the EQ-5D and the EQ-5D Visual Analogue Scale 
c 
Patients of the nurse who was incorrectly allocated to HIP Programme Training at randomisation 
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Primary outcome 
1.Physical health related quality of life:  
Complete baseline SF-36v2 PCS and 53 week SF-36v2 PCS data were available from 
128 (74%) patients. This represented 68 patients (under 25 nurses) in the intervention 
group and 60 patients (under 24 nurses) in the TAU group. Two patients in the 
intervention group and one in TAU were not included because their (matched) baseline 
PCS data was incomplete. 
Secondary outcomes 
2: Cost effectiveness of the HIP Programme:  
Quality of Life Years [QALYs]: there were two calculations of QALYs using the SF36v2 
and the combined EQ-5D and EQ-5D Visual Analogue Scale data. SF-6D scores were 
calculated from the SF-36v2 patient data completed at the baseline and 53-week time 
points for 111 (64%) patients in total; 58 in the intervention group and 53 in the TAU group 
EQ-5D-3L data was available from the two time points for 123 (71%) patients; 66 in the 
intervention group and 57 in the TAU group.  
Cost of the HIP Programme: Health Resource Use [HRU]-Patient data was available from 
both baseline and 53 week time points for 101 (58%) patients in total; 51 in the 
intervention group and 50 patients in TAU. 
Complete data was captured to allow the cost of training to be calculated for all 26 
CMHNs in the intervention group who received HIP Programme training. The CMHNs who 
completed HIPs with their patients were also asked to complete a HRU-Nurse form every 
time they used a HIP to capture the time taken to complete the process and estimated 
costs of action taken as a result. Where nurses returned a HIP but failed to return a 
corresponding HRU-Nurse form, a maximum of three emails or telephone messages were 
used to prompt them to do so. Twenty-six HRU-Nurse forms were returned that related to 
62% of the 42 HIPs completed at baseline. Ten HRU-Nurse forms were returned at follow-
up, corresponding to less than half (42%) of the 24 HIPs returned at this time point.  
3. Mental health related quality of life:  
Baseline and 53-week SF-36v2 MCS data was available from the same number of 
patients as the primary (PCS) outcome. One hundred and twenty-eight patients: 68 
patients (under 25 nurses) in the intervention group and 60 patients (under 24 nurses) in 
the TAU group provided complete data for analysis.  
4. CMHNs attitude towards and knowledge of physical health care: 
Every consented nurse was invited via an automatic email to complete the measure online 
and then up to a maximum of two email prompts were sent to the nurse over a two-week 
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period if the Data Manager did not receive notification that it was completed. This provided 
the option for a paper version to be sent out if preferred. At baseline 51 (85%) CMHNs 
returned the adapted PHASe questionnaire. Twenty-seven CMHNs in the intervention 
group completed the measure and 24 from TAU. At the 53-week follow-up the response 
rate was 35% (n=21), representing 8 nurses in the intervention group and 13 in TAU. The 
results of the analysis of the nurse outcomes related to objective 4 are presented in the 
next chapter with the Part 2 (process observation) outcomes. 
5: Modification of cardiovascular risk (patients in the intervention group) 
As discussed in the methodology chapter, the calculation of this outcome required 
detailed data from the completed HIP forms. Of the forms that were returned, nurses had 
not completed them in a standardised way, particularly regarding blood test results for 
lipids and glucose. Consequently it was not possible to reliably calculate cardiovascular 
risk scores as planned. 
6: Acceptability of the HIP Programme in the NHS. 
The results related to this objective are presented in the next chapter as they relate to Part 
2 of the study: the process observation that took place after Part 1 had been completed.  
Baseline characteristics of CMHNs (Part 1) 
Table 9.2 lists the baseline characteristics of the CMHNs taking part in the study by group. 
There were no discernable differences between the groups.  
Baseline characteristics of patients (Part 1) 
Table 9.3 lists the baseline characteristics of the patients by group. There were no 
discernable differences between the groups.  
Missing data 
The 53-week primary outcome PCS was collected for 131 (76%) those patients who 
consented and entered the start of study. Three of these had no corresponding baseline 
measure so their data so could not be used when estimating the effect of the intervention. 
All four NHS sites differed significantly in the proportion of patients with missing values. 
Follow up rates for site one were 80% (76/95), site two, 82% (14/17) site three, 60% 
(29/48) and 92% (12/13) for site four. As the NHS site was not identified as a predictor of 
primary outcome, this was not a concern for the main analysis. In further bivariate 
analyses, no significant difference was found between patients with missing and non-
missing PCS data with respect to any other variable in the patient baseline table (Table 
9.3) or the nurse baseline table (Table 9.2).  
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There was an error in data collection at baseline for the first 25 patients at the largest NHS 
site because field researchers initially failed to include the last two pages of the HRU-
Patient form in their printed CRFs. It was not feasible to go back and attempt to collect this 
missing data and the oversight was reported as a data risk to the Trial Steering 
Committee. The four questions omitted related to the calculation of NHS and personal and 
societal care [PSS] costs for the economic analysis. A further 37 patients from across all 
sites had missing or ambiguous HRU-Patient baseline data in one or more item on the 
form that was not resolved after raising a data query with the site. This meant that the 
estimate of baseline costs could not be calculated and used in the intention to treat [ITT] 
analysis as intended. All available HRU-Patient data was included in the sensitivity 
analyses. 
Sensitivity analysis  
The original per protocol analysis plan was defined as the participant remaining in the 
same arm of the study at follow up as at randomisation (White et al., 2011). At the Trial 
Steering Committee meetings after data collection had ended it was agreed that three per 
protocol analyses should also be performed as there were three different conditions that 
determined if the patient had received some or all of the intervention as intended by their 
randomisation status:  
Per Protocol Swap: This analysis took account of patients under the care of the single 
TAU group nurse who had been incorrectly assigned to the intervention arm at 
randomisation. It measured the intervention effect (adjusted for baseline score) between 
patients in the TAU group and intervention group, where patients of this nurse were 
allocated to the intervention arm in the analysis. 
As with the primary ITT analysis, the evidence that a HIP had been completed was that a 
copy had been returned to the Trial Coordinator. We were unable to determine if there 
were cases where the patient’s nurse had completed a HIP but forgot to return a copy to 
us. When prompting nurses in the HIP group to return HIPs and Nurse-HRUs two nurses 
reported they could not return copies to us because they could no longer access patients’ 
records as a result of service reorganisation. As we could not corroborate these reports 
these patients were not included in the final two per protocol analyses. 
Per Protocol 1: This only included intervention participants with documentation to prove 
they had completed a HIP at baseline in the analysis (n=42). 
Per Protocol 2: This only included intervention participants with documentation to prove 
they completed a HIP at baseline and 12 month follow-up in the analysis. (n=24). 
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Societal cost perspective: The ITT analysis was repeated, where costs were estimated 
from a societal perspective.  
Multiple imputation: Regression methods were used to predict cost and outcomes data 
based on their relationship with other covariates. As health resource use questionnaires 
were poorly completed at baseline, each cost component was disaggregated to achieve 
more accurate imputations. Disaggregated costs data was also imputed at 12-month 
follow-up, and EQ-5D and SF-6D values at each time point. Variables included in the 
imputation model were: nurse_ID, group, all baseline costs, all 12-month costs, 
intervention costs, baseline and 12-month EQ-5D, baseline and 12-month SF-6D, and 
baseline demographics, namely: age, sex, relationship status, smoking status, medical 
conditions, family history of cardiac disease, and years on nurse caseload. Imputation 
took place in five cycles, after which the total baseline costs, total 12-month costs; QALY 
(EQ-5D) and QALY (SF-6D) were generated. Imputed estimates were then pooled and 
calculated using Rubin’s rules (Rubin, 1976). All multiple imputation was performed for 
incomplete cost and outcomes components at the patient level using the mi impute and 
estimate procedures in STATA 12 (Marchenko, 2009).  
Blinding and data checks 
A check of 10% of all data entered into the trial database was undertaken by comparing it 
with source documentation in the CRF by one of the Trial Coordinators and one of the 
field researchers. The fidelity of blinding was tested in three field researchers who worked 
across two of the sites (1 and 2) at the end of baseline and at follow up data collection by 
asking them to predict the group allocation of participants from their site randomly 
selected by a Trial Coordinator. Tests indicated field researchers were no more likely than 
chance (50:50) to accurately predict patient group allocation. 
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Table 9:2 Characteristics of CMHNs at baseline (Intention to Treat Analysis). 
Group  HIP TAU 
Number of CMHNs  n=29 unless stated   n=31 unless stated 
 
 
 
(%) or mean (sd) unless stated 
 
NHS Site 
 
1 
2 
3 
4 
13 (44.8%) 
4 (13.8%) 
7 (24.1%) 
5 (17.2%) 
14 (45.2%) 
5 (16.1%) 
10 (32.3%) 
2 (6.5%) 
CMHT Type    
 
 
Recovery  
Assertive Outreach 
Rehabilitation 
Forensic 
 
18 (62.1%) 
9 (31%) 
1 (3.4%) 
1 (3.4%) 
 
18 (58.1%) 
10 (32.3%) 
0 (0%) 
3 (9.7%) 
    
 
Age in years at consent 
  
46.5(7.5) 
 
44.8 (8.9) 
Gender  Female 22 (75.9%) 21 (67.7%) 
Ethnicity  White British 28 (96.6%) 25 (83.3%)
 
n = 30 
 
Grade  
 
 
Band 5  
Band 6 
Band 7 
 
0  (0%) 
27 (93.1%) 
2  (6.9%) 
 
1 (3.2%) 
26 (83.9%) 
4 (12.9%) 
 
Highest Academic level    
              
 
 
Certificate 
Diploma 
Degree 
Masters 
 
6   (20.7%) 
14(48.3%) 
7  (24.1%) 
2 (6.9%) 
 
7 (22.6%) 
12 (38.7%) 
9 (29%) 
3 (9.7%) 
 
MHN Experience in years 
  
16.5(9.6) 
 
 
14.16 (7.7) 
Time in post  
 
  Less than 1 year 
  1 – less than 5 years  
  5 – less than 10yrs 
  10 or more years 
3 (10.3%) 
12(41.4%) 
10(34.5%) 
4(12.9%) 
3(9.7%) 
11(35.5%) 
13(41.0%) 
4(13.8%) 
 
Adult nursing qualification 
  
1 (3.4%) 
 
4 (12.9%) 
    
Knowledge
a
 MCQ score  
 
 9.7(2.6) n =27 8.8(2.2) n = 24 
Attitudes
a 
PHASe score 
 
 32.1(5.5) n = 17 29.1(4.7) n=21 
 
a. Identified as a potential covariate in patient analysis  
MCQ = multiple-choice questionnaire 
PHASe = Physical Health Attitude Scale. 
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Table 9:3 Characteristics of patients at baseline (Intention to Treat Analysis).  
Group   HIP  TAU 
  n=90  n=83  
    %(x/n) or mean (sd) unless stated 
NHS site
a
 1 60.0% (54/90) 49.4% (41/83) 
 2 10.0% (9/90) 9.6% (8/83) 
 3 21.1% (19/90) 34.9% (29/83) 
 4 8.9% (8/90) 6.0% (5/83) 
CMHT
c
 type
a
 Recovery 71.4%(60/84) 68.3%(56/82) 
Months on caseload
a
  median (min,max) 24(3,168) n = 84 36(1,300) n = 77 
Primary Diagnosis
a
                   Schizophrenia 58.4% (52/89) 69.9% (58/83) 
 Schizoaffective disorder 7.9% (7/89) 7.2% (6/83) 
 Bipolar Disorder 33.7% (30/89 21.7% (18/83) 
 Other 0.0% (0/89) 1.2% (1/83) 
Age
a
 in years at consent 47.6 (11.52) n = 87 45.1 (12.6) n = 83 
Gender
a
 Male 52.3%(46/88) 61.0%(50/82) 
Ethnicity White British 88.9%(80/90) 91.6%(76/83) 
Living status
a
 Lives alone  55.7%(49/88) 57.8%(48/83) 
Relationship Single, divorced or widowed 67.8%(59/87) 70.7%(58/82) 
    
Smokes cigarettes
a
  68.6%(59/86) 9.3%(48/81) 
Medical Comorbidity 
Diagnosis
a
 
 
 
None  
1-4 comorbidities 
5 or more 
26.7%(23/86) 
66.3%(57/86) 
7.0%(6/86) 
22.9%(19/83) 
69.9%(58/83) 
7.2%(6/83) 
    
Total number of 
medications
a  
 
median (min-max) 4(0-18) 4(0-20) 
Total number of antipsychotics
a
   
 None  3.6%(3/83) 12.3%(10/81) 
 One
 
 78.3%(65/83) 74.1%(60/81) 
 2 or more  18.1%(15/83) 13.5%(11/81) 
Prescribed an atypical antipsychotic
a
 
Prescribed a typical antipsychotic
a
 
75.9(63/83) 
28.9%(24/83) 
60.5%(49/81)  
33.3%(27/81) 
   
Family History of cardiovascular disease (CVD) 23.5%(19/81) 33.3%(25/75) 
Prescribed medicines for CVD
b
 28.9%(24/83) 27.2%(22/81) 
   
SF 36v2 PCS Baseline 
 
SF36v2 MCS Baseline  
43.2 (11.0) n=86 
 
39.2 (14.01) n = 86 
45.1 (11.94) n=82 
 
36.92 (14.3) n = 82 
   
EQ-5D VAS Baseline 
 
60.7 (20.8) n = 84 60.4 (19.1) n = 82 
EQ-5D Baseline median (min,max) 0.73 (-0.24,1.00) n=88 0.67 (-0.18,1.00) n=82 
    
 
a = potential covariate,  
b includes medications for diabetes, dyslipidaemia and hypertension 
CMHT = Community Mental Health Team, PCS = Physical Component Scale, MCS = Mental Component 
Scale, VAS = Visual Analogue Scale 
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Analysis of patient outcomes (Part 1) 
Intention to treat analyses 
A copy of the HIP was returned to the Trial Coordinator for 38 (42%) of intervention group 
patients at baseline and 22 (31%) at follow up 
The effect of HIP compared to treatment as usual was estimated using mixed effects 
models including a random effect for nurse to allow for the clustering. Models were fitted 
using STATA v12.1 and restricted log likelihood. Fourteen variables (indicated in the 
baseline tables 9.2 and 9.3) were identified a priori as potential covariates. We assessed 
the prognostic value of each of these in predicting the primary outcome SF36v2-PCS by 
fitting a mixed model for each with the potential covariate, baseline PCS as independent 
variables and follow up PCS as the dependent variable. It was decided a priority that any 
potential covariate with P < 0.10 would be included in models to obtain adjusted estimates 
(Pocock et al., 2002). Number of medications (P = 0.006), taking one or more typical 
antipsychotic (P = 0.077) and the nurses MCQ knowledge score at baseline (P =0.045) all 
had P < 0.10. Adjusted estimates in the ITT analysis were obtained by including all of 
these in mixed model to estimate effect size and are included in Table 9.4. 
The intervention effect (adjusted for baseline score) was not significant for the primary 
outcome (1.5 SF36v2 PCS points, 95% CI -1.5, 4.5 P=0.327, intra class correlation 0.036). 
No significant between group differences in secondary outcomes were found (Table 9.4). 
Further, no significant effect was found after adjustment for those potential covariates 
showing a prognostic relationship with the primary outcome (number of medications, one 
or more typical antipsychotics, nurse knowledge of physical health care). 
None of the three per protocol analyses demonstrated a significant primary or secondary 
effect (Tables 9.5,9.6 and 9.7).  
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Table 9:4 Estimated effects of HIP programme on primary and secondary outcomes at 12 months (Intention to Treat Analysis).  
 
Measure  HIP 
Mean (sd) 
 
TAU 
Mean (sd) 
 
Effect
b 
(95% CI) 
(adjusted for baseline) 
P = 
 
Intra class 
correlation 
Effect (95% CI) 
(+adjusted for covariates) 
P= 
Intra class 
correlation 
SF36v2   
n patients 
k nurses 
  
68 
25 
 
60 
24 
 
- 
 
- 
 
n =64,51 
k=25,21 
 
SF36v2 PCS Baseline
a
 
53 Weeks 
43.36(10.97)   
44.64(12.47) 
44.07(10.82)  
43.80(11.30)  
1.50 (-1.50, 4.50) 
P = 0.327 
0.054 1.01(-2.0,4.0) 
P=0.511 
0.036 
SF36v2 MCS Baseline
a
 
53 Weeks 
40.26(13.08) 
40.81(13.58) 
37.89(13.94)  
38.18(14.94) 
1.38(-3.07,5.82) 
P=0.543 
0.028 1.26(-3.0,5.5) 
p=0.561 
-0.035 
EQ5D VAS 
n patients 
k nurses 
  
63 
25 
 
61 
24 
   
n=58,51 
k = 25,21 
 
EQ5D VAS Baseline
a
 
53 Weeks 
60.08(20.18) 
55.57(24.61) 
60.25(19.36) 
58.11(20.35) 
-2.30(-10.70,6.10) 
P=0.592 
0.271
c
 -5.15 (-14.2,3.9) 
P=0.263 
0.312 
EQ5D 
n patients 
k nurses 
  
66 
24 
 
57 
24 
   
n=61,51 
K=24,21 
 
EQ5D Baseline
a
 
53 Weeks 
0.632(0.306) 
0.597(0.338) 
 
0.607(0.330) 
0.590(0.326) 
-0.01(-0.11,0.09) 
P=0.870 
0.030 -0.036(-0.134,0.063) 
p=0.478 
-0.012 
a = Effect of HIP versus Treatment as usual   
b = Baseline mean is of those with follow up data  
c = 95% CI for the ICC (0.05304,0.4639) Note: estimated ICCs can be negative.   
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Table 9:5: Estimated effect of HIP programme on primary and secondary outcomes 
at 53 weeks (Per Protocol Swap Analysis) 
Measure  HIP 
Mean (sd) 
 
TAU 
Mean (sd) 
 
Effect
b  
(95% CI) 
(adjusted for baseline) 
P = 
 
Intra class 
correlation 
SF36v2   
n patients 
K nurses 
  
67 
25 
 
61 
24 
  
SF36v2 PCS Baseline
a
 
53 Weeks 
42.5(11.5) 
43.5(12.9) 
45.0(10.1) 
45.0(10.8) 
0.51(-2.5,3.5)  
P=0.743 
0.056 
SF36v2 MCS Baseline
a
 
53 Weeks 
40.2(12.9) 
41.1(13.7) 
38.0(14.1) 
37.9(14.7) 
1.98(-2.4,6.4) 
P=0.380 
0.025 
EQ5D VAS 
n patients 
k nurses 
  
62 
25 
 
62 
24 
  
EQ5D VAS Baseline
a
 
53 Weeks 
59.5(20.4) 
56.2(24.2) 
60.79(19.1) 
59.5(20.4) 
-0.26(-0.68,8.2) 
P=0.951 
0.274 
EQ5D 
N patients 
K nurses 
  
65 
24 
 
58 
24 
  
EQ5D Baseline
a
 
53 Weeks 
0.621(0.3) 
0.588(0.3) 
0.618(0.33) 
0.600(0.32) 
-0.01(-0.1,0.1) 
P=0.800 
0.030 
a = Effect of HIP versus Treatment as usual   
b = Baseline mean is of those with follow up data 
  
 
 
Table 9:6 Estimated effect of HIP Programme on primary and secondary outcomes 
at 53 Weeks (Per Protocol 1 Analysis) 
 
Measure  HIP 
Mean (sd) 
 
TAU 
Mean (sd) 
 
Effect
b 
(95% CI) 
(adjusted for baseline) 
P = 
 
Intra class 
correlation 
SF36v2   
n patients 
K nurses 
  
32 
15 
 
61 
24 
  
SF36v2 PCS Baseline
a
 
53 Weeks 
44.2(12.6) 
45.5(12.6) 
45.0(10.1) 
45.0(10.8) 
1.01(-2.7,4.8) 
P=0.594 
-0.073 
SF36v2 MCS Baseline
a
 
53 Weeks 
39.5(14.4) 
40.9(15.0) 
38.0(14.1) 
37.9(14.7) 
2.32(-3.5,8.2) 
P=0.438 
0.028 
EQ5D VAS 
n patients 
k nurses 
  
33 
15 
 
62 
24 
  
EQ5D VAS Baseline
a
 
53 Weeks 
60.9(23.1) 
63.5(20.2) 
60.8(19.1) 
57.5(20.9) 
6.09(-2.6,14.7) 
P=0.170 
0.194 
EQ5D 
N patients 
K nurses 
  
34 
15 
 
58 
24 
  
EQ5D Baseline
a
 
53 Weeks 
0.654(0.310) 
0.622(0.354) 
0.619(0.330) 
0.600(0.315) 
0.000(-0.105,0.105) 
P=0.997 
-0.039 
a = Effect of HIP versus Treatment as usual   
b = Baseline mean is of those with follow up data  
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Table 9:7 Estimated effect of HIP Programme on primary and secondary outcomes 
at 53 Weeks (Per Protocol 2 Analysis)  
Measure  HIP 
Mean (sd) 
 
TAU 
Mean (sd) 
 
Effect
b 
(95% CI) 
(adjusted for baseline) 
P = 
 
Intra class 
correlation 
SF36v2   
n patients 
K nurses 
  
20 
8 
 
61 
24 
  
SF36 PCS Baseline
a
 
53 Weeks 
43.8(11.8) 
46.6(11.3) 
45.0(10.1) 
45.0(10.8) 
2.87(-1.9,7.6) 
P=0.236 
0.218 
SF36 MCS Baseline
a
 
53 Weeks 
43.3(14.6) 
39.7(15.6) 
38.0(14.1) 
37.9(14.7) 
-0.76(-7.9,6.4) 
P=0.834 
0.048 
EQ5D VAS 
n patients 
k nurses 
  
20 
9 
 
62 
24 
  
EQ5D VAS Baseline
a
 
53 Weeks 
67.1(23.2) 
66.5(18.6) 
60.8(19.1) 
57.5(20.9) 
5.84(-4.75,16.4) 
P=0.286 
0.194 
EQ5D 
N patients 
K nurses 
  
21 
9 
 
58 
24 
  
EQ5D Baseline
a
 
53 Weeks 
0.700(0.316) 
0.672(0.326) 
0.619(0.330) 
0.600(0.315) 
0.022(-0.102,0.147) 
P=0.724 
0.003 
a = Effect of HIP versus Treatment as usual   
b = Baseline mean is of those with follow up data  
 
Health economic outcomes 
A description of the resource use associated with the component parts of the intervention 
is provided in Table 9.8. Of the 90 participants allocated to the intervention arm, 42 were 
known to have received the HIP at baseline. Timings for HIP baseline completion were 
available for 26 of these 42 participants, where it was reported that the time taken to 
complete the HIP with the patient ranged from 30 minutes to 2 hours 10 minutes (mean = 
61.92 minutes). For 25 of these 26 participants, it was reported that further non-patient 
contact time was required to complete the associated paperwork, where the time ranged 
between 15 minutes and 1.5 hours (mean = 31.40 minutes). In total, across the 26 
participants, the mean time to conduct the baseline HIP was thereby 92.12 minutes (range 
45 minutes to 3.5 hours). On the assumption that half of the contacts took place at the 
nurses’ workplace (cost of £40 per hour) and half took place in the patients’ home (cost of 
£70 per hour), then this would equate to a mean cost of £84.44 across the 26 participants. 
This mean baseline HIP cost was also assigned to the 16 participants who were known to 
have received the HIP but failed to complete the nurse questionnaire. The other 48 
participants in the intervention arm were assumed not to have received the HIP at 
baseline and hence no cost for the completion of the HIP was assigned to them. Together, 
this meant that the mean cost of conducting the HIP at baseline was £39.40.  
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Table 9:8 Intervention costs 
Component part Resources costed, participant costing Mean cost (£ per 
participant) 
Training  Updating the HIP manual (2 trainer days), preparation of training materials (2 trainer days), preparation for the 
sessions, including agreement of time and venue (4 trainer hours), travel time (25 trainer hours, 6 trainee 
hours), travel cost (883 trainer miles and 212 trainee miles @45p per mile), and session time (49 trainer and 
trainer hours). Equally apportioned across N=90 participants. 
110.32 
HIP consultations 42 baseline (mean time = 92.12 minutes) and 23 follow-up (12 month) consultations (mean time = 54.50 
minutes) 
52.17 
Total 162.50 
 
Table 9:9 Mean levels of resource use per participant and associated costs 
 Mean levels of resource use (n respondents) Mean cost (£) 
 12 month follow-up 12 month follow-up 
Item HIP group  Control  HIP group Control 
Health professional visits 36.1 (67) 48.3 (61) £1,690.01 £2,125.80 
Hospital admissions 0.23 (65) 0.36 (61)   
Total number of days in hospital 6.4 5.2 £2,272.97 £1,989.46 
Other healthcare services 1.7 (65) 5.7 (61) £70.58 £249.65 
Medication prescriptions 59.8 (64) 62.4 (59) £1282.09 £1083.02 
Tests and investigations 1.5 (63) 1.7 (60) £39.13 £59.76 
Total other NHS and PSS costs (59) (58) £5,629.79 £5,710.07 
Total NHS and PSS costs  (59) (58) £5,796.08 £5,710.07 
Hours of care (per week) - paid 3.3 (63)  2.1 (57) £1,050.17 £719.42 
Hours of care (per week) - unpaid 7.0 (63) 3.6 (57) £3,246.11 £3,274.07 
Total care costs (63) (57) £4,296.29 £3,993.49 
Total societal costs (57) (54) £10,293.09 £9,854.67 
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At 12-month follow-up, 24 of the 90 participants allocated to the intervention arm were 
known to have received the HIP. Timings for HIP completion were available for 10 of 
these 24 – on average, completion of the HIP with the patient took 44 minutes (range 20 
to 60 minutes), 4 of the 10 reported additional non-contact time with a mean of 26.25 
(range 15 to 30 minutes). In total, across the 10 participants, the mean time to conduct the 
follow-up HIP was thereby 54.50 minutes (range 10 minutes to 70 minutes hours), which 
equates to a cost of £49.96 (at a cost of £55 per hour). This mean follow-up HIP cost was 
also assigned to the other 14 participants who were known to have received the HIP. The 
other 66 participants in the intervention arm were assumed not to have received the HIP 
at follow-up and hence no cost for the completion of the HIP was assigned to them. 
Overall, the mean cost of completing the HIP at follow-up was £12.66. When these 
baseline and 12 month follow-up HIP completion costs were summed together the mean 
cost was estimated to be £52.07 (56.80 minutes). To account for the 4 HIPs at baseline 
and 2 at follow-up conducted by the nurse who was trained in error no costs were 
assigned to these contacts in the base-case but the sensitivity analyses incorporated 
them. 
 
When the HIP completion costs are added to per participant total training costs the total 
intervention cost was estimated to be £162.50 per participant (range £110.32 - £302.82). 
One of the reasons that training costs are so high is that nurses found it difficult to take 
the time away from clinical activities in order to travel to training. As such, training was 
largely delivered on a one-to-one basis at the team base.   
 
Overall, the mean (per participant) total other NHS and personal social services [PSS] 
costs was £5,796 for intervention arm participants and £5,710 for control arm participants. 
When carer costs we included, the total societal costs were £10,293 and £9,8545, 
respectively (Table 9.9).  The main unit costs attached to the various resource use is 
summarised in a table in Appendix 7.  
 
The mean baseline and follow-up utility scores (for both the EQ-5D and SF-6D) are shown 
in Tables 9.10 and 9.11, along with the QALY score over the 12-month follow-up period. 
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Table 9:10 estimates of the mean utility and mean QALY scores based on the EQ-5D 
 
 
Table 9:11 Estimates of the mean utility and mean QALY scores based on the SF-6D 
 
Intention to treat analyses 
Estimates for the mean incremental cost and mean incremental effect are given in Tables 
9.12 (EQ-5D) and 9.13 (SF-6D). It can be seen that these are based on data from 64.7% 
of participants for the EQ-5D and 58.4% for the SF-6D. In both analyses it was estimated 
that there was no significant difference between the groups with regard to either costs, 
though the mean total NHS and PSS cost was estimated to be slightly lower in the 
intervention arm. For outcomes, the mean QALY score for the intervention group was 
estimated to be slightly higher for the SF-6D, but slightly lower for the EQ-5D, though 
again neither of these differences were significant. For both analyses, the net benefit 
figures were positive at the £20,000 per QALY mark. However, there was a large 
uncertainty associated with this decision as, at this value of λ, the CEAC estimated the 
probability that the HIP was cost-effective to be 59.4% for the EQ-5D and 58.1% for the 
SF-6D (at £30,000 per QALY the figures were 56.7% and 58.3% respectively) i.e. there 
was estimated to be a >40% chance of making the wrong decision, with regard to cost-
effectiveness, if we chose to implement the HIP Programme intervention. 
Sensitivity analysis  
Results for the societal cost perspective, the multiple imputation analysis and per protocol 
analyses are also shown in Tables 9.12 and 9.13. The estimated mean incremental cost 
and mean incremental effect did not change appreciably in any of sensitivity analyses that 
were performed, as it can be seen that the confidence intervals surrounding both 
estimates always encompassed zero. 
 Group Baseline score 12 month follow-
up score 
Unadjusted 
Difference 
12 month QALY 
score 
ITT        HIP 0.635 (N=88) 0.600 (N=67) –0.035 (N=66) 0.614 (N=66) 
 Control 0.611 (N=82) 0.592 (N=58) –0.017 (N=57) 0.598 (N=57) 
 Group Baseline score 12 month follow-
up score 
Unadjusted 
Difference 
12 month QALY 
score 
ITT        HIP 0.580 (N=82) 0.599 (N=64) 0.008 (N=58) 0.587 (N=58) 
 Control 0.580 (N=77) 0.588 (N=57) 0.011 (N=53) 0.588 (N=53) 
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Table 9:12 Estimates of the incremental cost, incremental effect (based on the EQ-5D) and incremental cost-effectiveness ratio 
based on regression analysis 
 
 
 
 
 
 
 
 
 
 
 
 
*Based on total NHS and PSS costs, unless otherwise stated; 95% CI = 95% confidence interval; SA=Sensitivity analysis 
 
 
 
 
 
Analysis  
(N in each group) 
Incremental cost* (£) 
(95% CI) 
Incremental QALY  Incremental cost-effectiveness ratio (ICER) 
/ Net monetary benefit (NMB) (£) 
Base-case (58 HIP, 54 C)  
 
–355.20 
(–3,213.65 to 2,503.26) 
–0.008  
(–0.059 to 0.044) 
NMB = 203.72 
SA: Societal cost perspective  (58 HIP, 
54 C)  
–228.63 
(–3837.71 to 4294.97) 
–0.008  
(–0.061 to 0.045) 
NMB = 68.62 
SA:  Multiple imputation (90 HIP, 83 C) –372.48 
(–3121.10 to 2376.14) 
–0.011  
(–0.074 to 0.052) 
NMB = 152.48 
SA: Per protocol swap (trained) (57 HIP, 
57 C) 
547.48 
(2211.12 to 3306.09) 
–0.009  
(–0.061 to 0.043) 
Dominated 
SA: Per protocol 1 (Baseline HIP) (29 
HIP, 55 C) 
–341.18 
(–3,213.65 to 2,503.26) 
0.016  
(–0.041 to 0.074) 
Dominant 
SA: Per protocol 2 (Baseline and follow-
up HIP) (19 HIP, 55 C) 
–49.87 
(–4140.85 to 4041.10) 
0.016  
(–0.042 to 0.074) 
Dominant 
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Table 9:13 Estimates of the incremental cost, incremental effect (based on the SF-6D) and incremental cost-effectiveness ratio 
based on regression analysis 
 
 
 
 
 
 
 
 
 
 
*Based on total NHS and PSS costs, unless otherwise stated; 95% CI = 95% confidence interval; SA=Sensitivity analysis 
 
 
 
 
Analysis  
(N in each group) 
Incremental cost* (£) 
(95% CI) 
Incremental QALY  Incremental cost-effectiveness ratio (ICER) 
/ Net monetary benefit (NMB) (£) 
Base-case  (51 HIP, 50 C) –230.81 
(–3,188.49 to 2,726.88) 
0.001  
(–0.024 to 0.026) 
NMB = 256.65 
SA: Societal cost perspective  (51 HIP, 
50 C) 
–65.62 
(–4,169.51 to 4,038.27) 
0.001  
(–0.026 to 0.027) 
Dominant 
SA:  Multiple imputation (90 HIP, 83 C)  –372.48 
(–3121.10 to 2376.14) 
0.011  
(–0.015 to 0.037) 
Dominant 
SA: Per protocol swap (trained) (51 HIP, 
50 C) 
738.74 
(–2,119.33 to 3,596.81) 
–0.003  
(–0.028 to 0.022) 
Dominated 
SA: Per protocol 1 (Baseline HIP) (26 
HIP, 51 C) 
459.15 
(–2,882.28 to 3,800.59) 
0.008  
(–0.026 to 0.041) 
ICER = 57,938.62 
SA: Per protocol 2 (Baseline and follow-
up HIP) (17 HIP, 51 C) 
866.32 
(–3,433.39 to 5,166.02) 
0.006  
(–0.031 to 0.044) 
ICER = 135,262.64 
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Adverse events (patients)  
Three patient deaths were reported to the research team during the course of the study 
although two of these occurred after follow-up data collection in Part 1 was complete but 
before the study site had closed. Two deaths were in the TAU group and one in the HIP 
group. A senior medical clinician investigated all adverse events according to the 
sponsor’s Standard Operating Procedures and requirements of the Research Ethics 
Committee. All three deaths were attributed to cardiovascular disease and none were 
considered related to participation in the trial (Table 9.14). All adverse events that met the 
definition of a serious adverse event [SAE] are summarised in Table 9.14. There were five 
adverse events that did not meet this criteria but were reported to the NHS research 
manager at each site and to the trial sponsor. These included potential medication 
interactions observed when collecting medication data that were reported back to the 
patient’s psychiatrist and GP (n=2 patients), day surgery (n=2, in the same patient) and a 
report of pain and dizziness from one patient to that was immediately communicated to 
their nurse. 
Table 9:14 Serious Adverse Events reported in the study (patient participants) 
Group  HIP TAU 
Number of deaths 
a
 1 2 
Number of episodes of 
self-harm 
1 0 
Number of psychiatric 
admissions 
11 11 
Number of general 
hospital admissions 
3 7 
Number of other serious 
medical conditions 
1 1 
Total SAEs 17 21 
 
a. One of the deaths in each group was reported after the follow-up data collection period for that patient 
had ended but before the close of study site. 
 
Chapter summary 
In this chapter I have reported the results of the HIP Cluster RCT. There was no 
significant difference between the HIP Programme and Treatment as Usual groups on the 
primary and secondary outcome measures in patient participants. This null effect 
remained after adjustment was made for those potential covariates showing a prognostic 
relationship with the primary outcome. A variety of sensitivity analyses that took account 
of missing data and deviations from the protocol also found no differences between the 
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groups. Implementation of the HIP programme was not estimated to result in a significant 
difference in either physical or mental health related quality of life, cost or QALYs. 
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Chapter Ten: Nurse outcomes (Part 1) and results of the process 
observation (Part 2) 
Nurse outcomes in the Cluster RCT (Part 1) 
Nurse attitude and knowledge 
The adapted Physical Health Attitude Survey [PHASe] was completed by 85% (51/60) 
nurse sample at baseline but only 37.5% (21/56) of the nurses who remained in the study 
at follow up (Appendix 5). The small number of nurses who completed both the baseline 
and follow up questionnaire in each of the study groups meant it was not possible to 
compare mean scores and subscales between groups, as intended in the protocol.  
Characteristics of nurses who returned a HIP 
The characteristics of the nurses in the HIP Group who did and did not return a copy of a 
completed HIP to the study team during Part 1 of the study are summarised in Table 10.1. 
Nurses not returning a HIP appeared more likely to be male and working in an assertive 
outreach team at baseline, than in the other types of community mental health teams 
represented in the sample. There were no other discernible differences between groups. 
Adverse Events (nurses) 
We collected data about nurses who went off on long term sick leave during the trial so we 
were aware not to contact them to attempt to follow them up while they were unwell. The 
member of staff involved either communicated this information directly to the research 
team or a message came from their Team Leader. In total three nurses were reported to 
the team to be on long-term sick leave during the trial period after randomisation and all 
three of these were in the HIP Group. One became unwell between randomisation and 
HIP Programme Training, so did not receive training or complete the baseline adapted 
PHASe. Two returned from leave before the end of the study at their site so were included 
in follow-up data collection. The remaining nurse returned just after their individual follow-
up window had closed but requested and was included in Part 2. The trial NHS sponsor’s 
Standard Operating Procedure for Reporting of Adverse Events was adhered to and it 
was determined that none of the Adverse Events were related to the trial. There were no 
other reports of adverse events regarding nurses in the trial. 
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Table 10:1  Characteristics of nurses in the HIP Group who did or did not return a 
HIP 
Group 
 
HIP returned a HIP not 
returned 
Total HIP 
Groupa 
Number of CMHNs 
 
n=15 unless stated n=12 unless 
stated 
n=30 unless stated   
 
 
X (%) or mean (sd)   X (%) or mean 
(sd)  
X (%) or mean (sd)  
 
NHS Site 
 
1 
2 
3  
4 
 8 (5.3%) 
 3 (20%) 
 3 (20%) 
 1 (6.7%) 
   4 (33.3%) 
   1 (8.3%) 
   3 (25%) 
   4 (33.3%) 
13 (44.3%) 
  4 (13.3%) 
  8 (26.7%) 
  5 (16.7%) 
CMHT Type    
 
 
Recovery  
Assertive Outreach 
Rehabilitation 
Forensic 
 
12 (80%) 
  1  (6.7%) 
  1  (6.7%) 
  1  (6.7%) 
 
   4 (33.3%) 
   8 (66.7%) 
   0 (0%) 
   0 (0%) 
 
19 (63.3%) 
  9 (30%) 
  1 (3.3%) 
  1 (3.3%) 
     
 
Age in years at consent 
  
 45.9 (9.2) 
 
  48.3 (5.7) 
 
46.9 (7.7) 
Gender  Female  13 (86.7%)     7 (58.3%)  23 (76.7%) 
Ethnicity  White British  14 (93.3%)   12 (100%) 29 (96.7%) 
 
Grade  
 
 
Band 5  
Band 6 
Band 7 
 
   0 (0%) 
 15 (100%) 
   0 (0%) 
 
  0 (0%) 
12 (100%) 
  0 (0%) 
 
  0 (0%) 
28 (93.3%) 
  2 (6.7%) 
 
Highest Academic level    
              
 
 
Certificate 
Diploma 
Degree 
Masters 
 
  1 (6.7%) 
  8 (53.3%) 
  5 (33.3%) 
  0 (0%) 
 
  4 (33.3%) 
  5 (41.7%) 
  2 (16.7%) 
  1 (8.3%) 
 
  6 (20%) 
14 (46.7%) 
  7 (23.3%) 
  2 (6.7%) 
 
MHN Experience in 
years 
  
 13.4 (7.4) 
 
  18.6 (10.4) 
 
16.5 (9.6) 
 
Time in post  
 
  Less than 1 year 
  1 – less than 5 years  
  5 – less than 10yrs 
  10 or more years 
 2 (13.3%) 
 5 (33.3%) 
 7 (46.7%) 
 1 (6.7%) 
   1 (8.3%) 
   5 (41.7%) 
   4 (33.3%) 
   2 (16.7%) 
  3 (10%) 
12 (40%) 
11 (36.7%) 
  4 (13.3%) 
 
Adult nursing 
qualification 
  
 1 (6.7%) 
 
   0 (0%) 
 
  1 (3.4%) 
     
Knowledge MCQ  (baseline) 
 
  9.9 (3.0) n=14   9.5 (2.2) n=11   9.7 (2.6) n=27 
Attitude
 
PHASe (baseline) 
 
28.7 (8.1) n=10 34 (3.1) n=8 31.1 (6.8) n= 18 
Confidence PHASe (baseline) 15.1 (7.2) n=10 15 (5.1) n=8 15.1 (6.2) n=18 
 
Barriers PHASe (baseline) 
 
30.8 (4.5) n=10 
 
29.9 (4.4) n=8 
 
30.4 (4.4) n=18 
 
Attitude towards smoking PHASe (baseline) 
 
18.6 (6.6) n=10 
  
19.1 (2.2) n=8 
 
18.8 (5.0) n=18 
 
a = includes the nurse who was allocated to TAU but received HIP Programme training in error. 
HIP returned represents all nurses in HIP group who completed at least one HIP with at least one of their 
study patients. 
HIP not returned represents all nurses in HIP group who received HIP training but did not complete a HIP 
with any of their study patients  (three nurses withdrew before training). 
Total HIP Group represents all nurses who were randomised to receive HIP Programme training 
MCQ = multiple-choice questionnaire 
PHASe = Physical Health Attitude Scale. 
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Results of the Process Observation (Part 2) 
The results of Part 2 of the study relate to the final secondary outcome (6); Acceptability of 
the HIP Programme in the NHS. 
Recruitment to interviews 
Postal invitations were sent out to all HIP Group nurses from the two largest NHS study 
sites who remained in the trial at follow-up in Part 1 of the study (N=15). Of these, five 
nurses agreed to participate in an interview, two from site 1 and three from site 4. Only 
two replied with reasons for not wanting to participate and both stated this was because 
they were too busy with their clinical work. The remaining 8 nurses did not return a 
response slip so their reasons are unknown. Four interviews were conducted face to face 
as per protocol but one was undertaken by telephone following a specific request from the 
nurse. All interviews were recorded and transcribed verbatim. 
Patient recruitment is summarised in Figure 10.1. The patient participants of the fifteen 
nurses invited to Part 2 who had been successfully followed up in Part 1 were identified by 
the Project Lead (n=55). The study nurse (or a study nurse in the same team if the nurse 
had withdrawn) was asked to hand deliver invitations to identified patients. At site 1 a 
pragmatic subsample of 6 nurses were selected (who worked nearest to the University) 
and asked to pass on invitations to 22 study patients. Of these, 4 initially agreed and 
13.6% (n=3) were interviewed .Two of these three patients had records of the HIP being 
returned to the study team during Part 1. At site 4 there were a total of 19 patients 
remaining in the HIP Group after Part 1 and invitation packs were distributed to their 7 
study nurses. 15.8% (n=3) patients responded to the invitations and agreed to be 
interviewed. Only one of these three patients had records of the HIP being returned to the 
study team during Part 1. 
Invitations were sent by post to the consultant psychiatrists and GPs of all 41 patients who 
had been sent Part 2 invitation packs. There was a certain amount of overlap between 
these clinicians in terms of their caseloads so that 12 psychiatrists and 28 GPs in total 
were invited. All interviews were conducted by the Process Observation Lead (at site 1) 
and myself (at site 4). 
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Figure 10:1 Patient recruitment to part 2 interviews 
 
Field notes were taken in the patient interviews with responses to each question captured 
verbatim. These notes were then read back and checked with the participant at the end of 
the interview and changed as necessary if they identified errors or misunderstandings of 
what they intended to say. 
The characteristics of nurses and patients who agreed to be interviewed are presented in 
Tables 10.2 and 10.3. Only two of the interviewed nurses completed the knowledge and 
PHASe attitude questions at follow-up, so it is only possible to present baseline means of 
these subscales in the nurse table. All interviewed nurses reported to the interviewer that 
they had experience of using the HIP with at least one of their study patients. Each one of 
them had used the HIP at baseline but only one had completed follow-up HIPs with the 
same study patients at 53 weeks. One of the nurses did not return any copies of the HIP 
form to the study team but in the interview stated they had completed a baseline HIP with 
one of their study patients and had attempted, but not completed it, with another. The 
subsample of interviewed nurses were slightly more likely to work in a forensic team, have 
a degree or a general nursing qualification than the baseline trial nurse sample. There 
were slight differences in the adapted PHASe subscales mean scores. Knowledge scores 
were 1.7 points higher and attitude and confidence scores 1.7 points lower in the interview 
sample but there were no other discernable differences between them. 
Medical comorbidities reported by the patient sample included allergy (hay fever) and 
chronic musculoskeletal problems (due to injury). There were two thirds less medical 
comorbidities in the interview sample than that seen in the total trial sample. Family 
history of cardiovascular disease was present in a quarter of the total trial sample but had 
not been reported in the interview sample. Only one patient in the interview sample was 
prescribed medication for CVD (a statin and an antihypertensive). Half of the interviewed 
patients were prescribed clozapine. 
Site 1 
22 patients  
(of 6 nurses) 
4 agreed 
1 (went on 
holiday) 
3 Interviewed 
(13.6%) 
Site 4 
19 Patients  
(of 7 nurses) 
3 agreed 
3 Interviewed 
(15.8%) 
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Table 10:2: Baseline characteristics of nurses who were interviewed 
Group 
 
Part 2 nurses at 
baseline 
Part 1 nurses at 
baselinea 
Number of CMHNs  n=5 unless stated n=51 unless stated 
  X (%) or mean (sd)  X (%) or mean (sd) 
NHS Site 
 
1 
4 
2 (40%) 
3 (60%) 
24 (47.1%) 
13 (25.5%) 
CMHT Type    
 
 
Recovery  
Forensic 
 
4 (80%) 
1  (20%) 
  
31 (60.8%) 
  3 (5.9%) 
 
 
Age in years at consent 
  
 52.4 (5.2) 
 
45.6 (7.8) 
Gender  Female    3 (60%) 36 (70.6%) 
Ethnicity  White British    4 (80%) 45 (88.2%) 
 
Grade  
 
 
Band 5  
 
 
   5 (100%) 
  
 
 
  1 (2%) 
 
 
Highest Academic level    
              
 
 
Certificate 
Diploma 
Degree 
 
 
    1 (20%) 
    2 (40%) 
    2 (40%) 
  
 
11 (21.6%) 
14 (43.1%) 
22 (27.5%) 
 
 
MHN Experience in years 
  
 13.6 (9.9) 
 
14.9 (8.1) 
Time in post  
 
1 – less than 5 years  
  5 – less than 10yrs 
   
   2 (40%) 
   3 (60%) 
 
22 (43.1%) 
18 (53.3%) 
 
 
Adult nursing 
qualification 
  
   1 (20%) 
 
 4 (7.8%) 
    
Knowledge MCQ  (baseline) 
 
11 (3.5) n=4 9.3 (2.4) n=51 
Attitude
 
PHASe (baseline) 
 
28.8 (4.4) n=4 30.4 (5.2) n=38 
Confidence PHASe (baseline) 12.5 (4.6) n=4 14.1 (3.8) n=38 
 
Barriers PHASe (baseline) 
 
30.5 (2.6) n=4 
 
30.6 (3.2) n=38 
 
Attitude towards smoking PHASe (baseline) 
 
19.5 (4.8) n=4 
 
19.7 (3.5) n=38 
a = nurses that returned adapted PHASe at baseline 
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Table 10:3: Baseline characteristics of patients who were interviewed 
 
Group 
 
Part 2 patients at 
baseline  
 
Part 1 patients at 
baseline 
 
Number of patients  n=6  n=173 unless stated 
 
  
X (%) or mean (sd) unless 
stated 
X (%) or mean (sd) unless 
stated 
NHS site 1   3 (50%)   95 (54.9%) 
 3   3 (50%)   48 (27.7%) 
CMHT type Recovery   4 (66.7%) 119 (67.1%) n=166 
Months on caseload  median (min,max) 24 (9,84) 29 (1,300) n=161 
Primary Diagnosis  Schizophrenia 
   
6 (100%) 
 
 
110 (63.6%) n=172 
 
Age in years at consent 42.7 (11.6) 46.3 (12.1) n=170 
Gender Male   4 (66.7%)   96 (55.5%) n= 170 
Ethnicity White British   5 (83.3%) 156 (90.2%) n=171 
Living status Lives alone    4 (66.7%)   97 (56.1%) n=171 
Relationship Single, divorced or widowed   5 (83.3%) 117 (67.6%) n=169 
    
Smokes cigarettes    3 (50%) 107 (61.8%) n=167 
Medical Comorbidity 
Diagnosis
a
 
 
 
None  
1-4 comorbidities 
 
  4 (66.7%) 
  2 (33.3%) 
 
  42 (24.3%) n = 169 
115 (66.5%) n = 169 
    
Total number of 
medications
 
 
 
median (min,max) 
   
   2.5 (1,5) 
 
    4 (0,20) 
Total number of antipsychotics
a
   
 One
 
   5 (83.3%) 151 (92.1%) n =164 
 2 or more    1 (16.7%)   26 (15%) n =164 
Prescribed an atypical antipsychotic 
Prescribed a typical antipsychotic 
  5 (83.3%) 
  2 (33.3%) 
112 (64.7%) n=164 
  51 (29.5%) n=164 
   
Family History of cardiovascular disease (CVD)   0 (0%)   44 (25.4%) n= 156 
Prescribed medicines for CVD
a
   1 (16.7%)   46 (28%) n=164 
   
a = includes medications for diabetes, dyslipidaemia and hypertension 
 
Part 2 patient interview results 
Six patient interviews were conducted either at the patient’s home (n=5) or community 
team base (n=1). Interviews lasted around 30 minutes. Fifty percent (n=3) patients 
interviewed recalled the HIP process although of these two had no record of a HIP being 
returned in Part 1. When patients did not recall the HIP at all a copy was shown to them in 
the interview (n=3). One of these patients commented on why it had not been completed 
as planned saying  
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“it’s a shame, with all the cutbacks that change of nurse and team meant that the 
HIP was not done” [Participant 5].  
Thematic analysis of the written record of responses to the 9 questions using NVivo 
Version 10 and the constant comparative method described in the methodology chapter 
identified five themes related to the use of the HIP: the HIP as an unobtrusive tool, 
enhancing the nurse-patient relationship, the importance of regular health checks, quicker 
pathways to care and changing health behaviour. 
The HIP as an unobtrusive tool 
Two participants talked about the HIP as something that didn’t take over their sessions 
with their nurse, but added to them.  
“Aware of it ‘in the background’ most of the time but more aware during the 
assessments, obviously… [the HIP] gave a reminder of the importance of physical 
health which continued throughout the other sessions, not always addressed, but 
‘always in mind’” [Participant 2] 
“Not really that aware – remember doing it, but not really at other times”. 
[Participant 3] 
One participant who had experienced the HIP process talked about feeling as if the focus 
on physical health helped them feel like they were treated as a person, not just being 
viewed in the context of their diagnosis. 
“Just more rounded, more complete. Felt more valued and less like it was ‘all 
about my diagnosis or index offence” [Participant 2]. 
Enhancing the nurse-patient relationship  
Two participants thought the use of the HIP meant they felt more engaged in the 
relationship with their nurse. 
“I felt like I was being valued, taken seriously. It helped build trust and the 
therapeutic relationship” [Participant 2]. 
“What I will say is that the HIP helped my nurse and I communicate about my 
needs more, and I felt listened to… I have had various health problems and it was 
nice to be able to talk about them and feel listened to” [Participant 3]. 
A third participant who recalled having a HIP done commented that they preferred having 
physical health care from their CPN because 
“it is good to be followed up by someone you know unlike the GP and nurse at the 
practice who are all different people” [Participant 6]. 
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The importance of regular health checks 
All six patients who were interviewed said they thought it was very important to have 
regular health checks. 
“If I have diabetes, I would like to know straight away so I can go on medication. If 
I get diabetic checks done monthly that will give me a peace of mind… regular 
weight checks help me to keep an eye on my weight. I would also like regular drug 
screenings as well. That will keep me out of trouble. Heart checks and blood 
pressure will be very helpful if possible.” [Participant 1]. 
“Very important, at least every year, maybe more often. It’s important for nurse to 
remember that the patient is a whole person and important for the patient to focus 
on what they have to do for themselves to be healthy”. [Participant 2]. 
“I have no real opinion as to whether it should happen at a certain time or not, but I 
do believe it should be used, especially if like me there are physical health 
problems that have not been previously addressed”. [Participant 3]. 
“Yes, rather with my CPN than my GP” [Participant 4]. 
“Yes, I think it is important every year” [Participant 5]. 
“Definitely at least one a year, it’s eye opening for the person” [Participant 6]. 
Quicker pathways to care  
Two participants talked about experiencing a quicker process in addressing their physical 
health needs due to use of the HIP. 
“It did seem to get my problems looked at quicker though, particularly referrals to 
the GP” [Participant 2]. 
“Quicker speed of referral, better communications, especially with my GP and my 
CPN… more happy with the overall standard of care” [Participant 3]. 
Changing health behaviour 
Three participants talked of positive life changes as a result of an increased focus placed 
on their physical health since use of the HIP. Two described making specific health 
behaviour changes (starting swimming or walking, reducing the amount they smoked, 
decreasing their caffeine, drug and alcohol use) and one also described how they 
believed these changes had helped them get and keep a voluntary job for the last 6 
months.  
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“Yes – cigarette use has fallen, decreased levels of alcohol and drug use. Some of 
these changes happened prior to HIP, but using it has helped keep focus on why 
these changes were made an helped maintain the healthy behaviours” [Participant 
2].  
“It made me look at caffeine. I was drinking 10 bottles of coke. Have stopped that 
all together, and am drinking squash now… I have taken up walking to help with 
my weight” [Participant 6].  
“On a wider level these [health improvements] have enabled me to get a 
volunteering job, the first job I’ve had, and keep it for 6 months now”. [Participant 
2]. 
The other three patient participants commented on how they had not implemented health 
behaviour change that had been suggested to them (e.g. starting swimming, going to the 
gym, introducing a healthier diet) stating they were not motivated to change (one 
commented they were “far too old” to make any changes to their lifestyle). 
 
Part 2 nurse interview results 
All interviews were conducted at the nurse’s team base with the exception of one 
telephone interview and lasted around 40 minutes. All interviewed nurses stated they had 
experience of using the HIP with at least one of their study patients. Each one of them had 
used the HIP at baseline but only one had completed follow-up HIPs with the same study 
patients at 53 weeks. One of the interviewed nurses had not returned any copies of the 
HIP to the study team but in the interview stated they had completed a baseline HIP with 
one of their study patients and attempted, but not completed it, with another.  
Analysis of the transcripts using NVivo version 10 and the constant comparative method 
described earlier initially generated twelve coded themes that were collapsed and 
summarised into seven final themes; the importance of physical health to holistic (nursing) 
care, uncovering physical health needs, health literacy (nurses), health literacy (patients), 
assessment is easier than intervention, communication of evidence and organisation of 
services. 
The importance of physical health to holistic (nursing) care 
In this theme, all five nurses identified the HIP as something that helped them maintain a 
focus on physical health care within their role. They talked about physical health care as 
an important part of providing holistic care, that physical health care was seen as located 
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within their role by the other workers in their team and was important to the care of their 
patients.  
“Other members of the team could see the benefits [of the HIP Programme] 
however it was seen as a nurse initiative and role… [it was] good for my practice 
as it raises awareness of physical health” [Nurse 1]. 
“You do have this label of nurse which does even just subconsciously say or 
suggest you should know something about these things you know. If we are talking 
holistically as well, physical is part of that holistic care” [Nurse 2]. 
“I think this in some ways gets us back to our basic skills of actually a holistic 
approach to care” [Nurse 3]. 
“Somebody comes onto the caseload… what might be considered a more 
mundane thing such as peoples kind of dental history their uh their eyesight um 
generally sexual health issues so there’re a lot of things that um that um won’t be 
won’t be available to you in terms of their sort of um written information that’s 
passed onto you so really its then very much down to you as a as a community 
mental health nurse to um to ask to ask those questions” [Nurse 4]. 
“[It’s] quite a major issue with a lot of our um community patients they tend to be 
on the more severe of the spectrum as far as their mental health is concerned or 
their mental health has been in the past consequently they’re also on lots of 
medication generally they also tend to have had substance misuse problems in the 
past as well um and all these things kind of sort of complicate the picture as far as 
their physical health is concerned so I think to actually have some form of 
structured assessment it’s very useful in fact I’d almost say it’s kind of vital looking 
to the future” [Nurse 4].   
“It has had an impact there’s been a total and utter reminder um of everything that 
we don’t do and um it’s made me now every time I have a new patient or I’ve got 
someone I am vigilant, basically I’m become sort of vigilant with the physical side 
of stuff” [Nurse 5]. 
“I think we can use that in a different way in a more positive way with them to say 
well let’s look at your diet you know what about [X] prescription you know giving 
them some solutions, some you know solution focused answers to these problems 
rather than just saying to someone randomly when you see them every six months 
you know you still haven’t lost any weight” [Nurse 3].  
“I just incorporate it now you see and go for whatever is needed then and nothings 
left to chance” [Nurse 4]. 
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Uncovering physical health needs 
In this theme, the nurses talked about how completing the HIP bought previously unknown 
information about the patient’s physical health into awareness. Alternatively where 
physical health needs were already known, the HIP acted as a reminder of the importance 
of keeping these physical health needs on the agenda. One nurse commented there was 
no other structured way of knowing about all the physical health parameters when a 
patient joined their caseload. 
“Picking up things that the patient would definitely not gone to their GP for - not 
without some of our team being involved in that negotiating that with the GP yes 
that wouldn’t have happened without the HIP” [Nurse 3]. 
“You can kind of see at a glance the things that that you need to kind of address 
with them with the patient themselves as far as the physical health is concerned 
sometimes those are quite surprising you know. Well they were for me, things that 
I didn’t know and I wasn’t aware until I wasn’t aware of until I’d done the 
questionnaire um with people and there are things that maybe you know patients 
have never kind of thought about in relation to their physical health” [Nurse 4]. 
“[What] the HIP did was either to highlight a physical health issue that I wasn’t 
aware of and I sort of then kind of build that into the physical healthcare plan or 
physical health care provision for that for that patient so it would either highlight 
you know a problem that you weren’t aware of or it would kind of act as a sort of 
reminder for something that you were aware of” [Nurse 5]. 
“[X] went to the GP’s about her eyes and she actually had to have an appointment 
at the [Hospital] so that was very good, the questionnaire prompted something that 
we would have missed” [Nurse 5]. 
“Her liver function test was way out of date and in actual fact that was because 
we’d had changes in consultants an awful lot and it hadn’t been followed up and it 
did pull that up… there was another one that it highlighted that wasn’t done um I 
think it was the lipids… I don’t think we ever do tests for cholesterol so it changed 
what we did in that respect” [Nurse 2]. 
Health literacy (nurses) 
In this theme, the nurses spoke about how using the HIP had made them reflect on their 
lack of knowledge, confidence or competence around physical health and do (or consider 
doing) something about it. 
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“Clinical skills needed jenning up on, an awful lot of these things… the blood 
pressure one I did because I was having to use it… look it up or ask colleagues (I 
did both) and practice on each other… it was surprising how much of us didn’t 
know… so that in itself having to complete that questionnaire made you think I 
need to look these things up” [Nurse 2]. 
“My knowledge…. with menstrual cycle as well believe it or not it’s more personal 
what I know as a woman than what I know as a nurse… but it prompted learning I 
did go and look up some menstrual cycle stuff [on the internet] and I did actually 
go and talk to a midwife [about hormones] and asked colleagues as well” [Nurse 2]. 
“I maybe need to do a bit work on myself is around fluid intake, caffeine intake um 
urinary flow and those kind of inter related issues which have been highlighted in 
one or two of the questionnaires that I’ve carried out with patients. I think it’s 
probably down to me to do a bit more kind of research in those areas myself” 
[Nurse 4]. 
It’s years since I have been in education. Like more than and less than and little 
mathematical things like that I just had to sort of think about because I’ve just been 
out of education for so long I never did maths anyway um so you know it’s just 
again looking at a different document isn’t it and just getting your head round it” 
[Nurse 5]. 
“it’s about getting nurses to pick up the pieces and to become experts in their field 
really within the mental health field but where it overlaps with physical healthcare, 
not be afraid to go and spend some time at the sleep clinic and see what they, how 
they diagnose and what are [the best interventions]” [Nurse 5]. 
Health literacy (patients) 
In this theme, the nurses discussed the benefits of having a physical health conversation 
and using feedback from the HIP to raise awareness of the patient’s need for health 
behaviour change. 
“It’s giving evidence to the patient… they’re finding that themselves it’s not us 
having to say well they’re saying “oh actually” when you say that that’s that and it 
gives them that boost that motivation to actually look at ways they can address it 
and the support groups that are available out in the community for them to do 
that… it gives them a time line as well because if you’re going back like we went 
back they wanted to be focused to try and do something about it so that when we 
complete the next um profile they’ve actually they have achieved they have and 
they’ve looked at their own wellbeing and what they can do to address some of 
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those needs it’s making them a bit more self-aware as well and more in control of 
their wellbeing” [Nurse 1]. 
“I didn’t realise you know is the sort of attitude of the other person when they listen, 
and so they got talking about what their physical concerns were so even it raised 
their awareness to a new level completely, not just to talk to a nurse or a health 
professional but actually with their own [partner]” [Nurse 3]. 
“They’re finding that [out]  themselves it’s not us having to say well they’re saying 
oh actually when you say that’s that and it gives them that boost that motivation to 
actually look at ways they can address it and the support groups that are available 
out in the community for them to do that” [Nurse 1]. 
Assessment is easier than intervention 
Nurses talked about how it was relatively easy to undertake physical health assessment  
using the HIP and that patients welcomed the focus on physical health measurement from 
them. One nurse thought it may be an advantage to build trust to initially focus on physical 
health, rather than the usual focus on mental health and risk early in the nurse-patient 
relationship. Two nurses talked about paying more attention to parameters they felt more 
comfortable talking about. Barriers were experienced when trying to implement a health 
care plan. Some of these barriers were related to the nurse’s own practice, some to 
resistance from patients and some to systems (organisational) factors. 
“I think doing the questionnaire can actually be a way of helping build your 
relationship with that person when they first come on to your caseload. You’re not 
having to ask the kind of more intrusive questions about their mental health that 
they may find more difficult in trying to answer. Indirectly I think it might help in sort 
of building that relationship” [Nurse 4].   
“[it is] easier to do blood tests and physical monitoring, take your temperature and 
can I take your blood pressure, those sorts of very practical things were very easy. 
I think that the service user’s actually like that sort of medical attention” [Nurse 1]. 
“[I] would make a clinical judgement about asking certain questions or not, for 
example if I anticipated it would make the patient verbally aggressive towards 
me… particularly with the diet and the caffeine and the all those sorts of things and 
the sleep um but the things like the waist circumference… things that they 
perceive to me as becoming a nag about. People might even become a bit more 
resistant through you asking them (talked about the sighing sound heard from the 
patient when asking questions about diet).” [Nurse 2]. 
 146 
“Actually implementing the care plan is often the most difficult… um physical 
health tends not to be a priority a lot of the time for us as practitioners so it is more 
about the implementation of a care plan and um you know I’ll hold my hand up and 
say I could have been better implementing parts of physical healthcare plans” 
[Nurse 5]. 
“I don’t, didn’t like the um you know the bit about the sexual side of stuff I think 
that’s very difficult for us to ask” [Nurse 5]. 
“I don’t think um the patients found it all that difficult I mean, the safer sex and the 
sexual satisfaction, some of those questions you’re probably more embarrassed 
than the patients were in asking them you know um I mean even if the answer was 
they weren’t… yes I think that’s interesting that’s something once you ask the 
question you get quite a reasonable response)” Nurse 3]. 
“With the kind of patient group that we’re dealing with getting them actually to go to 
an optician can take take you ages”   [Nurse 1]. 
“That’s more of a sort of technical issue really about getting the GP’s to do the 
blood samples and also getting the patient down to the GP to have a have a 
sample have the samples taken” [Nurse 4]. 
“I tell you what it did lead on to, an awful lot um um opticians and dental referrals. I 
would think that they increase more because I think you’re comfier asking about 
that sort of thing” [Nurse 2]. 
“Talking about medication and obesity with patients is probably more of a sensitive 
issue than sex. I wasn’t embarrassed about asking about their weight and you 
know what are you going to do about it, and that was the one that probably there 
was slightly more confrontation over” [Nurse 2].  
Communicating evidence  
In this theme the nurses talked about how the HIP allowed evidence of physical health 
need to be more easily communicated to patients and GPs. 
“We have the evidence there to support physical health needs which I found quite 
useful and I think that helped the service user um address the needs that they 
needed to and be listened to, aided communication with consultant reviews and 
provided specific evidence to GP of need. It’s like it almost builds that relationship 
working relationship with GP’s” [Nurse 1]. 
“It’s giving evidence to the patient… they’re finding that themselves it’s not us 
having to say” [Nurse 1]. 
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“I feel by having this addressed in their wellbeing plan they always get a copy of 
the wellbeing plan so that sort of looks at physical health needs they’re aware and 
that makes also future appointments for the service user a lot more it’s more 
beneficial” [Nurse 1]. 
“it gives [patients] a time line as well because if you’re going back like we went 
back they wanted to be focused to try and do something about it so that when we 
complete the next um profile they’ve actually they have achieved they have and 
they’ve looked at their own wellbeing and what they can do to address some of 
those needs it’s making them a bit more self-aware as well and more in control of 
their wellbeing” [Nurse 1]. 
Organisation of services  
In this theme systems that supported and prevented successful use of the HIP process 
were highlighted, this included access to equipment and regular training updates but also 
issues related to workload and caseload pressures, and recent reconfiguration of services 
that were perceived as preventing follow-up and the implementation of physical health 
interventions. Problems with interface communication and working with GPs were also 
highlighted in this theme.  
“[There was] lots of scrabbling around looking for it, tape measures and things like 
that” [Nurse 3].  
In contrast another nurse highlighted how having the right equipment was now on the 
team’s agenda. 
“[In the team’s six weekly business meeting] part of the time is set aside to talk 
about how we’re monitoring physical health and whether or not we need more 
equipment… they’ve bought a portable weighing scales and portable height 
measuring thing so these are things that you know we weren’t getting the money 
for before” [Nurse 3]. 
Two nurses commented on how the recent introduction of mandatory physical health 
training updates by the Trust was positive and highlighted management support for the 
role. 
“The physical health training recently introduced by the Trust is positive to make 
sure everyone up to speed and at the right level in their practice” [Nurse 1]. 
“We’re now being sent on training and various other things so there’s some things 
in the trust though there are some negatives in the way that our caseloads have 
been managed over the last year I think on the health side of it, I think there is a 
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recognition that this is really important… skill sides they’re actually making sure 
that we’re up to date and you know that’s something that wasn’t on the agenda 
before” [Nurse 3]. 
Time and workload pressures were discussed in relation to the need to see patients often 
and for long enough time to conduct an annual health check and implement interventions, 
despite an acknowledgement of the importance of doing so. Nurses discussed the 
difficulties of balancing workload pressures with including the HIP process in their work. 
They emphasised the work required after completing the HIP as the most time-consuming. 
“From my experience it, to actually effect a behaviour change generally it will 
require revisiting the issue quite a number of times before you’ll see uh a definite 
change” [Nurse 4]. 
“Having enough time to complete the HIP (including looking back at past results 
and the trail afterwards) with everything else there is to do. Some items took more 
time as needed explanation (bowels, sexual parameters) – service users were 
sometimes surprised by the questions so needed time to explain. It increased my 
workload to do it properly” [Nurse 1]. 
“[It] created more follow up stuff because if I’d asked and got a negative response 
that needed chasing up it had a sort of knock on effect because once you’ve 
identified that you can’t just leave it” [Nurse 2]. 
“it’s a high value in that on that half an hour spending to get to know to get to know 
a lot more about the physical health of somebody that you’re caring for in the 
community um so that’s a half an hour well spent I think… where it can get time 
consuming um is if there are issues that are highlighted and then you’re then 
following those up that that’s where it can get time consuming and that’s not a fault 
of the questionnaire. I mean in a way that’s a plus of the questionnaire because 
um if you don’t do something about that those issues or somebody doesn’t do 
something about those issues then probably you know that’s got serious 
consequences for the patient further down the line” [Nurse 4]. 
“it’s not just about completing the form… it could stop  you doing other things that 
are important such as… the relapse prevention all the things on the care plan the 
wellbeing plans all those sorts of things that you’ve got to clock through.” [Nurse 2].  
“if you’re not careful with the pressures of your caseload um things like patients 
physical health can be put to one side because they’re not pressing they’re not 
pressing issues very often” [Nurse 4].   
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The perceived impact of recent changes to services within and outside of their 
organisation was highlighted as a barrier by nurse participants from both organisations. 
“I think the limitations were more to do with how we’re set up to work and what’s 
going on with our Trust than limitations to do to with the project because teams 
were swapped about a lot and it’s still going on so we kept losing patients they 
would be redistributed so there was no continuity with what you did um you were 
concentrating on building up the relationships with the patients and probably that 
first contact where you might have used that [the HIP] but then by the time it had 
come round to probably doing the follow up bit you had lost the patient [from your 
caseload]” [Nurse 2]. 
I’d only see a very limited role [for the HIP in future practice] because with um as 
now being pushed to discharge people quicker we wouldn’t be able to follow up or 
know where they’re at if they’ve gone now… and loads of people wouldn’t be a 
year” [Nurse 3].  
“Virtually almost as soon as I’d done, well in fact even before I did the baselines 
um somebody else took that caseload on” [Nurse 5].  
There was the observation from one nurse that (since reconfiguration) patients do not get 
a care coordinator (at Agenda for Change Band 6) unless they relapse but remain on a 
large maintenance caseload of a Band 5 nurse who has tasks to complete that prevent 
them from implementing health behaviour interventions. 
“They don’t get a Care-Coordinator unless they relapse and I think that is a big 
issue that we are struggling with. As we are now seeing band 5 nurses do not stay 
very long [they] tend to be people who have just qualified and as soon as they get 
a chance of a six somewhere else they’re going to move on so they’re really quite 
elusive fluid group of people… by their very nature they’re only going to be six 
months to a year [in post] and they’re going to move on… They are doing very set 
tasks like depots, like medication management issues and then there is an impact 
on whether they have the time to look at wider health” [Nurse 4]. 
One nurse talked about the disappearance of useful local NHS resources. 
“What resources we’ve got available as well it that um really sort of kicked off with 
diet, exercise, smoking. We had a new NHS resource set up in the town so it 
made it very easy for us. We identified this, asked people if they were interested, 
they’d get one to one support but then the funding was pulled and we lost that and 
I think there was a few things like that so you just get a bit sort of downhearted” 
[Nurse 2]. 
 150 
There was an expressed willingness to work with primary care but frustration that 
communication and co-working is difficult to achieve because it is not usual practice and 
systems are not set up to facilitate this easily. 
“The issues with it are how we follow it up and how we how we um sort of 
interconnect with other health services to actually follow up the information that 
comes outs of the questionnaire, It’s not the questionnaire as far as I am 
concerned you could tweak a little bit but the questionnaire the way it’s laid out is 
fine um it’s just um how you follow up and follow through the information that you 
that you get from the questionnaire and the more I think about it the more that 
really um that sort of entails a better linking between our service and GP services” 
[Nurse 4]. 
“There are some measures in the HIP which although I think are very valid they 
need to be taken by the practice nurse at their GP surgery and I have asked. I 
have asked um GP surgeries to do that when I as part of the study uh but again 
the response from GP’s is patchy” [Nurse 5]. 
“They [GPs] never come along to the CPA reviews, never known one in all the 
years” [Nurse 2]. 
“[CPA] reviews that GPs do not engage in, sometimes try to do it at the GPs 
surgery but that’s not often possible” [Nurse 1]. 
“Obviously all our all our patients will get registered with a GP um but I’ve found 
that the interaction between our patients and GP’s is very patchy so useful to have 
a structured checklist very often so again the information is not it’s not being um 
gathered by GP’s either so again it comes back to us really” [Nurse 4]. 
“[There is the] difficulty of patients coming to the CMHT base in large rural area – 
would have to go out to surgeries to run a clinic but why aren’t GPs and practice 
nurses doing this? They’re about 30,000 some of these GP surgeries with 15 
active GP’s and I guess the physical health of you know a few thousand people 
with mental health problems is not their priority” [Nurse 3].  
Part 2: Results of the audit 
Lists of patients remaining in Part 1 at follow-up for each of the three audit conditions were 
identified by one of the Trial Coordinators at Site 1 as per protocol. Field researchers 
worked though these lists until the sample size was achieved as planned and 30 sets of 
patient case notes were audited; 10 patients in the HIP group whose nurse had returned 
at least one HIP to the study team in Part 1, 10 from the HIP group whose nurse had not 
returned a HIP and 10 patients from the TAU group.  
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Data was collected by two field researchers based at the NHS site and entered into the 
HIP Audit form, these were then collated and analysed by myself using SPSS 19. The 
characteristics of the audit sample are presented in (Appendix 6). There was a greater 
proportion of patients with a diagnosis of schizoaffective or bipolar disorder in the audit 
sample compared to the entire Part 1 patient sample at baseline. In the HIP Group where 
a HIP had not been returned to the study team patients appeared to be more likely to 
have spent longer on their study nurse’s caseload and have a recorded medical 
comorbidity than patients in the HIP returned group. In the HIP returned group patients 
appeared more likely to have a record of family history of cardiovascular disease [CVD] 
and have been prescribed CVD medication. However, the numbers in each group are too 
small to perform any meaningful inferential statistical tests of significance of these 
apparent trends. There were no other discernable differences between groups. 
During the process of completing the audit questions it was identified that two patients in 
the HIP not returned group had evidence of completed HIPs in their case notes. Because 
of this the results of the audit analysis are presented in per protocol groups, i.e. in groups 
where there was any evidence of HIP completion (Table 10.4).  
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Table 10:4: Audit Table (per protocol version where HIP completed even if not 
returned) 
Group 
 
HIP completed HIP not 
completed 
TAU 
Number of patients  n=12 unless stated n=8 unless stated n=11 unless stated 
   X  X  X  
Any record of physical 
health check  
 
8 (66.7%) 3 (37.5%)  3 (27.3%) 
HIP recorded  7 (58.3%) 0 (0%) 0 (0%) 
Who completed heath 
check 
Consultant  
Junior doctor 
Nurse 
Other 
0 (0%) n=8 
2 16.7%) n=8 
6 (50%) n=8 
0 (0%) n=8 
0 (0%) n=3 
1 (12.5%) n=3 
2 (25%) n=3 
0 (0%) n=3 
1 (9.1%) n=3 
1 (9.1%) n=3 
0 (0%) n=3 
1 (9.1%) n=3 
Care planning      
Care plan was available 
to audit 
 7 (58.3%) 5 (62.5%) 6 (54.5%)  
 
Use of HIP identified 
 
 
3 (25%) n=7 
 
0 (0%) n=5 
 
0 (0%) n=6 
Needs   6 (50%) n=7 4 (50%) n=5 4 (36.4%) n=6 
Interventions   5 (41.7%) n=7 3 (37.5%) n=5 4 (36.4%) n=6 
Outcomes  3 (25%) n=7 2 (25%) n=5 2 (18.2%) n=6 
     
Care Programme 
Approach [CPA] 
 
 
   
CPA document was 
available to audit 
 
7 (58.3%) 5 (62.5%) 8 (72.7%) 
 
Use of HIP identified 
 
 
0 (0%) n=7 
 
0 (0%) n=5 
 
0 (0%) n=8 
Needs   5 (41.7%) n=7 5 (62%) n=5 5 (45.5%) n=8 
Interventions   5 (41.7%) n=7 5 (62%) n=5 5 (45.5%) n=8 
Outcomes  5 (41.7%) n=7 5 (62%) n=5 2 (18.2%) n=8 
     
Record of 
communication with 
primary care  
    
Use of HIP identified  0 (0%) 0 (0%) 0 (0%) 
Needs  9 (75%) 3 (37.5%) 8 (72.7%) 
Interventions  9 (75%) 3 (37.5%) 10 (90.9%) 
Outcomes  9 (75%) 3 (37.5%) 8 (72.7%) 
 
Other than where a HIP had been entered into the record and completed by a nurse (n=9) 
all other reported health checks were by medical staff (n=5) and one ‘other” (a health care 
assistant). There was no evidence of any increased interface communication with primary 
care or in CPA documentation in the HIP group patients. In all three groups this evidence 
existed in the record for patients who had health checks recorded or not. 
Chapter summary 
In this chapter the results of the nurse outcomes in the trial and the outcomes of the 
process observation were reported.  Due to poor follow up rates of the adapted PHASe it 
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was not possible to assess the impact of the HIP Programme on CMHNs attitude towards 
or knowledge of physical health care (Objective 4). There were few discernable 
differences between CMHNs in the HIP Group who returned a copy of the HIP to the 
study team and those who didn’t other than male gender and working in an assertive 
outreach team at baseline (more likely in the HIP not returned subset). No harms were 
reported related to participation in the research. 
A third of all invited HIP group nurses agreed to the Part 2 interviews but only fourteen 
percent of invited patients. The interview samples were broadly representative of the 
baseline trial sample, although the nurse sample were more likely to be educated to 
degree level and have ever used a HIP and the patient sample were more likely to be 
prescribed CVD medication. All the interviewed nurses reported they had used the HIP at 
least once and half of the patients recalled having a HIP completed. This was new 
information to the research team, because copies of the HIP had not been received for 
one of the nurses and patients. That return by post was not a reliable method of capturing 
HIP completion was supported by the HIP Audit results where 2/10 patients in the HIP not 
returned group had a record of HIP completion in their patient record. In the audit patients 
in the HIP group with evidence of HIP completion were a third more likely to have had a 
health check undertaken by a nurse than in the other groups. There was no evidence of 
any impact on the care planning processes or communication with primary care. 
Interviewed patients reported the HIP process as unobtrusive and that they believed it 
enhanced the relationship they had with their nurse, enabled a regular health check and 
facilitated quicker access to care. There was some ambivalence expressed about the 
potential of the HIP to change health behaviour, with half reporting they had made positive 
changes and half stating they experienced internal motivational barriers to change. 
Nurses highlighted how the HIP Process raised the profile of physical health in their work 
and enabled them to uncover previously unknown physical health needs in patients 
prompting them to reflect on and attempt to enhance their knowledge and skills. Physical 
health conversations and specific HIP feedback to patients was identified as positive. 
However barriers were experienced when attempting to move beyond assessment to 
intervention.  These comprised internal (resistance to change,) and external 
(organisational) factors.  
 
 154 
 Chapter Eleven: Discussion of the outcomes of the trial and 
process observation  
Patient outcomes in the Cluster RCT (Part 1) 
The fieldwork for this trial was undertaken in generic and specialist community mental 
health services across the East of England between May 2011 and April 2012. Baseline 
scores for the SF36v2 PCS and MCS indicate our sample was similar to community 
patients with SMI in the USA, and primary care patients with at least one comorbid long-
term physical health condition in Germany (Wang et al., 2008, Druss et al., 2001). Where 
the HIP was completed at baseline a mean of 6.6/27 (SD 3.5) items were marked red per 
patient, this is consistent with the level of comorbidity identified in our community case 
series in Lanarkshire in Scotland (Shuel et al., 2010). An RCT of joint crisis plans reported 
similar baseline demographics to our sample in a study of 569 SMI patients from generic 
and specialist community mental health teams (Thornicroft et al.). These authors reported 
a more ethnically diverse sample than ours, but patients were recruited from sites serving 
the three largest urban areas of England, as opposed to our mixed urban (but largely) 
rural county population. The characteristics of our patient sample therefore indicated that 
the Part 1 trial results can be generalised at least to SMI patients of secondary community 
mental health services in England outside of major cities. 
Randomisation was effective, as demonstrated by the lack of discernible differences 
between patient demographics across the two groups. We had robust procedures for 
maintaining researcher blinding and there were no breaches during the trial. In a 
population where attrition rates in clinical trials can be considerable we achieved a 74% 
follow up at 12-months despite tightly defined timings for patient assessment. A threshold 
of 80% is often used to separate “high”- and “low”-quality” randomised trials, and by some 
journals as a threshold for publication (Sackett et al., 2000, Brueton et al., 2014). The 26% 
attrition we experienced may have introduced bias and reduced power because, for 
example, patients who remained in the trial at follow up were more or less motivated 
towards making physical health related lifestyle changes.  
The intention to treat analysis demonstrated there was no effect of the intervention on the 
primary or secondary outcomes. Intent-to-treat principles are applied in randomised 
controlled trials to avoid biases associated with non-random loss of participants. Analysis 
of the primary outcome was based on sample sizes of 68 and 60. On the surface this 
seems underpowered compared with the 32 nurses with three consented patients each 
planned for. However, our sample size calculations assumed a within cluster correlation of 
0.1 or 0.2 for 80% and 86% power respectively. The intra class correlation obtained in the 
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study was substantially lower (0.036) than that planned for and average cluster sizes in 
the two randomised groups were 2.7 and 2.5 respectively. Rough retrospective power 
calculations, although not usually recommended, for cluster sizes of 2 or 3 with an ICC of 
say, 0.05, suggest power of over 80% to detect an effect size of 0.55 standard deviations. 
Hence our study may not be underpowered. The 95% confidence interval for the SF36v2 
Physical Component Score [PCS] suggests that the intervention may reduce PCS by 1.5 
points or increase it to 4.5 points compared to TAU but I have been unable to identify any 
published evidence that this is clinically meaningful in SMI.   
Patient baseline scores on the primary outcome measure (SF36v2-PCS) indicated 
considerable physical impairment in both groups. There were three patient deaths during 
the course of the trial, all attributed to cardiovascular disease. Completed HIPs 
emphasised the substantial physical health problems that patients were experiencing.  
That just under half of the patients participating in the HIP arm of trial had a HIP 
completed and returned to the study team at baseline by their study nurse was 
unexpected. It is reasonable to assume that few would have implemented interventions 
subsequent to the baseline assessments. Fidelity to the intervention at 12 months was 
weak, only 28% of the patients in the HIP Group had a HIP returned by their CMHN at 
follow-up. If nurses were motivated to sign up to a trial it might be expected that their 
adherence to delivering the intervention would have been relatively good, but this was not 
the case. Consequently, that patients’ physical health related quality of life did not appear 
to improve in either the HIP or TAU groups is not surprising as the majority of HIP patients 
effectively received TAU.  
We performed a per protocol analysis of those patients whose nurses who received HIP 
training and those who did complete and return HIPs, as opposed to those in the HIP 
group who didn’t. The Trial Steering Committee did not define the per protocol analyses a 
priori and only selected this method after we knew about the poor fidelity to HIP 
completion. Per protocol analyses (either pre planned or not) are considered acceptable 
as long as they are labeled secondary comparisons and over inflated claims are not made 
for efficacy as a result (Schulz and Grimes, 2002). If the per protocol analyses had 
identified a difference this could only have indicated a trend towards an effect because as 
well as undermining the equal groups achieved at randomisation, the subsequent analysis 
was underpowered. However we did not find any evidence of an effect at all in any of the 
per protocol analyses 
Our trial had some notable weaknesses. Less than half of the participating nurses 
completed HIPs with just under half of the study patients, consequently the study can be 
justifiably criticised as not providing a straightforward test of the effectiveness of a health 
check using the HIP in this population. The SF36v2 PCS measures the patient’s 
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perception of their health status. SF36 summary scores may be too broad and general to 
capture changes in health status over the time frame of the trial and changes to the items 
used to calculate PCS may take a long time to improve in this population (Simon et al., 
1998, Druss et al., 2010). Some authors have criticised the use of generic quality of life 
scales in SMI due to the impact of psychopathology on accurate judgements of subjective 
wellbeing (Bobes et al., 2010). A disease specific quality of life measure may have 
addressed this but a validated measure of physical health related quality of life was not 
available for all three SMI disorders. More specific measures of health status such as 
body mass index (BMI) were considered as alternatives but were rejected because 
collection of health status data from the TAU group would have contaminated the usual 
care condition.  
We had planned in our protocol to calculate CVD risk in HIP group patients using 
QRISK®2-2013 (a measure of the risk of having a heart attack or stroke over the next ten 
years) with data from the health check. The low quantity and quality of data from the 
returned HIPs was such that this was not possible. Clustering in this trial was at the level 
of the nurse and not the team. We could be criticised for not addressing possible 
contamination (sharing the HIP Programme knowledge) by nurses working in the same 
team but in different arms of the trial. We have no evidence this occurred. Randomising at 
the level of the team may have reduced this risk but would have required more sites to 
access a sufficient number of teams. Four NHS mental health service provider sites 
across the East of England were required to achieve recruitment. We were not able to 
control for the non-specific effects of time spent training nurses and additional time nurses 
spent with patients completing the health check. We did not monitor and consequently do 
not know what proportion of patients in the trial had a health check carried out in Primary 
Care during the study period. Theoretically, a primary care health check might have 
cancelled out any effect of the HIP but this seems unlikely given the comparatively poor 
state of participants’ health.  
Any intervention has the potential to do harm and beyond routine adverse event reporting, 
we did not monitor any unwanted effects the HIP could have caused. The HIP and training 
attempted to target physical health screening and intervention in SMI through supporting 
the existing role of the CMHN. Although pragmatic, this was still a complex intervention 
that required several interacting components, including engagement and involvement in 
the process from patients, nurses and multiple provider services. More attention to the 
feasibility of implementation may have highlighted areas that required attention such as 
management support, resources, interface communication and working/professional 
culture. 
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The trial phase found no evidence that CMHN facilitated health checks following HIP 
Programme training are effective at improving the physical wellbeing of patients on their 
caseload. Previous studies have shown that general health checks carried out in 
asymptomatic people do not reduce morbidity (Krogsbøll L et al., 2012). Despite this, 
national guidance in England directs clinicians to conduct annual health checks in adults 
with psychosis and these are now to take place following admission to a secondary care 
service and then for at least a year (National Collaborating Centre for Mental Health, 
2014). A number of small case series have suggested the possible value of health checks 
in this group of patients in secondary care (Shuel et al., 2010, Bressington et al., 2014, 
Phelan et al., 2004). This is the first randomised controlled study that provides evidence 
that challenges the value of health checks provided by CMHNs in this population.  
Nurse outcomes in the Cluster RCT (Part 1) 
Outcomes from nurse data collected in Part 1 of the trial were intended to be analysed to 
test any change in CMHNs attitude towards and knowledge of physical health care at 12 
months in the HIP Programme Group (Objective 4). The poor response rate to the 
adapted PHASe survey at 53 weeks prevented this analysis. Of those nurses in the HIP 
group who responded at follow-up only seven had enough complete data for analysis.  
At baseline, there was considerable contact between field researchers (who were actively 
recruiting study patients) and nurse participants. Despite reassurances from the NHS sites 
at the protocol stage that access to the online survey (located on a server at the University 
of East Anglia) would not be prevented by NHS firewalls, study nurses reported delays 
and security warnings when trying to access the survey. Those who were confident users 
of technology ignored these and worked around the problem by cut and pasting the 
survey web address into a new browser window. Postal questionnaires were issued to 
nurses who reported problems to field researchers and requested a paper version. The 
high baseline response rate (85%) reflects that the CMHNs were motivated to consent 
and participate in data collection at this time point. At follow-up the survey completion 
window was less synchronised with patient follow-up and contact with field researchers 
was not routine. Completion at this stage completely relied on nurses accessing and 
responding to the website link within an email generated from the trial database. A much 
lower follow-up response rate of 35.7% was achieved despite a two email reminders that 
included information about how to overcome potential NHS firewall problems. Only 14% 
(n=7) had complete baseline and follow-up data, not enough to allow a statistical 
comparison between groups. Response rates to web based surveys amongst health care 
professionals rarely achieve 20% and can be much lower where there are problems with 
familiarity and access (Dykema et al., 2013).  
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Compared to the sample of MHN who responded to the postal questionnaire by the 
developers of the PHASe (n=585) (Robson and Haddad, 2012), our sample was slightly 
older, more predominantly female and much less ethnically diverse. The HIP group who 
returned any HIPs were more similar to Robson’s sample in terms of their mean years of 
MHN experience (13.4 vs 13.3) than the group who did not return a HIP at all (18.6 years 
experience). These differences may reflect the nature of the South London sample where 
two thirds of MHN respondents worked in inpatient, rather than community settings. 
Inpatient MHNs tend to be younger and less experienced than CMHNs because the 
majority of MHNs start their preceptorship in inpatient services. The age, gender and 
ethnicity profile of the CMHN workforce in England was last reported in a September 2010 
census (Health and Social Care Information Centre, 2011). Our total trial sample was very 
similar in age and gender to this national sample, but 19% more likely to report White 
British ethnicity. Differences in ethnicity are not surprising in a sample from mental health 
provider organisations covering largely rural populations outside of London. In the 2011 
general population census, 93% and 92.4% people in the counties of Lincolnshire and 
Norfolk described themselves as White British (Office for National Statistics, 2013). 
When compared visually, the attitude and confidence subscale mean scores of our total 
trial sample at baseline were lower than in the Robson et al (2012) sample (by 6.1 and 8.2 
points respectively) and the perceived barriers subscale mean score was higher (by 6.7 
points). The total possible score for each of these subscales is 50 for attitude, 30 for 
confidence and 35 for perceived barriers so these differences represent a 12% less 
attitude and 21% less confidence score. The perceived barriers score was 27% higher. It 
is not possible to analyse whether these differences are statistically significant or a feature 
of the large disparity between sample sizes (e.g. by paired sample t-tests). Differences 
could reflect the different context of community work and the community nursing 
workforce, but it is not possible to compare with the Robson et al data because these 
authors did not disaggregate community results. There were no discernable differences 
between randomisation groups in terms of their confidence in performing a physical health 
role and their attitude towards smoking, similarities that were also seen within the subsets 
of the HIP Group. There was a more positive subscale score for attitude in the HIP non-
returned group compared to the HIP returned group, but the larger standard deviation in 
the non-returned group indicates this is likely to be a feature of the very small sample size 
(n=8) rather than a true difference.  
The physical health knowledge of nurses was measured with 20 multiple-choice questions 
[MCQs] that could achieve a maximum score of 20. All nurses who completed the adapted 
PHASe at baseline completed the MCQs (n=51) with a mean score of 9.3 (sd 2.4). Little is 
known about the physical health knowledge of MHNs although they consistently identify it 
as a training need (Robson and Haddad, 2012, Happell et al., 2013). The MCQ result in 
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the trial was very similar to the baseline results of 46 MHNs who attended a HIP training 
workshop as part of a regional masterclass series at the University of Huddersfield in 
2013. In this cohort mean knowledge was 4.47 (sd 1.5) at baseline with half of the (same 
set of) MCQs was used (White et al., 2013). The adaption of the PHASe by addition of the 
MCQs has not been psychometrically tested but the questions were designed (by an 
experienced nurse educator) to test fundamental knowledge of physical health care for 
nursing practice (e.g. normal ranges for vital signs such a blood pressure). At the 
University of Hull, a sample selected from these MCQs has been included in an 
assessment since 2011 to test the achievement of learning outcomes in undergraduate 
student nurses at the end of their foundation year. The majority of nurses in Part 1 of the 
Trial were working in Agenda for Change Band 6 roles that include mentorship of student 
nurses. It is worrying that experienced MHNs are achieving less than 50% in this 
assessment. We were not able to test if participation in the HIP Programme led to an 
increase in knowledge, confidence and attitude that was sustained at 12 months as 
intended. 
The important findings from the nurse data are that randomisation had worked in Part 1 of 
the trial in terms of equal distribution of nurses between groups and, like other MHNs in 
the UK, our nurse subjects held predominantly positive attitudes towards physical health 
care at baseline. Other than membership of an assertive outreach team at baseline, there 
was no indication from the nurse data of characteristics predicting non-return of a HIP 
form to the study team. The characteristics of our nurse sample were similar enough to 
the profile of CMHNs from across England, to indicate that the Part 1 trial results can be 
generalised at least to CMHNs working with patients with SMI outside of London. 
Part 2 Process Observation 
The process of using the HIP, including patient and staff experience and impact on 
communication and care planning was explored (Objective 6). The response rates for 
nurse and patient interviews were disappointing but reflect the difficulties of keeping 
participants in the study beyond the trial phase and the lack of resources available to do 
so.  
Part 1 of the trial did not include medical staff although they were informed of participation 
of their patients by letter (a year or more before the interview invitation). Within the 
resources available in the grant it was only possible to contact psychiatrists and GPs by 
post in Part 2 and this method of recruitment completely failed. The Trial Steering 
Committee promoted recruitment in the NHS secondary care sites, including updates and 
information about the progress of the trial to all staff via the Trust bulletins. There was no 
promotion of the study in primary care although a personalised invitation letter and 
stamped addressed return envelope for response slips were used. GP response rates 
 160 
may be improved by a personalised approach, monetary incentives and promotion by 
professional associations (Cho et al., 2013). We cannot be certain if the failure of 
response was due to a failure to receive or open the invitation letters, a lack of interest or 
time to complete the response slip or prioritise a telephone interview, or a general lack of 
awareness of the HIP Programme. 
The method of recruiting nurses and patients meant that it was not possible to be certain if 
those recruited had experienced use of the HIP clinically before their interview. Part 1 of 
the trial tested the results of the HIP Programme so it seemed reasonable to target 
patients who had been successfully followed-up and their nurses to maximise the ability to 
recruit participants who had some experience of this process. The only measure of 
completion of the HIP available to the research team was that a copy had been returned. 
The interviews demonstrated that this was not a reliable measure. Study nurses and 
patients who had not returned HIPs described using them in practice and the audit 
demonstrated documented evidence of use that did not match the record of returns. 
Despite this, a third of patients and a fifth of nurses interviewed stated they had not been 
able to implement a HIP. These are participants who were motivated enough to participate 
and stay in the study beyond the 12 months trial phase, supporting the evidence from Part 
1 that there were significant barriers to implementation.  
The audit indicated that where a HIP had been used there was evidence of a physical 
health check in the secondary care patient record. In the groups where there was no 
evidence of completion of a HIP, there had been less health checks and they were more 
likely to have been completed by a doctor than a nurse. In the first published case series 
of the HIP improved interface communication was reported through sharing of the HIP 
form with GPs, but this was due to the efforts of one senior nurse (Shuel et al., 2010). In 
the trial there was no evidence of improved interface communication. Evidence within the 
Care Programme Approach documentation appeared to point to a standardised method of 
recording physical health need and communication with GPs, rather than an individualised 
approach that could be corroborated elsewhere in the patient record.  
The overarching theme (or meta theme) from the analysis of the interview data was that 
the HIP was experienced as a useful tool to promote health and wellbeing. However, its 
routine application was inhibited by barriers in the areas of clinical engagement and 
organisation of CMHNs’ work. There was some discrepancy in the nurses’ expressed 
views about practising outside of traditional CMHN boundaries, compared with those of 
the patients. Patients valued the HIP experience and welcomed MHN taking a stronger 
interest in their physical health care. Nurses stated they were motivated to develop their 
health literacy and role, but struggled to communicate across service interfaces and 
involve patients in interventions after assessment. Where the HIP indicated a referral was 
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required, those to dentists and opticians were reported as easier to facilitate than those to 
primary care. Despite the increased emphasis placed on the need to talk about sex when 
using the HIP in the training part of the intervention, two of the interviewed nurses were 
inhibited to do so. All patients had been motivated to try to implement lifestyle changes but 
all nurses except one (who worked in a forensic team) reported being unable to evaluate 
their progress due caseload pressures and a reported shift of focus to crisis care through 
reconfiguration of services. It is interesting that half of the interviewed patients were 
prescribed clozapine. Clozapine patients remain on a CMHNs caseload over time when 
relatively well because prescribing and monitoring is not usually accepted by GPs (due to 
specific monitoring and dispensing requirements).  
There is evidence that service reconfiguration has had a negative impact on the quality 
patient care and staff morale at the highest recruiting study site (Care Quality Commission, 
2015, NHS England, 2014). It is also reported that where providers have disbanded their 
assertive outreach services and redistributed patients and caseloads there has been an 
increase in the patient suicide rate (National Confidential Inquiry into Suicide and 
Homicide by People with Mental Illness, 2013). It is difficult to see how the new policy of 
annual health checks provided in secondary care can be achieved with a secondary care 
workforce who remain ambivalent about such a role and have limited time to spend with 
SMI patients who have recovered from an acute episode of illness. 
There were a number of important limitations that should be considered when interpreting 
the results of the process observation. The study took place in two mental healthcare 
organisations in the UK that have made a considerable investment in establishing and 
supporting the HIP. The experience of the HIP in other organisations may be different. 
The research group, who collectively hold largely positive views about the HIP, may have 
introduced bias in the phrasing of questions and how the analysis was performed. There 
was tension in the analysis stage between attempting to minimise observer bias and 
needing to understand the context of the data. An example of this is where NVivo 
identified a subtheme when the only evidence was a quote from one participant who had 
not used the HIP. Due to this and a wish to understand which nurses and patients had 
actually experienced the HIP, there was a return to hand coding data and themes. Finally, 
only small numbers of MHN and patients were available to participate and we were unable 
to reach a point where we were confident that we had achieved saturation of data. 
Chapter summary 
The trial phase was well conducted, randomisation was successful and blinding of data 
collectors was maintained. The intention to treat analysis demonstrated no effect of the 
HIP Programme on the primary outcome or any of the secondary trial outcomes and this 
was supported by per protocol analyses that explored outcomes where there had been 
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fidelity or not to the intervention. Fidelity to the intervention from CMHNs randomised to 
the HIP Programme group was disappointing at baseline despite their largely positive 
attitude towards a physical health care role, and at follow-up was far too low to allow the 
planned statistical analyses. This was mirrored in the low response rate for the adapted 
PHASe in nurse subjects. The trial phase found no evidence that CMHN facilitated health 
checks following HIP Programme training are effective at improving the physical wellbeing 
of patients on their caseload over 12 months.  
The process observation phase provides some indication of why nurses who were 
motivated to enter the trial and held a largely positive attitude towards improving the 
physical wellbeing of their patients were unable to do so. Despite patients’ expressing a 
wish for their CMHN to undertake their physical health care, nurses experienced barriers 
related to clinical engagement and organisation of their work and reported this impacted 
on their ability to intervene beyond assessment. These important results are broadly 
generalisable to patients with SMI and CMHNs working in generic and community mental 
health teams across England outside of major cities. 
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Chapter Twelve: Impact of practice application of the HIP  
Since the publication of the HIP development paper in 2009, I regularly received requests 
for HIP resources and reports from those who had attempted to implement it into practice. 
I specifically requested assurances that the resources I disseminated would not be shared 
with others without permission to avoid contaminating the trial. This chapter summarises 
the data either reported to me about the use of the HIP or published by others.  
Survey of HIP contacts  
I sent PDFs of the HIP and HIP Manual to 72 people who contacted Professor Richard 
Gray or myself requesting copies and further information. I maintained an email contact 
group of these enquirers (after seeking their permission) and in 2013 I sent a short email 
invitation to an online survey about use of the HIP (using SurveyMonkey©). These 
contacts included mental health nurses, pharmacists, policy project officers and 
academics. Twenty percent of these contacts (n=14) were from outside the UK (Ireland, 
the Netherlands, Switzerland, Australia, New Zealand and the USA). Sixty-three contacts 
went on to complete the online survey representing a 63% response rate. Twenty six 
respondents (36%) reported using the HIP for research, education and/or to develop 
policy, practice or nurse education programmes. Nineteen respondents (26%) said they 
had used the HIP in clinical practice to support health checks in their organisations, 
completing at least one HIP with a total of 2450 patients. 
Care pathways and commissioning targets  
Two nurses from the initial 2009 trainer cohort reported success in getting the HIP 
Programme embedded in their organisations as a standard for all patients. The HIP was 
adopted as the standard physical health risk assessment tool in NHS Lanarkshire in 2011 
and is included in care pathways for adult mental health service users in North East 
Lincolnshire, Nottinghamshire, Northampton, South Gloucester, Hull and East Yorkshire.  
In Nottinghamshire Healthcare NHS Trust the HIP is implemented via an integrated care 
pathway across all adult inpatient services. Two NHS Commission for Quality Innovation 
[CQUIN] targets identified the percentage number of patients to have a completed HIP 
and physical health care plan per quarter from the beginning of 2011. In the final quarter 
of 2012, 98.2% (n=2,821) had a completed HIP and 96.9% (n=2,783) patients had a 
physical health care plan, exceeding both local CQUIN targets and translating into 0.1% of 
the total income of the Trust (increasing to 1.5% in 2012-13). Four further provider 
organisations in England have adopted a similar CQUIN model (serving the populations of 
North East Lincolnshire, Northampton, South Gloucester and Hull & East Yorkshire). 
However, only in North East Lincolnshire does the target relate to community care. The 
service manager in the organisation that provides community adult mental health services 
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(Navigo) won the 2013 Medipex NHS Innovations Champion award for integration of their 
physical health in SMI service with primary care. In this service where nurse led CMHN 
clinics are located in primary health care centres the HIP is integrated into care and 
referral pathways and the electronic patient record system. 
http://www.medipex.co.uk/news/latest-news/medipex-nhs-innovation-awards-2013-
winners-announced/ . 
The HIP in Primary Care 
The primary care version of the HIP [HIP-PC] is used across Hull, Northampton and NHS 
London. Dr Sheila Hardy, when working as a Nurse Consultant in Primary Care Mental 
Health adapted the HIP with permission into templates for all primary care IT systems 
(Hardy and Gray, 2010) A pilot project that supported practice nurses to deliver annual 
health checks for SMI through education and use of the HIP templates informed CQUIN 
targets in Northampton, winning the Nursing in Practice Award, 2013. The project was 
cascaded across Northamptonshire, Leicester, Nottingham, Norwich and NHS London 
(Hardy et al., 2014). Dr Hardy trained 21 GPs who are Clinical Commissioning Group 
[CCG] mental health leads as part of the NHS London Primary Care Mental Health 
Leadership Development Programme. Feedback from these GPs was that they intended 
to recommend use of the HIP-PC and resources across their CCGs. The HIP-PC and 
resources (including the manual) can be accessed at http://physicalsmi.webeden.co.uk/ 
signposted from the Royal College of Psychiatrists website as a recommended resource 
for primary care. 
(http://www.rcpsych.ac.uk/quality/nationalclinicalaudits/schizophrenia/nationalschizophreni
aaudit/nasresources.aspx). Working with NHS England’s National Clinical Director for 
Mental Health, Dr Hardy continues dissemination of this important strand of the HIP work. 
 
I introduced the HIP to mental health and learning disability nurses employed to improve 
physical health checks in primary care by the Hull City Healthcare Partnership in late 2010. 
Templates for serious mental illness, dementia and learning disability were adapted from 
the SMI HIP by the team, with an innovative pre-screening form developed to be 
completed by patients and carers before their visit to the clinic to maximise consultation 
time. Templates were piloted in 10 general practices across the city to support the annual 
health checks of 713 patients (444 patients with SMI. 136 with LD and 133 with dementia). 
The process was well received by patients, carers, GPs, practice nurses and 
commissioners and the intention was to cascade this across all Hull CHP GP practices. 
However, the physical health in mental illness team was disbanded in 2013 when local 
services were reconfigured and staff redeployed into the Improving Access to 
Psychological Treatment [IAPT] teams. 
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International and translated versions  
In 2010 the HIP, the HIP Manual and Programme resources were translated into Swiss 
German, adapting to fit Swiss referral pathways and policies. In August 2011, I delivered a 
series of nurse workshops and a physical health care in SMI conference for 60 nurse 
leaders and educators from across Switzerland at the University of Bern through 
translators. One hundred and forty-six patients had the Gesundheitsförderungsprofil 
Psychiatrie [GEPPSY] implemented in a pilot cohort of community and inpatients with SMI 
(Bänziger 2013).  
Two hundred and seven patients had a HIP completed by their CMHN in Hong Kong in 
2012 following adaptation and translation of the HIP Programme into Hong Kong Chinese  
[HKC-HIP] (Bressington et al., 2014). In this study fidelity to implementation of the HIP 
was maintained and at 12 months 71.5% (n=148) of the baseline patients had a repeat 
HIP completed with their nurse. At follow up there were statistically significant increases in 
self-reported levels of exercise and the numbers of prescriptions for diabetes. Some 
general positive trends in other cardiovascular risk parameters, including improvement in 
some health behaviours and the total numbers of medicines prescribed for physical 
comorbidities were reported. There was an unexpected increase in the mean waist 
circumference between groups, probably reflecting the inaccuracy of this measure in 
practice. As a result of the feasibility of the HIP Programme intervention demonstrated in 
this study in Hong Kong a grant has been awarded for a Cluster RCT of the HKC-HIP to 
begin later in 2015. 
Chapter Summary 
While the HIP Cluster RCT was under development and then in progress the HIP, the HIP 
Manual and the training was widely disseminated to clinicians and academics who 
requested it and were not working in the clinical trial NHS sites. As a result by 2013 it was 
reported that 5,249 people with SMI had completed a HIP. The HIP became the focus of 
local commissioning for quality innovation targets in 6 provider organisations in England 
and 678 practice nurses were trained in primary care. Staff from12 countries worldwide 
have accessed the HIP and HIP resources (manual and training material) for 
adaptation/translation for their SMI populations. 
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Chapter Thirteen: Synthesis  
There was no vehicle to promote the education of registered mental health nurses in 
physical health care across the NHS in 2008. The clinical trial research that had taken 
place that tried to improve the physical wellbeing of people with SMI through nurse-led 
intervention relied on sponsorship from the pharmaceutical industry for specific ‘add on’ 
nurse roles in secondary care (Ohlsen et al., 2005, Smith et al., 2007b). There was no 
evidence that the service improvements implemented to date could be sustained or make 
a difference on a population level to people with SMI.  
This programme of research started with the design of a pragmatic tool to support mental 
health nurses to care for the physical health needs of the SMI patients with who they had 
contact. The HIP identified the physical health parameters at most risk and what mental 
health nurses could measure in routine practice and recommended action to bring about 
positive change. We intended to use an adapted traffic light system (red or green) to 
indicate when additional monitoring or intervention was required. We based the included 
parameters on a literature review and the thresholds and interventions on published 
guidelines and standards. Space on the one-sided document led to choices about what to 
include and in what order based on our collective experience. On the whole we 
successfully designed a document that had an evidence base and (we thought) could be 
easily incorporated into the practice of individual nurses. Initial piloting was successful and 
the documents and training workshops designed to facilitate the use of the HIP in practice 
were very well received and evaluated by mental health nurses from across the UK. We 
published a paper about the development of the HIP Programme and were inundated with 
UK and international requests for copies of the HIP and training materials. I maintained a 
database of (email) contacts and shared resources with those who asked for them. 
The case series in Scotland was pragmatic. The implementation of the HIP into the 
routine monitoring at a nurse-led clinic provided a sample where data had been entered 
into an excel database constructed by the nurse who ran the clinic. The organisation 
approved a service evaluation of this data, and an evaluation of the clinician and patient 
experience. The resulting published case series provided evidence of utility and 
acceptability. It also described considerable physical comorbidity (and therefore need) in 
the sample. This cross section of health status data highlighted how difficult it was to 
positively change physical parameters in people with SMI because these were patients 
that were already engaged in regularly attending a nurse led clinic for the management of 
their medication. I compared the clinic data with results of cohort studies into SMI patients 
in primary care and found similar levels of comorbidity. The extension of the service 
evaluation of HIP data to the two acute inpatient wards of the same hospital (the HIP-100) 
demonstrated much higher rates of comorbidity. It was therefore possible that attendance 
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at the clinic was already having a positive impact on patients’ health outcomes (e.g. by 
supporting medicines adherence, by engaging patients in smoking cessation, by regular 
monitoring). 
When writing the NIHR Research for Patient Benefit grant application for a clinical trial 
and the outline trial protocol within it I paid more attention to some aspects of the research 
design than others. So for example public and patient involvement, ethical issues, 
governance and the financial cost of conducting the research were addressed as was the 
feasibility of recruitment and retention. There was no requirement from the funders to 
demonstrate fidelity of the intervention i.e. if the intervention could be implemented as 
intended by CMHNs in their routine work, rather than in a clinic setting.  
The trial demonstrated that the HIP Programme (training to use the HIP and an 
encouragement to use the HIP to support an annual health check in secondary care) did 
not improve patients physical health related quality of life at 12 months. It was 
disappointing that only around half the nurses in the HIP Programme group returned a 
copy of the HIP to the research team at baseline and just under a third at follow up. The 
assumption that CMHNs could easily adopt the HIP into their clinical work to change the 
health behaviour of SMI patients they worked with was not true. 
Does the HIP have utility? 
The evidence for utility of the HIP is strong. By 2013 over 5,000 patients in the UK had a 
HIP completed with their mental health nurse and at least 294 internationally. Five 
secondary care provider organisations in England and a health board in Scotland had 
adopted the HIP into standardised care pathways for adult patients admitted to secondary 
care. In two large NHS mental health provider Trusts, the use of the HIP was 
commissioned with completion within two weeks of admission, a Commissioning for 
Quality and Innovation [CQUIN] target. Reports suggest these targets have been 
achieved and often exceeded. The HIP has been adapted into a primary care, Swiss-
German and Hong Kong Chinese versions. However, HIP completion rates do not tell us 
what use is made of the HIP data in terms of individualised physical care planning or 
health improvement over time. 
Where organisations have attempted to expand the HIP into community services 
professional and organisational barriers have been highlighted including that not all 
patients have Care-Coordinators who are nurses, time (including time on caseload), 
caseload size, staff knowledge and skills deficits, lack of equipment /facilities and 
problems with secondary-primary care interface working. The only places in the UK where 
the HIP has been successfully implemented by CMHNs are in nurse-led clinics. The nurse 
prescriber led wellbeing clinics in the community enterprise company in North East 
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Lincolnshire (and their CMHTs) are co-located with primary care services in health 
centres. Co-location has the potential to facilitate joint working and may help to normalise 
access to mental health care and start to address stigma. It is intriguing that in a pilot 
study in Hong Kong, CMHNs used the HIP and were able to repeat it with SMI patients at 
a year, demonstrating a significant improvement in some metabolic risk parameters. It is 
not known if this has something to do with the culture and organisation of CMHN work in 
Hong Kong, or was a feature of their involvement in the research project. 
Is the HIP acceptable? 
There is evidence from the two case series and the HIP contact survey that having a 
physical health check with a mental health nurse using the HIP is acceptable to patients, 
clinicians and commissioners of services. In those organisations where the HIP is part of a 
CQUIN, data is entered into the HIP within the electronic patient record with drop down 
boxes, indicating green, amber (for increased frequency of monitoring) or red flags and a 
choice of intervention. The nature of the CQUIN target determines the focus of 
intervention on process outcomes (e.g. that all staff are trained, that HIP data is entered 
within two weeks of admission, that patients are satisfied with their physical health care), 
rather than health outcomes. In many acute inpatient services the HIP data entry takes 
place away from patients and risks the decision making part of the HIP being overlooked 
(i.e. the choices as a result of feedback on a parameter are not discussed and agreed with 
the patient). However the CQUINs have targets not just for completion but for intervention 
(usually those aligned to standards in the National Schizophrenia Audit and/or NICE 
Guidelines). Informal feedback from nurses who use the HIP every day and their 
managers are that problems are experienced with the database interface and the time 
limits imposed for data entry per patient (e.g. data cannot always be entered if the 
standard time for completion has passed). Despite these problems they report that the 
focus on physical health using the HIP is useful and means that physical health needs 
and interventions are discussed in sessions with patients and other disciplines with an 
increased emphasis on physical health in recovery (care) plans.  
Does the HIP work?   
The result of the trial does not mean that the HIP (form) does not work to assess physical 
health parameters, to indicate when they are out of range and intervention is needed or to 
help focus a collaborative care plan. The trial did not measure these outcomes. The trial 
results showed that the process of using the HIP (or knowledge from it) after the training 
intervention did not improve patients’ health related quality of life over a year. Quality of 
life is the outcome required by NICE and is also necessary for economic analysis. The 
choice of the SF36v2 PCS for the primary outcome measure may not have been 
appropriate. It may not be specific enough (to SMI) or sensitive enough (to change over 
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12 months) in the SMI population. So far, no trials of health checks in any population have 
demonstrated improved quality of life outcomes.  
The strength of the trial was that it tested the effectiveness of recommended best practice 
in a real world clinical setting. The trial was conducted with nurses that are typical of those 
working in community mental health services in England today. The trial was conducted to 
a high standard and was commended for its research governance processes following two 
sponsor audits. Robust procedures for maintaining researcher blinding were implemented  
and there were no breaches of this during the trial. In a population where attrition rates in 
clinical trials can be considerable, we achieved a 74% follow up at 12-months. This was 
particularly impressive given that we tightly defined timings for patient assessment, as 
patients had to be assessed within two weeks either side of the assessment due date.  
Three aspects of treatment fidelity have been identified as important to the reliability and 
validity of studies of health behaviour change interventions: delivery of the intervention by 
the practitioner, receipt of the intervention and it’s enactment (use) by the patient (Bellg et 
al., 2004). It is not possible to attribute a non-significant trial result to ineffectiveness of an 
intervention where fidelity is unknown. In the HIP Cluster RCT, considerable problems 
with delivery of the HIP by CMHNs were identified. Where a nurse completed the HIP as 
intended with a study patient, there was an assumption that the recommended action 
would take place and impact directly on patient health outcomes, including the primary 
outcome of the patient’s perception of their physical health state. 
The recently published mixed methods pilot study of the ‘Traffic Light Method for Somatic 
Screening and Lifestyle’ (TLM) in community and inpatients with SMI in the Netherlands 
demonstrated a significant reduction of patients body weight and waist circumference at 
three months (van Meijel et al., 2014). The intervention required 12 hour training of the 
four mental health nurses who delivered the intervention from one clinical nurse specialist, 
assessment using the TLM and three months of weekly 15 minute sessions (3.25 hours of 
intervention) and supervision (time not specified) from the same nurse specialist. The cost 
of this was covered by a specific grant. This is an example of a study where there has 
been considerable attention to the implementation of an evidence based health behaviour 
change intervention alongside health screening. However this approach relies heavily on 
the skills and knowledge of the clinical nurse specialist and the authors acknowledge the 
challenges in scaling up such an intervention into a research design that can test efficacy. 
The HIP trial took place against a background of redesign of services, a third of CMHNs 
recruited into the study worked in assertive outreach teams that no longer existed at 12-
month follow-up. Teams were reconfigured, caseloads dispersed or merged and/or 
patients discharged. Assertive outreach teams are more effective at engaging patients 
with SMI than generic community mental health teams, but no more effective in preventing 
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readmission to inpatient care (Killaspy et al., 2006). In times of austerity, commissioners 
may focus on short-term expensive outcomes such as preventing admission rather than 
health promotion that may take considerable time to result in measurable change. 
Physical health care has only recently been highlighted as a core competence of mental 
health nursing (Nursing and Midwifery Council, 2010b). Staff and managers have been 
observed to be less likely to adopt and prioritise new ways of working that breach existing 
organisational divisions and culture when they perceive services and teams to be under 
threat (Popay et al., 2004).  
Methodological challenges 
Merely identifying which physical comorbidity parameters are at risk and requiring nurses 
to have the skills and ability within their work and workplace to engage and intervene to 
positively change these could be rightly criticised for being a naive approach to a complex 
issue. We just do not have the evidence of what is needed in this population to change 
these health behaviours (and for many of them little evidence how to change them in the 
general population). We have some limited evidence in some areas, for example, in 
smoking cessation and the management of weight gain in schizophrenia, but not in others, 
for example, the majority of metabolic outcomes, health outcomes in women with 
schizoaffective disorder (the most at risk). It appears we may have got methodologically 
ahead of ourselves in forging ahead with a clinical trial without establishing fidelity to or 
efficacy for individual aspects of the intervention.  
The interventions in the HIP for the most part were based on guidelines and we know that 
guidelines alone do not change practice. Guidelines are supposedly based on the best 
available evidence but they do not usually indicate how the recommended action should 
be implemented. They tend to rely on the skills, motivation and confidence of the 
individual clinician, including their ability to work and communicate across multiple 
professional and service boundaries to achieve results. It is not unusual for healthcare 
improvements to be attempted through interventions aimed at the knowledge, routine and 
attitude of individual healthcare practitioners. This approach ignores systems factors that 
may act as barriers to implementation. Most of the attention to barriers when designing 
the HIP and the training to implement it were based around minimising barriers to nurses 
being able to access the HIP (e.g. designing a paper-based tool that was free to access). 
The HIP prompted intervention by highlighting risk and the recommended intervention but 
it relied on the individual nurse to make this happen with the patient and within their usual 
system. Barriers to implementation, and therefore the fidelity of MHNs using the HIP in 
their practice to change patient health behaviour were largely ignored. Nurses were asked 
to identify barriers to implementation of the HIP in the training workshops and to come up 
with ways of overcoming them themselves. It was implicit within the design of the 
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intervention that nurses could act as change agents and had the skills to make this 
happen.  
Guidance on the development and evaluation of complex interventions includes the 
recommendation that enough preparatory work has been completed to be confident that 
the intervention can be delivered as intended (Medical Research Council, 2008). There is 
an increasing interest in implementation science as a way to improve the translation of 
evidence into the practice of healthcare professionals. This would tend to be the focus 
once an intervention has demonstrated efficacy (e.g. when an intervention has enough 
evidence to be recommended in practice guidance). However, attention to fidelity at the 
earliest stage of the design of the complex intervention is important. A process 
observation at an earlier stage in the design related to a small pilot in routine CMHN 
practice may have allowed us to identify strategies to overcome some of the barriers that 
were encountered in the trial phase. 
The HIP Programme met the definition of a complex intervention because it relied on 
several interacting components to have an effect (Medical Research Council, 2008). 
These included the ability of the nurse to bring about change in the patient and the system 
of care and the ability of the patient to improve their health as a result. One of the key 
questions in evaluating complex interventions is how the intervention works and how 
aspects of the intervention exert their effect (Craig et al., 2008). The functional relationship 
between the components of a complex intervention and its outcomes are rarely described 
or reported (Michie et al., 2009). We did not investigate the various elements of the 
intervention as to their ability to bring about change in the patient. This meant it was not 
possible to identify weaknesses in this strategy and attempt to strengthen these within the 
design. So, for example, there was the assumption that CMHNs working in secondary 
care could order a range of blood tests but the process observation demonstrated this 
was not routine and often difficult to facilitate. In the training, the availability of vital signs 
equipment was commonly highlighted as a barrier by nurse subjects. To obtain this 
equipment required nurses to access a budget (through their manager) and make sure 
any purchase met specific medical equipment governance requirements. Once equipment 
was obtained, some nurses needed to find ways to develop (or refresh) their clinical skills 
to be able to use it. Patient and service factors were not targeted. So, for example, the 
HIP assumes that once abnormal weight is identified, the nurse has the required skills and 
knowledge (and access to appropriate interventions) to engage the patient in changing 
their diet and exercise behaviours.  
There are well-documented barriers to implementation of interventions aimed at improving 
the health outcomes of people with SMI by medical and nursing staff and these have been 
identified at the patient, professional and systemic level (De Hert et al., 2011a) (Happell et 
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al., 2012, Robson et al., 2013). Interventions tailored to prospectively identify and address 
barriers are more likely to improve professional practice than no intervention or to 
dissemination of guidelines or educational materials alone (Baker et al., 2010).  
Little is known about the ability of community mental health nurses to implement physical 
health interventions. A recent pilot project in Greater Manchester that focussed on training 
of key staff, leadership and methods to improve shared care across the primary-
secondary care interface improved the availability of cardiovascular risk data for SMI 
patients in primary care (National Institute for Health Research Collaboration. for 
Leadership in Applied Health Research and Care  (CLAHRC) for Greater Manchester, 
2013). However use of the selected physical health check, the Rethink tool (Phelan et al., 
2004), by Care-Coordinators was limited by a lack of clinical (nursing) skills amongst the 
multidisciplinary secondary care community workforce, low confidence in skills application 
and the time available to conduct the health check. These authors recommend targeting 
barriers to implementation through a boundary spanning role, knowledge integration, 
standardisation and a supportive organisational culture but other than appointment of 
primary-secondary care link workers did not identify what may be required to achieve 
these.  
Implementation science is a relatively new area of health research but models and 
methodologies have been published that may help guide health researchers to better 
identify and target barriers to implementation. For example the normalisation model aims 
to help identify the factors that enable complex interventions to be embedded in routine 
clinical work (May, 2006). This appears particularly relevant to an intervention like the HIP 
programme because it was designed to support the implementation of complex 
interventions in chronic disease management and considers the work that needs to take 
place at a micro (between nurse and patient) and macro level (the organisational context).  
Authors consistently identify patient, professional and organisational barriers to 
implementation of interventions in mental health services. Examples of all three were 
highlighted in the process observation: patient barriers included those related to 
motivation to change their own health behaviours and belief that this was possible, 
professional barriers included difficulties knowing how best to help patients change their 
health behaviours. Both of these could be addressed by more of an emphasis on 
motivational interviewing and problem solving approaches within the education of MHNs, 
and skilled supervision to build and maintain practice competence. Organisational barriers 
included the size of CMHNs caseload, the focus of the work they do and are used to 
(culture) and the way mental health and physical health services are organised and 
incentivised within the NHS. New ways of commissioning mental health care may provide 
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a way to break down the traditional ways of working and boundaries between services 
that act as barriers to true holistic care. 
Chapter summary 
The problem of increasing morbidity and early mortality in the population of people with 
SMI remains. Targeting the mental health nurse as an agent of intervention to impact on 
these important health disparities at a population level has not yet been demonstrated to 
make a difference. There are some promising findings, from the TLM intervention and the 
Hong Kong Chinese-HIP (van Meijel et al., 2014, Bressington et al., 2014) and both of 
these are due to be tested in clinical trials. In primary care, there is, as yet, no evidence 
that targeting practice nurses or GPs to implement intervention makes a difference to 
health outcomes. However, it has been possible to increase the numbers of patients who 
receive health checks in secondary or primary care, with the implementation of training 
and (funded) resources (Smith et al., 2007b, Hardy et al., 2014, National Institute for 
Health Research Collaboration. for Leadership in Applied Health Research and Care  
(CLAHRC) for Greater Manchester, 2013). Contextual factors appear to be very important 
but have not yet been addressed. The Greater Manchester CLAHRC pilot study showed 
that where some attention is given to designing methods to support physical health care 
roles in CMHTs and promote integrated working, other factors continue to inhibit health 
checks. Future research should aim to specifically identify and target these barriers. This 
would appear to be best applied to one aspect of physical comorbidity in SMI where there 
is the most evidence of effect of the intervention. 
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Conclusion and recommendations 
The programme of work presented in this thesis included a systematic review, 
development of the HIP programme, two pragmatic case series, a pre and post training 
evaluation, a cluster randomised controlled trial, a process observation and a survey of 
contacts with whom HIP resources had been shared. The systematic review identified that 
despite evidence of a considerable knowledge and skills deficit in healthcare professionals 
working in secondary mental health services, information about how best to educate them 
to meet the physical healthcare needs of people with SMI was absent from the literature. 
A pragmatic tool and education intervention (the HIP Programme) was designed to 
address this deficit based on the available published evidence about health parameters 
and interventions in SMI and the authors’ experience. An early case series in a 
convenience sample of community patients who were engaged in a nurse led SMI clinic in 
secondary care demonstrated utility of the intervention and considerably physical 
comorbidity in patients, with similar results but greater comorbidity in an acute in-patient 
sample from the same hospital. A comparison with primary care SMI data from a similar 
geographical area suggested the HIP was a reliable measure of comorbidity parameters 
in this population.  
Mental health nurses consistently report a positive attitude towards a physical healthcare 
role in SMI, but state they require training to enable them to enact the role. Their 
perception of low baseline knowledge to inform physical health care practice in SMI was 
confirmed and significant knowledge gain immediately after HIP training demonstrated in 
38 MHNs via a pre and post training evaluation.  The results of the clinical trial 
demonstrated that the process of using the HIP (or knowledge from it) by CMHNs in 
routine practice after training did not improve patients’ health related quality of life over a 
year. Fidelity to implementation of the intervention by the CMHNs randomised to the 
training was 42% at baseline and only 28% at a year, considerably weakening the 
inferences that could be drawn about effectiveness. The process observation immediately 
after the trial in a subsample of HIP group participants showed that despite patients’ 
expressing a wish for their CMHN to undertake physical health care, nurses experienced 
barriers related to clinical engagement and organisation of their work. These barriers were 
reported to impact on their ability to intervene beyond assessment and/or repeat the HIP 
at a year.  
The HIP is well liked by clinicians and patients and there is no evidence of any harm from 
its use. It continues to be used across the UK and internationally by nurses, services and 
commissioners of mental health services. A survey of 72 contacts with whom HIP 
resources had been shared indicated at least 5,000 people with SMI worldwide had their 
health checked using the HIP. The results of this entire programme of research do not 
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mean that the HIP (form) does not work to assess physical health parameters and indicate 
when intervention is needed or that the education package is not useful or appropriate. 
None of the research elements measured these outcomes. However, it does indicate that 
CMHNs cannot currently use the HIP in secondary mental health services in England to 
conduct annual health checks in patients with SMI on their caseloads to improve physical 
health related quality of life over the time frame of a year. 
Recommendations for practice, education, research and health policy 
Nurses should continue to use the HIP resources if they wish to support and develop their 
practice. MHNs working in community settings should consider implementation of a nurse-
led clinic for patients with SMI to focus on physical health care that has a budget for staff 
training, equipment and health outcome measurement.  Routine risk assessment in care 
pathways for people with SMI should include an assessment of the risk of cardiovascular 
disease and metabolic syndrome. Data should be routinely collected for all cardio-
metabolic outcomes in SMI and care plans (including those under the Care Programme 
Approach) should be individualised to attempt to address and evaluate those parameters 
that are out of range. Mental health nurses should explore the potential of collaborative 
working with primary care including boundary spanning roles and co-location of clinics.  
Low levels of physical health knowledge and the skills and confidence of MHNs in 
engaging patients in health behaviour change still needs to be addressed. The 
measurement of physical health parameters and engagement of patients in conversations 
about their health are identified by the professional regulatory body as essential skills for 
all nurses. The strategies used by educators and practice mentors to achieve and 
measure these are currently unknown, so should be investigated and disseminated. A 
longer period of generic nurse training before MHN field specialisation may help to 
address skills deficits in practice over time, but would depend on access to appropriate 
placements where the skills can be observed and then used under supervision to achieve 
competence.  This depends on a workforce that is already using these skills. As these are 
likely to be limited in number, early implementers should be supported and nurtured. Peer 
networks should be initiated and used to enable learning from local projects to be shared. 
Commissioners should incentivise specific projects or education initiatives and the 
collection, reporting and evaluation of data so that outcomes can be rapidly disseminated. 
We designed the trial without first testing that health checks in the SMI population are 
effective or examining fidelity to implementation of health checks using the HIP by CMHNs 
in their routine work. It could be argued that there is a case for testing individual elements 
of a health check before combining them and then carefully considering the clinical setting 
and organisational culture in which they are to be implemented. This should include 
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assessment of the readiness of the organisation and workforce to adopt the intervention 
and a scoping of the potential barriers and levers to success early on in the process.  
Attention to the fidelity of the intervention (to include methods to enhance delivery, receipt 
and enactment) should be included in future research designs. Researchers in all areas of 
chronic disease management, comorbidity research and implementation science should 
combine their efforts to develop appropriate subjective and objective measures of health 
status in SMI and strengthen future research designs. It would also be prudent to explore 
the potential of nurse-led clinics and the benefits of co-location of secondary and primary 
care services for people with SMI. 
Funders should incentivise research teams to attempt to address barriers to 
implementation by requiring these to be identified and methods to be included to address 
them in grant applications. Health policy writers should acknowledge the paucity of 
evidence for annual health checks in SMI and work to standardise a minimum set of 
physical health outcome data to enable evaluation of future initiatives to improve health 
and reduce mortality in this population. The National Schizophrenia Audit could be 
expanded to enable this by including data from people with a diagnosis of schizoaffective 
or bipolar disorder. Mental health provider organisations should routinely investigate any 
death that occurs in patients with SMI under their care where the cause of death is 
“natural” and this data should be reported and investigated at a local, regional and 
national level to afford deaths due to physical comorbidity in SMI as much attention as 
death by suicide. NICE should revise its recommendations about health checks in SMI to 
reflect the current state of research evidence. 
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